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THESIS SUMMARY 
 
The human gastrointestinal tract, extending from mouth to rectum, hosts complex microbial 
communities. Dysbiosis is a term used to indicate a shift in the balance of these residents towards a 
pathogenic state, typically associated with a breakdown of the relationship with the host and tissue 
degradation (disease onset). In the mouth, chronic inflammation may lead to periodontitis and 
destruction of the periodontium, a complex process in which the Gram-negative nanaerobe 
Porphyromonas gingivalis, has been implicated (Hajishengallis et al., 2011). Dysbiosis of the distal 
gut largely manifests as mucosal inflammation and loss of epithelial integrity, including a suite of 
inflammatory bowel diseases that may be associated with members of the Clostridium genera. 
Broad-spectrum antibiotics, frequently chosen as a treatment, are a problematic solution to mediate 
restoration, with extensive ‘off target’ action. Also, colitis associated with overgrowth of 
endogenous Clostridium difficile is frequently linked to previous broad-spectrum antibiotic therapy. 
The unmet challenge in treating diseases associated with dysbiosis is the guided reconstitution of a 
so-called ‘normal microbiota’.  
Previously, in an attempt to selectively control P. gingivalis, a porphyrin auxotroph sensitive 
to nitroimidazole antibiotics, deuteroporphyrin-linked nitroimidazole adducts were synthesised 
(Fig. 1). These adducts were designed as a ‘Trojan-horse’ delivery system for nitroimidazoles into 
P. gingivalis, through recognition of the porphyrin macrocycle. In this thesis, the activity in vitro of 
amide- and lysine-linked deuteroporphyrin- nitroimidazole adducts (termed ‘P5’ and ‘P8’  
 
 
Figure 1: Deuteroporphyrin IX (DPIX, A), and amide-linked adduct, termed ‘P5’ (B). Carbons 13 and 
17 of the DPIX macrocycle are labelled.  
xi 
respectively) was explored. Growth curve and viable count assays were used to assess the response 
of nanaerobic bacteria sensitive to metronidazole (a nitroimidazole drug), in enriched brain heart 
infusion (enriched BHI) growth medium, chosen to support growth of the fastidious nanaerobe 
Tannerella forsythia. Like metronidazole, both adducts were bactericidal for P. gingivalis. Uptake and 
reductive activation of P5/P8 was rapid, with the majority (99% of 5 × 105) of inoculated bacteria 
being killed within 30 minutes. Since none of the other nanaerobic Bacteroidetes tested (Bacteroides 
fragilis, Prevotella melaninogenica, Tannerella forsythia) or Fusobacterium nucleatum were killed in 
enriched BHI medium, preliminary evidence indicated P5 and P8 were specific for P. gingivalis, killing 
this bacterium only. 
In order to examine the specificity of adducts for P. gingivalis within complex ecosystems 
two models were explored. In the first human dental plaque was inoculated into growth media and 
microorganisms were cultured under anaerobic conditions for short periods of time. Overgrowth by 
(presumably) facultative bacteria obscured the capacity to discriminate the fate of slower growing 
bacteria. Next a rat model for alveolar bone loss, due to introduced P. gingivalis ATCC 33277, a 
known infective strain, was examined. Kanamycin, an aminoglycoside which does not affect P. 
gingivalis, but does target dominant clades of bacteria inhabiting the rat oral cavity, including Gram-
positive facultatives, Rothia (Actinobacteria) and Streptococcus (Firmicutes), was added to drinking 
water for two weeks. Despite daily gavages of ≈2 × 1010 viable cfu of P. gingivalis 33277, colonisation 
rate, assessed by real time PCR primers specific for P. gingivalis, was poor. Since none of the rats 
exhibited gross anatomical changes, introduction of ‘foreign’ bacteria such as P. gingivalis into the 
rat oral cavity is notoriously difficult (Manrique et al., 2013) and as the anatomy and bacterial 
composition differs from human counterparts, pursuit of this model was discontinued. 
It was decided instead, that the gastrointestinal tract, dominated by nitroimidazole-sensitive 
nanaerobes, including Clostridia (of the Firmicutes phylum) and Bacteroidetes (including 
porphyromonads), was a more suitable model to test the specificity of porphyrin-nitroimidazole 
adducts. As a reference point, growth curves in BHI were prepared for strains representing major 
bacterial clades of human origin. Surprisingly, the growth of all representative laboratory strains of 
Bacteroides spp. (five strains), originating from human gut was enhanced by the amide-linked adduct 
‘P5’. Further, when titrated below minimal inhibitory concentrations, growth of Prevotella spp. (two 
strains) was stimulated. In contrast, P5 retained nitroimidazole activity for nanaerobes within the 
Firmicutes clade, killing all examined Clostridiaceae (five strains) with a three-fold average increase 
in potency (1.6 µM) over metronidazole (5.6 µM). None of the examined facultative bacteria, 
including representatives from the Proteobacteria (two strains) or Actinobacteria (three strains) 
were killed by P5, nor was the metronidazole-sensitive F. nucleatum (a member of the Fusobacteria 
xii 
phylum). These results were confirmed in an ex-vivo human faecal model, in which viable 
Bacteroides populations grown in P5 were approximately double the population of DMSO control at 
10 hours. These results indicate not only growth support of Bacteroides, but taken with Illumina 
sequencing, confirm killing capacity for nanaerobic Clostridia in a complex bacterial human faecal 
population and secondly, that Bacteroides spp. were advantaged by depletion of Clostridia.  
Based on these observations, and a re-examination of the literature, it is apparent that many 
Bacteroidetes do not encode the full porphyrin biosynthetic pathway. These Bacteroidetes 
incorporate porphyrin into a b-type cytochrome, encoded by the three-component fumarate 
reductase operon (frdC, frdA, frdB), reducing fumarate to succinate, thereby forming an essential 
component of the reductive arm of the tricarboxylic acid (rTCA) cycle. In Bacteroidetes that encode 
both oxidative and reductive arms of the TCA cycle (Bacteroides), porphyrin supplementation is not 
essential, but it permits optimal growth, whereas in genera that encode only a portion of the rTCA 
(Prevotella and Porphyromonads), a porphyrin source is essential to synthesise succinate and 
additional ATP, for redox maintenance (NAD+/NADH ratio) and for synthesis of amino acids including 
glutamic acid, arginine, proline and aspartic acid. Growth of two mutant Bacteroides fragilis 
defective in components of the fumarate reductase operon (frdC or frdB) was suppressed following 
challenge with P5 indicating the nitroimidazole moiety was activated, albeit with a lower potency 
than for metronidazole. Importantly, no stimulation of growth was detected for either mutant, 
indicating P5 or metabolites of P5 were not acting as a source of porphyrin in the absence of a 
functional fumarate reductase system. In cell-free biochemical assays utilising B. thetaiotaomicron, 
fumarate reduction was stimulated by a metabolite/s of P5 albeit around half the rate of biotic 
(haem) and abiotic (DPIX) controls. The data were interpreted as indicating that metabolised 
product/s of P5 were incorporated into a functional b-cytochrome. The B. thetaiotaomicron-
metabolised and sodium-dithionite (reduced) products of P5 were studied by high resolution mass 
spectrometry. Structures consistent with the several ions shared between these treatments and 
candidates for incorporation into the b-cytochrome are proposed. 
When P5 was reduced in sodium dithionite to inactivate the biologically-active nitro group of 
the adduct, the rate growth and final biomass of B. thetaiotaomicron was higher than for the control 
P5 treatment. Reduced P5 lost killing capacity for C. difficile, confirming that adduct bactericidal 
action was tethered to nitroimidazole activity (P5 retains prodrug-like properties). Data also 
indicated that P5 was activated in Bacteroides although this was insufficient to cause death. From 
these findings, it is apparent that nanaerobic Bacteroidetes have efficient porphyrin uptake 
machinery, including previously unappreciated flexibility for the types of porphyrin that can be taken 
up and incorporated into b-cytochromes. Both processes appear to be independent of the metal 
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ligand in examined Bacteroidetes. More broadly, growth curve and a faecal growth curve model 
indicate other clades, including representatives within the Actinobacteria and Firmicutes also have a 
previously unappreciated flexibility for the types of porphyrin that can be taken up. 
Having characterised some of the elements of P5 metabolism in nanaerobic Bacteroidetes, 
the response of complex bacterial communities in the rat gut was explored. Despite concentrated 
five-day administration of metronidazole (25.7 mg kg-1 per day), little change was observed in the 
faecal bacteria of rats, based on real time PCR estimates of total bacterial load independently and 
with respect to the Bacteroidetes population. Next generation sequencing confirmed that at finer 
taxonomic resolution, little change occurred in faecal bacteria populations. The data are compatible 
with a report indicating reductions in viable Bacteroides in rats exposed to metronidazole, was 
restricted to mucosa-associated microbiota of the ileum and colon and not in the digesta (Mikelsaar 
and Siigur, 1992). Dysbiosis of the distal gut microbiota is not well defined, however prolonged 
mucosal inflammation and loss of barrier function, or inflammatory bowel disease (IBD), is at least 
partly mediated by bacteria, such as C. difficile from the Clostridia clade. Since growth of 
B. thetaiotaomicron was stimulated by therapeutic concentrations (20 nM - 20 µM) of P5, adducts 
may have a practical use in treating clostridial-mediated IBD, where it is envisaged that the guided 
restoration of Bacteroides, to the detriment of Clostridia, could be a new treatment modality. 
 
Thesis aims 
I) Characterise the metabolism of deuteroporphyrin-nitroimidazole adducts 
II) Define the consequences of administering deuteroporphyrin-nitroimidazole adducts 
into complex bacterial communities in vitro and in vivo  
 
 
 
 
 
 
 
xiv 
Thesis Summary References 
 
HAJISHENGALLIS, G., LIANG, S., PAYNE, M. A., HASHIM, A., JOTWANI, R., ESKAN, M. A., MCINTOSH, 
M. L., ALSAM, A., KIRKWOOD, K. L., LAMBRIS, J. D., DARVEAU, R. P. & CURTIS, M. A. 2011. 
Low-Abundance Biofilm Species Orchestrates Inflammatory Periodontal Disease through the 
Commensal Microbiota and Complement. Cell Host & Microbe, 10, 497-506. 
MANRIQUE, P., FREIRE, M. O., CHEN, C., ZADEH, H. H., YOUNG, M. & SUCI, P. 2013. Perturbation of 
the indigenous rat oral microbiome by ciprofloxacin dosing. Molecular Oral Microbiology, 28, 
404-414. 
MIKELSAAR, M. & SIIGUR, U. 1992. Metronidazole and the intestinal microecology of rats. Microbial 
ecology in health and disease, 5, 139-146. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
 
Chapter I   Introduction 
1 
 
 
 
 
 
 
 
 
CHAPTER I 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter I   Introduction 
2 
1.1 The mammalian gastrointestinal tract 
1.1.1 Anatomy and microbial diversity 
The human gastrointestinal tract, extending from the mouth to the anus, hosts an enormous 
diversity of microbial inhabitants, including Archaea (largely methanogens), Fungi, Bacteria and their 
viruses. In the mouth, the phyla Firmicutes, Proteobacteria, Bacteroidetes, Actinobacteria and 
Fusobacteria tend to dominate, with common genera including Streptococcus, Fusobacterium, 
Actinomyces, Capnocytophaga, Haemophilus, Neisseria, Corynebacterium, Prevotella, Veillonella, 
and Rothia (Aas et al., 2005, Bik et al., 2010). Fungi are also present, as are Archaea. In the oral 
cavity, the imbalance of the microbial residents towards a pathogenic state, dysbiosis, may be 
accompanied by inflammation and degradation of the tissues supporting the teeth, termed 
periodontitis. The Gram-negative nanaerobe Porphyromonas gingivalis (see Fig. 1.1), is implicated in 
periodontitis, in concert with other oral bacteria, a process suggested to involve activation of 
complement components C3a and C5a (Hajishengallis et al., 2011). Other virulence characteristics of 
P. gingivalis are discussed in Section 1.2. 
The mature gut epithelium consists of a series of undulating protrusions, termed villi, at the 
base of which are crypts of Lieberkühn with populations of epithelial stem cells that populate the 
midpoint of crypts with differentiated cell lineages, including columnar absorptive colonocytes, 
 
 
 
 
 
 
 
 
Figure 1.1: Transmission electron micrograph of P. gingivalis W50 grown under ‘haem limited’ 
(A, 0.46 µM) and ‘haem excess’ (B, 7.7 µM) growth medium from McKee et al., 1986. Note that 
extracellular vesicles present in 0.46 µM haem, were effectively absent with 7.7 µM haem and were 
replaced with extensive fimbriae. Scale bar = 0.5 µM. 
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enteroendocrine, Paneth, and mucin-producing goblet cells. Mature goblet cells secrete mucins, 
forming a barrier. Mucin is sparse or non-existent in the small intestine and increases in thickness 
with descent into the colon (Johansson et al., 2011). The underlying ≈50-100 µm mucus layer is thick, 
being primarily composed of mucin2 (Muc2) polymers (of around 100 MDa, consisting largely of 
sulfated glycans) (see Fig. 1.2). In healthy individuals limited strains of bacteria inhabit this thick 
primarly tightly linked layer (Davis et al., 1972, Swidsinski et al., 2005). In contrast, many bacteria 
inhabit a second more loosely arranged outer mucus layer which is up to 800 μm thick in the colon 
of rats (Johansson et al., 2008, Atuma et al., 2001). In the gut, the number and types of bacteria 
varies in a given site within individuals and between individuals. Constant turnover and shedding of 
epithelial cells, overlying mucus and peristaltic movements, all contribute to variation in microbial 
populations. Variation is also driven by diet (including carbon, nitrogen and vitamin flux), gastric, 
pancreatic and biliary secretions from the bile duct (at the proximal end of the small intestine). 
Lastly, the appendix, an addendum to the caecum (Fig. 1.3) which contains mucus and also supports 
bacteria, has been proposed to re-seed the caecum and colon after catastrophic events, including 
diarrhoea (Bollinger et al., 2007). How these factors govern microbial stability is not well 
 
 
Figure 1.2: A Section of the mouse distal colon showing mucosa and overlying mucus layer from 
Johansson et al., 2008. Goblet cell mucus was stained with anti-MUC2C3 antiserum (green). The 
inner mucus layer (marked a and s) and outer mucus layer (marked o) are linked by muc2 extensions 
from the epithelium (arrowed). DAPI was used to stain nuclei (blue) of the ‘invaginating’ crypts of 
Lieberkühn. The base of the crypts of Lieberkühn are not shown. The scale bar is 50 µm. 
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characterised, partly because sampling is often performed from faeces, which is not ‘spatially 
defined’, so is a crude metric. Broad trends, with emphasis on development and spatial distinctions 
in microbial assemblage are summarised below.  
In neonates, bacteria colonising the (sterile) gastrointestinal tract are thought to originate 
predominantly from the mother’s vagina. Organisms include Bifidobacterium and Lactobacilli, with 
lower colonisation of Proteobacteria (including Escherichia coli), Clostridia, and Bacteroidetes 
(Rotimi and Duerden, 1981, Koenig et al., 2011). In developing neonates, the acidity of the stomach 
is presumably low enough to allow passage of these microbes. Upon secretion of H+ and Cl- ions 
(hydrochloric acid) by parietal cells, the pH in the gastric compartment is maintained at 1-2. The low 
pH, along with secretion of the proenzyme pepsinogen (which is converted to pepsin A) largely 
inhibits the transfer of viable microbes through the stomach. Facultative bacteria of the Firmicutes 
phylum, predominantly the Bacilli class (Lactobacilli and Streptococci) which are resistant to bile 
salts, maintain residence in the small intestine. Bacteria tend to increase in number with decent into 
the large intestine. These bacteria are widely considered anaerobic, although they are capable of 
respiring in nanomolar concentrations of oxygen, so are more accurately called ‘nanaerobes’, 
(Baughn and Malamy, 2004, Morris and Schmidt, 2013). These nanaerobes include Clostridia (a class 
of mostly spore forming bacteria, within the Firmicutes phylum) and the non-spore forming 
Bacteroidetes phylum, consisting largely of Bacteroides, Prevotella, Porphyromonas and Rikenella 
(Eckburg et al., 2005) (Fig. 1.3). Depending on the region sampled, nanaerobes of the Bacteroidetes 
and Firmicutes phyla outnumber by up to 2 orders of magnitude facultative and aerobic bacteria 
including Actinobacteria, Proteobacteria, Fusobacteria (a nanaerobic phylum) and divisions of 
prokaryotes that are uncultured, although have sufficiently different 16S rDNA to be considered 
novel (candidate phyla), such as TM7 (Eckburg et al., 2005). Up to 1012 microbial cells per gram may 
be found in the colon, the vast majority of which reside in the digesta of the lumen and not on the 
mucosa. 16S rDNA surveys in mice, indicate Lachnospiraceae and Ruminococcaceae (Firmicutes) 
(Nava and Stappenbeck, 2011, Nava et al., 2011) dominate the colonic mucosa, while 
Bacteroidaceae, Enterococcaceae and Lactobacillaceae are enriched in the digesta (Pédron et al., 
2012). Despite differences in diet, anatomy and physiology, at a coarse phylum resolution, 
Bacteroidetes and Firmicutes phyla dominate the faeces of mammalia (Ley et al., 2008).  
Several mechanisms have been proposed to explain how the host spatially confines 
microbial inhabitants and how populations of bacteria colonise the gut and maintain long-term 
residence. Some regulatory influences involve the host and others are intra-bacterial. As noted 
above, few bacterial species are closely associated with the intestinal epithelium. These include  
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Figure 1.3: Bacterial and proposed chemical gradients in the human gut from Donaldson et al.,2015. 
The duodenum, jejunum and ileum, making up the small intestine, are not labelled. Note that the 
appendix may serve as a reservoir, seeding the caecum, for example after diarrhoea (Bollinger et al., 
2007). 
 
Acinetobacter spp. and Proteobacteria associated with intestinal crypts of mice (Pédron et al., 2012), 
while in chickens (Yamauchi and Snel, 2000) and a variety of other non-mammalian 
vertebrates(Klaasen et al., 1993), Segmented Filamentous Bacteria (SFB, a spore forming clade, 
Candidatus Savagella of the Clostridia) are found. The secretion of an antibacterial lectin, RegIIIγ, has 
been proposed to limit microbial colonisation within 50 µm of the epithelium in the small intestine 
(Vaishnava et al., 2011). The secretion of other antimicrobials by Paneth cells, which are mostly 
confined to the small intestine, has also been proposed to limit colonisation of this region [see 
(Bevins and Salzman, 2011) for a detailed review]. The expression of polysaccharide A on (the 
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surface of) B. fragilis, results in ‘immune tolerance’ allowing colonisation on the mucosa by down 
regulating TLR2-mediated recognition by T helper cells (CD4+ T cells) (Round et al., 2011). 
Modifications to the bacterial surface, such as the addition of L-fucose to surface glycoproteins and 
capsular polysaccharides by Bacteroides spp., mimicking mammalian intestinal epithelial cell glycans, 
which also contain L-fucose, may allow colonisation of the mucosal surface (Coyne et al., 2005). 
Human faecal bacteria are generally amenable to culturing (Goodman et al., 2011) and 
remarkably, ex vivo culture models maintain the numerical ratio of bacterial populations found in 
the murine caecal lumen (Freter et al., 1983b, Freter et al., 1983a). The maintenance of bacterial 
populations in the absence of cues from the host, suggests these populations are partly internally 
regulated, for example by bacteria occupying specific nutritional niches or by the secretion of 
inhibitory molecules. For example, in a single-species gnotobiotic mouse model, carbohydrate 
utilisation systems uniquely encoded by B. fragilis and B. vulgatus enabled the catabolism of specific 
carbohydrates allowing colonisation and dominance of these clades in the gut (Lee et al., 2013). 
Also, hydrogen sulfide (H2S) has been shown to supresses the growth of E. coli in an ex vivo culture 
model (Freter et al., 1983a). The excretion of H2S is probably the result of dissimilatory sulfur 
metabolism (anaerobic respiration). A possible mechanism is that dominant clades, rather than 
E. coli, take up sulfur containing proteins/peptides and liberate oxidised sulfur containing 
compounds (SO32-, SO42-) and reduce them. Members of the Clostridium genus generally lack the 
capacity for dissimilatory sulfate reduction (Collins et al., 1994) so it is unlikely to be members of this 
clade that liberate H2S. These results could indicate that more dominant members, including 
bacteria within the Bacteroides and Clostridia have more efficient metabolisms than E. coli. 
Members of these clades could also occupy specific nutritional niches not available to E. coli or 
generate inhibitors other than H2S, suppressing growth of E. coli. Consistent with these observations 
a decrease in members of the Clostridia is associated with an increase in E. coli on the Illeal mucosa 
of human subjects during Crohn’s disease (Baumgart et al., 2007). Overgrowth of Proteobacteria 
during IBD indicates that limitations of total numbers of these bacteria are not based on the lack of 
nutrients. Whilst not the focus of these investigations, it is intriguing that E. coli (and other 
Proteobacteria) or other low abundance clades maintain residence in the human gut, implying these 
clades perform a function/s such as the catabolism of ‘waste’ metabolites from more abundant 
clades or provide essential nutrients to bacteria or the host.  
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1.1.2 Some nutritional and immunological interactions of microbial 
inhabitants with their mammalian hosts 
Given that mammals have co-evolved for millennia with microbes in their gastrointestinal 
tracts, it is not surprising there is an extensive network of inter- and intra-domain interactions, some 
of which are based on metabolism such as vitamin synthesis (folate, B12) and others based on 
immune stimulation and repression. While only beginning to be characterised, the gut microbiota 
collectively encode several functions absent in human hosts (Hooper and Gordon, 2001). Mass 
spectrometry of conventional and germ free mice detected up to a five-fold increase in the number 
of metabolites extracted from blood of conventional mice, including the absence of various flavones 
and phenyl derivatives in germ free mice (Wikoff et al., 2009). Also, in germ free rats the caecum is 
dramatically enlarged, in part due to undegraded mucus (Gustafsson et al., 1969) which is reversible 
by introduction of single bacterial strains including Peptostreptococcus micros (Carlstedt-Duke et al., 
1986).  
Of the 97 glycoside hydrolases in the human genome, 8-17 are estimated to be involved in 
digestion (El Kaoutari et al., 2013). Human digestive glycan cleaving enzymes are limited to starch, 
sucrose, lactose, trehalose and possibly some chitins (Cantarel et al., 2012). Glycans not digested by 
humans are typically plant derived. These glycans are cleaved by intestinal microbiota and 
fermented into short chain fatty acids (SCFA), largely acetate, propionate and butyrate (in the range 
of 20-60 mmol kg-1, Fig 1.4) before excretion and absorption, particularly of butyrate in the large 
intestine (Macfarlane and Macfarlane, 2003). In germfree mice, reduced expression of enzymes 
supporting the TCA cycle in colonocytes leads to reductions in total NADH/NAD+ and ATP, resulting 
in autophagy which is ameliorated by butyrate (Donohoe et al., 2011). Butyrate production is 
considered to be limited to clades within the Clostridia class, including Eubacterium spp., Roseburia 
spp., Clostridium spp. and Faecalibacterium prausnitzii (Louis and Flint, 2009). However, 
Porphyromonas spp. and Prevotella spp. also produce butyrate [(Sawyer et al., 1962, McKee et al., 
1986), see Section 1.2]. Also, emerging evidence indicates lactate is preferentially oxidised by 
neurons, even in the presence of glucose (Wyss et al., 2011). It is possible lactate is produced in the 
small intestine by bacterial clades, including the Lactobacilli, before absorption, transport in the 
bloodstream and oxidation by neurons. 
The microbial inhabitants (Lathrop et al., 2011), B. fragilis (Round and Mazmanian, 2010) 
and Clostridium spp. (Atarashi et al., 2011) stimulate the development of T-regulatory cells (Tregs). 
More recently, bacterial fermentation products have been shown to stimulate the development of 
Tregs (Arpaia et al., 2013, Smith et al., 2013). In Tregs isolated from mice, butyrate enhances surface  
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Figure 1.4: Simplified schema of microbial carbohydrate catabolism, showing fermentation 
(glycolytic/pentose phosphate pathways), portions of the TCA cycle (boxed) and excreted end 
products (from Macfarlane and Macfarlane, 2003). PEP=phosphoenolpyruvate. Note the redox cycle 
of NAD+/NADH, largely driven by glycolysis and TCA cycle, which is relevant to the activation of 
metronidazole. 
 
expression of Foxp3 protein through the intronic enhancer conserved non-coding sequence 1 (CNS1) 
(Zheng et al., 2010, Arpaia et al., 2013) which in turn is proposed to dampen the immune response. 
Propionate dampens the capacity of dendritic cells to drive extrathymic Treg development, probably 
through inhibition of histone deacetylase (EC 3.5.1.98) (Arpaia et al., 2013). Since Tregs limit the 
immune response in the intestine (Josefowicz et al., 2012), microbes in the gut indirectly modulate 
the immune response through butyrate and propionate production. SFB, noted above to inhabit 
‘privileged’ sites adjacent to the mucosa, also induce CD4+ T-helper (Th) cells in a mono-associated 
mouse model (Ivanov et al., 2009). Induction of these Th cells results in cell lineages in the lamina 
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propria producing interleukins 11 and 17, increasing expression of genes associated with 
inflammation (Ivanov et al., 2009). Lastly, in mice, B. fragilis produces sphingolipids that inhibit 
invariant natural killer T cells (iNKTC), limiting proliferation of these cells during infant development 
and reducing adult colonic iNKTC populations. This could limit autoimmune disorders mediated by 
overactive iNKTC responses (An et al., 2014). 
 
1.1.3 Dysbiosis of the gut 
As noted above, the healthy epithelium of the large intestine is lined by colonocytes, over 
which lies a sheath of tightly packed mucus generally harbouring low numbers of microbes. 
Degradation of the underlying mucus and mucosa (in the large intestine) of the gastrointestinal tract 
as a result of inflammation and microbially produced effectors, is a common feature of ulcerative 
colitis (primarily of the large intestine) and Crohn’s disease (occurs throughout the gastrointestinal 
tract). Notably, Enterobacteriaceae (typically E coli) are typically enriched during IBD (Darfeuille-
Michaud et al., 1998, Frank et al., 2007, Baumgart et al., 2007), often at the expense of 
Bacteroidetes (Chang et al., 2008). Proponents of the so-called ‘like with like’ hypothesis suggest 
that a ‘bacterial bloom’, or overgrowth of a particular clade, is most likely to occur when genera are 
related (Stecher et al., 2010). For example, mice harbouring large populations of Proteobacteria are 
more susceptible to infection with Salmonella enterica and Campylobacter jejuni (Stecher et al., 
2010, Haag et al., 2012). However, Proteobacteria such as E. coli have a rapid growth capacity similar 
to genera within the Clostridia (see Chapter III). Therefore, it is likely that the Proteobacteria phylum 
is normally suppressed in the gut and the capacity for a new member of the Proteobacteria to 
colonise or expand is due to the failure of this mechanism/s. Alternatively, degradation of the 
intestinal epithelium may provide molecules (tetrathionate, S4O62-) permitting anaerobic respiration 
unique to members of the Proteobacteria (Winter et al., 2010).  
Transplant from a ‘healthy’ human donor reduces active inflammation in recipients, 
suggesting at least in some instances, inflammation is mediated by resident microbes (Eiseman et 
al., 1958, Bennet and Brinkman, 1989). It is unclear to what extent the replacement of a dysbiotic 
community with a healthy transplant remediates an inappropriate immune response by the host or 
the function of the dysbiotic community. Also, the inoculating-microbe/s required to ameliorate 
inflammation remains poorly defined. However, a diverse mixture of six bacteria (Staphylococcus 
warneri, Enterococcus hirae, Lactobacillus reuteri, with three novel isolates: Anaerostipes sp., 
Bacteroides sp. and Enterorhabdus sp.) cultured from mice, displaced an epidemic strain of 
C. difficile (027/BI) in a murine model of persistent disease and also increased bacterial diversity 
Chapter I   Introduction 
10 
(Lawley et al., 2012). A recent model has also implicated a murine Lachnospiraceae isolate in 
reduced C. difficile colonisation and associated colonic degradation (Reeves et al., 2012).  
Some explanations of how the mucus layer and underlying cells are degraded involve 
modulation of host immune response by changing cell surface ligands and the excretion of microbial 
effectors. For example, metalloproteinase 60 (M60-like) peptidases which degrade mucins, are 
present in many bacteria, including representatives within the Firmicutes, Bacteroidetes and 
Proteobacteria (Nakjang et al., 2012). The metalloprotease YghJ is secreted by enterotoxigenic 
Escherichia coli, facilitating delivery of heat labile toxin and heat-stable toxin to receptors of 
intestinal enterocytes, disrupting fluid homeostasis (Luo et al., 2014). Another example is the 
overgrowth of C. difficile and release of the AB toxin associated with pseudomembranous colitis and 
toxic megacolon. While C. difficile and M60-like proteinase generating bacteria are associated with 
inflammatory bowel diseases, other bacteria also contribute to inflammation, by production of 
effectors that cross mucus barriers, contacting host immune cells. In a mouse model, double 
mutants of T cell serine/threonine kinase TGFβRII receptor and interleukin-10 receptor 2 (IL-10R2) 
developed microbially driven spontaneous colitis, indicating a partial role for these receptors in 
reducing intestinal inflammation (Kang et al., 2008). Re-inoculation of Bacteroides spp. (Bacteroides 
vulgatus, Bacteroides TP5 and B. thetaiotaomicron), enriched from mice by selective antibiotics into 
this model also drove inflammation, similar to the full microbial assemblage (Bloom et al., 2011). 
More recently, mutant B. thetaiotaomicron, deficient in sulfatase maturation enzyme (anSME) and 
therefore sulfatase production, colonised although did not induce inflammation in the double 
knockout mouse model (Hickey et al., 2015). The investigators proposed sulfate-containing outer 
membrane vesicles (OMV) mediate degradation of host mucins and also activate underlying immune 
cells, including macrophages (Hickey et al., 2015). These results are a reminder that the function of 
B. thetaiotaomicron, normally considered a symbiotic organism (Goodman et al., 2009), is 
dependent on context. 
 
1.1.4 Factors impeding the study of the gut, future directions and 
therapeutic strategies 
Explaining why extreme microbial diversity (and function) is supported, characterising the 
interplay between tolerance, nutrient exchange and immune function, periodicity of microbial 
populations and how a healthy intestinal microbiota shifts towards dysbiosis continues. Several 
questions remain, for example, does the spatial segregation of certain microbes indicate a 
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mutualism, parasitism or ‘tolerance’ with the host? Also, why do low abundance clades maintain 
long-term residence? Some of the technical hurdles in further understanding of the human 
gastrointestinal tract include the complexity of the harboured microbes, with inter-individual 
differences not only in numbers at phylum resolution, but also at strain and sub-strain resolution. 
Further, molecular profiling techniques based on ribosomal signatures such as those in 16S rDNA, 
provide a taxonomic framework to assess microbial populations, which may not concur with 
function per se. For example, the Clostridia are a phylogenetically (Collins et al., 1994) and 
metabolically (Seedorf et al., 2008) diverse clade, yet they are grouped together as a class. Indeed, 
taxonomic frameworks ignore functional redundancies. The abundance of a particular clade does 
not necessarily have a relationship to magnitude of interaction with the host or other microbes. 
Also, the contribution of other domains and their viruses is another appreciable layer of complexity. 
Lastly, distinguishing between causality and epiphenomena is difficult amongst such complexity. 
Dealing with such complexity requires a careful choice of model systems.  
Regardless of these impedances, progress has been made. Germ-free animal models in 
which the absence of detectable harboured life results in poorly developed organs and a poor 
immune response to stimuli, suggest that gut microbes are so ingratiated in the biology of their host 
that they are now essential for proper development. Introduction of particular microbes into germ-
free animals, termed gnotobionts (with defined inhabitants), may be used to infer interactions 
between host and introduced microbes, such as the augmentation of nutrient uptake or other 
molecules that are traded. Such models have been used to define trade between species of bacteria 
(Mahowald et al., 2009) or have been used to understand the capacity of a particular bacterium to 
modulate an immune response, as discussed above. However, making inferences from such models 
may be difficult, since both introduced microbes and host may differ from ‘normal’ animals in which 
the full microbiota is present (Freter et al., 1983a). 
These vagaries make it difficult to modulate the microbiota in a rational way. For example, 
modulation of resident human gut microbes or their function with probiotic (live) strains of bacteria 
may be hampered by poor uptake of introduced strains. Faecal transplants, in which stools from 
healthy donors are used to replace the microbiota in unhealthy recipients have had some success, 
however these remedies remain crude, without an understanding of the specific microbes that 
remediate inflammation, nor how or where introduced microbes colonise. Ironically, without an 
understanding of the specific bacteria involved in dysbiosis, phage therapy, which relies of the 
recognition of specific receptors to target prokaryotes, may be too specific. However, the discovery 
that a murine RNA norovirus supports intestinal homeostasis in the absence of bacterial inhabitants, 
provides an intriguing therapeutic strategy (Kernbauer et al., 2014). Lastly, antibiotics are also 
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problematic, often targeting broad groups of bacteria, impairing or killing non-target microbes, 
which may result in overgrowth of undesirable bacteria. 
 
1.2 An overview of the Bacteroidetes phylum  
The Bacteroidetes are a clade (phylum) of Gram-negative nanaerobes, including Bacteroides, 
Prevotella, Porphyromonas and Rikenella which are genera that inhabit the human gut and the 
mouth (only Prevotella and Porphyromonas). Aerobic genera of the Bacteroidetes include 
Cytophaga, Flavobacteria and Salinibacter, which dwell in soil, freshwater and oceans. Several 
changes to classification of these bacteria have been made over time. Most recently the human 
associated strains were split based on capacity to ferment saccharides. Prevotella may be highly 
fermentative (such as P. melaninogenica), intermediate (such as P. intermedia) or unlike the 
Bacteroides have little or no fermentative capacity, including the porphyromonad P. gingivalis (Shah 
and Williams, 1987). 
Early growth curve studies established that Bacteroides tend to have relatively simple 
nutritional requirements including ammonia (NH3), which rather than amino acids supplies nitrogen 
(Varel and Bryant, 1974), a fermentable carbohydrate (such as glucose), sodium (~1mM) (Caldwell 
and Arcand, 1974), cysteine and sulfide (S2-) which serve as sources of sulfur (Varel and Bryant, 1974, 
Thauer, 1988). Sulfite (SO32-) and sulfate (SO42-) are not metabolised (Varel and Bryant, 1974). In the 
absence of methionine, a source of B12 is required for some, but not all Bacteroides (Varel and 
Bryant, 1974). Vitamin B12 acts as a cofactor for methyl-malonyl-CoA mutase, catalysing the 
isomerisation of methylmalonyl-CoA to succinyl-CoA. Also methionine synthase catalyses methyl 
group addition to homocysteine, forming methionine. Bacteroides spp. have the most diverse and 
largest number of genes encoding polysaccharide cleavage enzymes, largely homologous to the 
starch utilisation system of B. thetaiotaomicron (Salyers et al., 1977a, Salyers et al., 1977b, Martens 
et al., 2008). The monomers of a wide variety of plant polysaccharides that humans are unable to 
cleave (Martens et al., 2008) are fermented and funnelled into the TCA cycle, the products of which 
are fumarate and malate, or succinate (in the presence of porphyrin) and propionate (if B12 is 
present) (Macy et al., 1975, Macy et al., 1978). Bacteroides also produce acetate and D-lactate (Macy 
et al., 1978) and tend to be weakly proteolytic (Moore and Holdeman, 1972). Interestingly, the 
Bacteroides encode oxidative and reductive portions of the TCA cycle, although use of the reductive 
portion requires a source of porphyrin (see Section 1.3.2 for an overview). Aconitase, an enzyme of 
the oxidative portion of the TCA cycle of B. fragilis (and other Bacteroides) has high homology to 
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human mitochondrial aconitase, suggesting that enzymes of the TCA cycle may have a common 
ancestor (Baughn and Malamy, 2002). Also, interestingly, the ribosomal binding site and 
transcription machinery differ from that used by the canonical Shine-Dalgarno sequence (5’-
AGAAAGGAG) (Wegmann et al., 2013). 
As mentioned, Prevotella and Porphyromonas are considered to be intermediate- or non-
fermentative. In intermediate-fermentative strains, such as P. melaninogenica, radiolabelled 
aspartate is oxidatively deaminated, forming oxaloacetate, which is then reduced via fumarate 
reductase, forming succinate (Wong et al., 1977). Aspartate may also be deaminated by 
P. melaninogenica, forming fumarate (Wong et al., 1977), a reaction suggested to be shared by 
P. gingivalis (Dashper et al., 2009). Notably, in contrast to current views that butyrate production is 
limited to Firmicutes (Louis and Flint, 2009), assacharolytic members of Prevotella and 
Porphyromonas genera produce butyrate (Sawyer et al., 1962, McKee et al., 1986), probably via the 
crotonyl-CoA pathway, a metabolism requiring exogenous porphyrin (Dashper et al., 2009). 
Fermentative strains produce acetate and lactate, whilst non-fermentative strains catabolise 
peptides, largely forming butyrate and propionate (Sawyer et al., 1962). The finding that Prevotella 
and Porphyromonas spp. invariably produce H2S, suggests they might have a functional dissimilatory 
sulfur-type metabolism (Sawyer et al., 1962). Oral Prevotella spp. tend to be slightly more 
proteolytic, degrading collagen (Sawyer et al., 1962). Growth curves and radiolabelled tracing studies 
indicate Bacteroides, like Prevotella and Porphyromonads tend not to encode the capacity to 
synthesise porphyrin (Macy et al., 1975, Macy et al., 1978, Caldwell and Arcand, 1974, Sperry et al., 
1977, Lev et al., 1971, Rizza et al., 1968, Gibbons and Macdonald, 1960, Paramaesvaran et al., 2003), 
yet fumarate reductase, which requires a source of porphyrin for incorporation into a b-cytochrome 
linked FRD is conserved in these genera (Shah and Gharbia, 1993). These Bacteroidetes therefore 
generally take up exogenous porphyrin. 
Being porphyrin auxotrophs, it is unsurprising that many of the virulence mechanisms of the 
the assacharolytic porphyromonads are haem-dependent. For example, a P. gingivalis mutant 
deficient in haem uptake upregulated extracellular membrane vesicles and was more virulent in a 
mouse periodontal model than the parental strain (Genco et al., 1995), again indicating haem (and 
other tetrapyrrole) limitation may lead to tissue damage. Other investigators have demonstrated 
that extracellular vesicles are highly proteolytic (Grenier and Mayrand, 1987), degrading tissue 
proteins, including collagen (Smalley and Birss, 1987, Smalley et al., 1988), immunoglobulin A and 
immunoglobulin G (Grenier et al., 1989). Being 50-200 nm in size, released vesicles could diffuse to 
regions inaccessible to P. gingivalis and contribute to degradation of the epithelial barrier. Also, 
under high haem P. gingivalis displays multiple penta- and tetra- acetylated lipid A structures (Al-
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Qutub et al., 2006). In contrast, under low haem, one major penta-acetylated lipid A structure is 
displayed. The low haem penta-acetylated lipid A functions as a Toll-like receptor 4 agonist (Al-
Qutub et al., 2006), promoting E-selectin expression on human endothelial cells (Reife et al., 2006). 
In contrast, high haem associated tetra acetylated lipid A is a TLR4 antagonist (Coats et al., 2005, 
Reife et al., 2006), expected to dampen this innate immune response. 
 
1.3 The biosynthesis, uptake and use of tetrapyrroles 
1.3.1 Tetrapyrrole biosynthetic pathways 
Tetrapyrroles form the backbone of the ordered extraction of chemical energy (life); from 
maintenance of the proton motive force (cytochromes), assimilatory sulfur and nitrogen metabolism 
(haems), extraction of electrons from water (chlorophylls) and oxygen carriage 
(haemoglobin/myoglobin). Indeed, the co-option of chlorophyll by cyanobacteria, initiated the great 
oxygenation event (circa. 3.2 billion years ago), converting electromagnetic radiation into chemical 
energy (ATP), shaping biological systems henceforth. Tetrapyrrole structural and functional diversity 
in various life forms is not surprising given the relative ease of formation with gamma radiation 
(Szutka et al., 1959) visible/ultra violet light (Szutka, 1964) and heat (Hodgson and Baker, 1967). How 
the genes for tetrapyrrole biosynthesis arose remain mysterious, however, the formation of ionic 
water-soluble precursors, steadily modified into hydrophobic molecules that aggregate, agrees with 
the Oparin-Haldane hypothesis for genesis of life (Mauzerall, 1992). 
Tetrapyrroles, as the name indicates, consist of four pyrroles, tethered by four methene 
bridges in a linear or cyclic fashion. Each pyrrole is 5-membered, consisting of 4 carbon atoms and a 
nitrogen with a lone pair of electrons. The lone pair of electrons on the inner nitrogen atoms allow 
chelation of metals with varying valencies, which in biological systems is typically magnesium, cobalt, 
nickel and iron. For example, haem (iron-protoporphyrin IX), the prosthetic group of several 
proteins, cycles between Fe2+ (ferrous) and Fe3+ (ferrous) oxidation states, allowing the carriage and 
release of an electron, depending on the local pH and other physicochemical parameters. Being 
aromatic (with 26 delocalised elections) porphyrins exhibit 5 absorbance peaks, one broad peak in 
the Soret region (around 400nm), followed by four additional shoulder peaks at higher wavelengths. 
The addition of light to the soret peak or q-band peaks, results in an emission of photons at a higher 
wavelength (typically within 20 nm) and depending on the porphyrin, also between 607-625 nm. 
Whether metallated or not, porphyrins absorb in the Soret region. When metallated, porphyrins 
display reduced emission during excitation (Das, 1972).  
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The canonical eight-enzyme tetrapyrrole biosynthesis pathway, in which protoporphyrin IX is 
metallated with iron to form haem b, mostly studied in Escherichia coli (a Gammaproteobacteria) 
and Bacillus subtilis (a Firmicute), has been commonly adopted by metazoans. In the first of eight 
steps, 5-aminolevulinc acid (ALA) is synthesised via two routes. The first (route I, Fig. 1.5), using one 
enzyme, is present in humans and some Alphaproteobacteria (Panek and O'Brian, 2002). The 
majority of plants and metazoans synthesise ALA via route II (Fig. 1.5) (Dailey et al., 2015). Following 
ALA synthesis, two molecules of ALA are condensed into porphobilinogen, four of which are 
combined, forming the linear hydroxymethylbilane. The four pyrroles of hydroxymethylbilane are 
cyclised into uroporphyrinogen III. Uroporphyrinogen III is the first major branching point in the 
tetrapyrrole biosynthetic pathway. It was recently demonstrated that haem b may be synthesised 
via both deviations (see below). Next, in the canonical tetrapyrrole pathway, a series of de-
carboxylations and condensations of side chains occur, making the porphyrinogens less water 
soluble. Isomers and spontaneous oxidation products of uro- and copro-porphyrinogens are 
generated. Some of the enzymes in the canonical pathway are dissimilar, used during anaerobic 
(underlined), aerobic or both (bold) conditions (HemF/HemN and HemG/HemY/HemJ). Finally, 
oxidation of protoporphyrinogen occurs before ferrochelation to form haem b (Fig. 1.6). 
Interestingly, in metazoans, following the synthesis of ALA (route II of Fig. 1.5), condensation of 
propionate groups on coproporphyrinogen to vinyl groups and oxidation of protoporphyrinogen 
occurs in the mitochondria.  
An ‘alternative haem biosynthesis’ pathway (AhbA,B,C,D), originally described in the 
Deltaproteobacterium Desulfovibrio vulgaris (Ishida et al., 1998, Akutsu et al., 1993), has recently 
been confirmed in other denitrifying/sulfate-reducing bacteria as well as Archaea (Bali et al., 2011) 
in which haem b and haem d1 (the cofactor in dissimilatory nitrate reductase cd1 or NirS) are 
synthesised via precorrin-2 (Nir proteins). Also, in a recent addendum to the canonical porphyrin 
biosynthetic pathway, Firmicutes and Actinobacteria (Gram-positive bacteria unable to synthesise 
protoporphyrin) oxidise coproporphyinogen III forming coproporphyrin III (HemY), before iron 
insertion (HemH) and then carboxylation (HemQ) to generate haem b (Dailey et al., 2015). 
 
Figure 1.5: The two routes, ‘ALA synthase’ (I) and C5 (II) for ALA synthesis (ALA is shown in Fig. 1.6).  
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In the most comprehensive survey conducted (1606 genomes), haem b synthesis by the 
canonical pathway was present in approximately 50% of the Bacteroidetes and the alternative 
pathway (AhbA,B,C,D) was absent [(Sousa et al., 2013) and (Fig 1.7)]. The authors did not include 
specific details of the search strategy, nor were details given of subclades, including lifestyle (host 
associated or free living). A particularly scathing commentary was given regarding accuracy of the 
analysis (Ducluzeau et al., 2014), in part because the ‘HemQ’ pathway was discovered after the 
analysis was performed. Nevertheless, the study is currently the most inclusive overview of quinone 
and tetrapyrrole biosynthesis. In an analysis of the presence and absence of haem b synthesis (using 
refSEQ), none of the Bacteroidetes examined in this thesis synthesised haem b (data not shown). 
The ‘HemQ’ and alternative pathways, are limited to Firmicutes/Actinobacteria and most 
denitrifying/sulfate-reducing bacteria as well as Archaea. Therefore, it is likely that the true number 
of host-associated Bacteroidetes that synthesis haem b is lower than 50%, although a thorough 
analysis of the canonical haem b biosynthetic pathway in Bacteroidetes is required. Note also that 
the capacity to synthesis porphyrin by a particular bacterium does not mean that exogenous 
porphyrin is not taken up (Cavallaro et al., 2008). 
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Figure 1.6: Tetrapyrrole biosynthetic pathways. Dashed arrows represent summarised pathways. 
SAM=S-adenosyl-L-methionine). Only bacterial enzyme nomenclature is shown.  
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Figure 1.7: A summary of haem b ‘canonical’, ahbA-D (‘alternative’) and quinone biosynthetic 
pathways in Archaea (117 genomes) and Eubacteria (1489 genomes) from Sousa, 2013.  
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1.3.2 Bacterial tetrapyrrole acquisition systems 
Several strategies and receptors have been described for porphyrin uptake, most of which 
are described from Proteobacteria and focus on haem uptake, based on a persistent dogma that 
iron, rather than the porphyrin macrocycle per se, is required for growth. Gram-positive bacteria use 
several strategies for recognition and import of haem. For example, recognition and transfer of 
haem across the cell envelope of Staphylococcus aureus is mediated by IsdA/B/C/H; after which the 
ATP binding cassette transporters (ABC-transporters) IsdDEF (note that IsdE=HemT and Isdf=HemU) 
ferries haem into the cytoplasm, largely for degradation by the oxygenases IsdG/I (Grigg et al., 2007, 
Andrade et al., 2002, Pluym et al., 2008) and iron acquisition. Corynebacterium diphtheriae also uses 
an ABC-type transport system, encoded by hmuT/U/V (Drazek et al., 2000). Notably, haem has been 
demonstrated to passively diffuse across lipid bilayers in vitro. However, the outer membrane 
permeability in Gram-negative bacteria is less than 600 daltons, so this is unlikely to be a mechanism 
for tetrapyrrole assimilation (Genco and Dixon, 2001). 
A common strategy used by Gram-negative bacteria after recognition of haem, is TonB-
dependent import through the periplasm, coupled to the ExbB/D import system (Higgs et al., 2002). 
Gram-negative bacteria also excrete haemophores, such as the HasA system of Serratia marscens, 
which then import haem from the periplasm into the cytoplasm with ABC transporters, much like 
those in Gram-positive bacteria (Izadi et al., 1997). In B. fragilis, an outer membrane protein and 
‘haem binding complex’ are implicated in haem uptake (Otto et al., 1991, Otto et al., 1994). In 
response to low haem, Prevotella intermedia expresses a high affinity receptor, depending on the 
strain, approximating 10-9 and 10-11 M Kd with around 4,000 binding sites per cell (Tompkins et al., 
1997). More recently, an outer membrane lipoprotein with high homology to P. gingivalis HmuY 
(PIN0009) and a homologue of the tonB-dependent outer membrane receptor used by various 
Gram-negative bacteria, including the HmuR receptor of P. gingivalis (PINA0611) were detected in 
P. intermedia grown with PPIX and the ferrous iron chelator dipyridyl (Yu et al., 2007). PINA0611 
product is predicted to function in a seven gene operon, which has recently been characterised in 
Capnocytophaga canimorsus, a Flavobacteriaeae within the Bacteroidetes phylum. The seven-gene 
polysaccharide utilization locus (‘PUL3’) encoded by C. canimorsus, has been shown to acquire iron 
from serotransferrin, although the authors suggested this operon does not facilitate haem uptake 
(Manfredi et al., 2015). Interestingly, the gene in the centre of this locus in P. gingivalis (hmuS) and 
P. intermedia (PIN0012) is annotated as a magnesium chelatase, while in C. canimorsus it is 
annotated as a methyl transferase (03660). In P. gingivalis and P. intermedia, it is likely these genes 
are misannotated and that this is in fact a magnesium chelatase subunit I. It is also possible the gene 
encodes a magnesium-protoporphyrin IX methyltransferase in C. canimorsus. 
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Several receptors for and types of tetrapyrroles recognised and imported are characterised in P. 
gingivalis, the growth of which is supported by a wide array of porphyrins, including protoporphyrin 
IX, plus the derivative deuteroporphyrin IX (PPIX without the vinyl groups) and mesoporphyrin IX, 
although not by protoporphyrin IV or chlorin E4 (Hunter et al., 2002, Paramaesvaran et al., 2003). 
Various modifications to the vinyl groups normally present on haem b supported growth, and 
although growth was not as well stimulated, modification to both propionic acid side chains, 
including deuteroporphyrin IX di-taurine amide stimulated improved growth relative to DMSO (Fig. 
1.8) (Paramaesvaran et al., 2003). Indeed, on the basis that various derivatives of the propionic acid 
side chains are recognised and imported by P. gingivalis, several amide and lysine linked 
deuteroporphyrin adducts were synthesised (see also Section 1.5), the majority of which were also 
taken up (Yap et al., 2009, Dingsdag et al., 2015). However, several of these adducts did not support 
growth, suggesting tetrapyrrole uptake receptors in P. gingivalis have a broader recognition of 
porphyrin derivatives that can be incorporated into b-cytochrome to enable fumarate reductase 
activity. 
The highest affinity receptors originally described in P. gingivalis under haem-depleted 
conditions approximated 0.4- 1 × 10 -12 M Kd for haem, with around 1,500 binding sites per cell, 
depending on the strain (Tompkins et al., 1997). The same study described a low affinity receptor, 
with a lower binding affinity for haem (0.2-7 × 10-8 M Kd), and around 1.5 × 105 binding cites per cell. 
The outer membrane haem-binding protein HmuY and associated receptor HmuR, appear to form an 
operon in P. gingivalis that is also conserved in B. thetaiotaomicron and B. fragilis (Olczak et al., 
2008). Also in P. gingivalis, Omp26 is a low affinity outer membrane protein, which binds haem 
before the protein-haem complex is imported (Bramanti and Holt, 1993). P. gingivalis also expresses 
on the outer membrane and secretes HusA, which has high affinity for haem (Gao et al., 2010). 
 
 
Figure 1.8: Haem b (A), deuteroporphyrin IX di-taurine amide (B) and P5 (C). 
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HusA may be the receptor originally described by Tompkins et al., 1997. As mentioned, uptake of 
haem and other tetrapyrroles is better characterised in Proteobacteria than Bacteroidetes, including 
the Bacteroides. While high affinity (approximating 10-10 Kd M or higher) tetrapyrrole receptors have 
yet to be described in Bacteroides, it is known that B. thetaiotaomicron encodes three B12 transport 
systems, BtuB1-B3, which have some specialisation and also duplication in the types of corrinoids 
recognised and taken up (Degnan et al., 2014). Given redundancy is a general feature of biological 
systems, it is possible that Bacteroides also express more than one high affinity porphyrin-uptake 
receptor, with similar redundancy and/or specialisation for porphyrin recognition. It is also possible 
the BtuB1-B3 recognise and mediate uptake of porphyrins. 
 
1.3.3 Respiration and the tricarboxylic acid cycle 
Over 200 years ago, Charles MacMunn described respiratory pigments, ‘myohematin and 
histohematin’ in animal tissue (Munn, 1886). Then in the 1920s, working with horse tissue, David 
Keilin renamed these respiratory pigments as cytochromes, classifying them as a, b or c type, 
depending on the type of haem (a, b, c and later d) molecule that was coordinated with proteins and 
which region of the visible light spectrum absorbed the most photons (Keilin, 1925). The 
cytochromes involved in this electron transport chain function in the inner mitochondrial membrane 
using oxygen as a terminal electron acceptor and with mediation by dehydrogenases, ubiquinone 
(coenzyme Q10) and menaquinone (K2) (Vos et al., 2012, Beyer, 1958). Soon after, Krebs described a 
series of cyclic reactions involving the complete oxidation of an unknown ‘triose’ 
(phosphoenolpyruvate) produced from the fermentation of sugars (glycolysis) or tricarboxylic acid 
cycle (TCA) (Krebs and Johnson, 1937). The TCA cycle, common in aerobic metabolism, oxidises 
acetate generated from carbohydrates, fatty acids and amino acids, giving rise to precursors for 
amino acids such as alanine, aspartate and glutamate. Operating in the mitochondria of metazoans, 
the TCA cycle also liberates NADH which is required for oxidative phosphorylation. The aerobic 
oxidation of NADH, which generates ATP, relies on electron transport phosphorylation (‘ETP’), using 
the proton translocating F1F0 ATPase (Thauer, 1988). 
As early as 1886, Hoppe-Seyler described the complete oxidation of cellulose in anaerobic 
sediments supplemented with CaSO4 (Hoppe-Seyler, 1886). The quantitative recovery of H2S, 
suggested the existence of an anaerobic electron transport chain. Then, work in the 1950s 
established the requirement for haem as a growth factor for Prevotella spp. (Evans, 1951). It was 
known that Prevotella spp. stored ‘haematin’ (ferric-PPIX) on the surface (Schwabacher et al., 1947) 
and it was postulated that haem was involved in an electron transport system, although the function 
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of this system was unknown (Gibbons and Macdonald, 1960). It was also known that photosynthetic 
(Vernon and Kamen, 1954), sulfate reducing (Postgate, 1954, Adams and Postgate, 1959) and other 
anaerobes used cytochromes (Hayward and Stadtman, 1959). However, it wasn’t until the 1960s 
that incorporation of haem b into a b-cytochrome, enabling fumarate reductase (FRD) activity, was 
described for Prevotella ruminicola (formerly Bacteroides ruminicola) (White et al., 1962). The use of 
FRD implied P. ruminicola was generating ATP by substrate level phosphorylation and also by 
anaerobic respiration (see Thauer et al., 1977 for an exhaustive review). Secondly, this implied 
succinate-forming members of the Bacteroidetes might also use b-cytochromes with a similar 
metabolism (Macy and Probst, 1979). 
Soon the first reductive (or reverse) tricarboxylic acid cycle (rTCA) was described in the 
anoxygenic photosynthetic bacterium, Chlorobium thiosulfatophium, that used reduced ferredoxin 
to drive CO2 assimilation, generate α-ketoglutarate, a precursor of the amino acids (glutamate, 
aspartate and alanine) and lipid precursors (Evans et al., 1966). The rTCA cycle used by 
C. thiosulfatophium is endergonic (requiring energy in the form of ATP), so must be linked with 
energy yielding (exergonic) reactions, supplied by photochemical production of ATP and reduced 
ferredoxin. The rTCA cycle is considered the precursor to the Krebs cycle (Buchanan and Arnon, 
1990). Portions of the rTCA cycle, particularly the reductive carboxylation of succinate to form α-
ketoglutarate, would later be found to be shared by the Bacteroidetes. 
The use of a b-cytochrome, forming a FRD, was later described in a diverse range of 
prokaryotes including: Bacteroidetes [Bacteroides spp. (Macy et al., 1975, Macy et al., 1978, Reddy 
and Bryant, 1967), Prevotella spp. (Rizza et al., 1968, Gibbons and Macdonald, 1960, Caldwell et al., 
1965) and Porphyromonas spp. (Shah and Williams, 1987, Dashper et al., 2009)], Firmicutes 
[Clostridium spp., (Gottwald et al., 1975), Selenomonas rumantium and Veillonella alcalescens (de 
Vries et al., 1974)] and Proteobacteria [Wollinella succinogenes (Reddy and Peck, 1978)]. The b-
cytochrome system in these bacteria employs two molecules of haem b as a prosthetic group, in 
concert with NADH, formate of H2 as an electron donor (Asanuma and Hino, 2000). Some 
Bacteroidetes maintain a portion of the oxidative (oTCA) and rTCA (as in Bacteroides) (Macy et al., 
1975, Macy et al., 1978, Baughn and Malamy, 2003), while other nanaerobes only encode a 
reductive portion (as in the majority of the Prevotella and Porphyromonas) (Shah and Gharbia, 1993) 
(Fig. 1.9). Parts of the rTCA performed by Bacteroidetes are similar to the full rTCA cycle employed 
by C. thiosulfatophium, including the incorporation (fixation) of CO2 into larger molecules.  
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Figure 1.9: rTCA (‘haem-dependent’) and oTCA (haem-independent) portions of the TCA cycle 
proposed in B. fragilis (from Baughn and Malamy, 2002). The use of the rTCA is broadly conserved in 
Bacteroidetes, whereas the oTCA is limited to the Bacteroides. 
 
The FRD of Bacteroides, Prevotella and Porphyromonas has high homology (see Chapter III 
and Appendix Table A4), consisting of three genes (frdC, frdA and frdB). In B. fragilis frdC encodes 
the b-cytochrome with five inner-membrane spanning helices that coordinate two molecules of 
haem. Two of these helices anchor an iron sulfur cluster encoded by frdB and a third unit, frdA, 
encodes a flavoprotein (Baughn and Malamy, 2003). In Bacteroides, exogenous haem is used for b-
cytochrome formation enabling FRD activity (Macy et al., 1975, Macy et al., 1978, Allison et al., 1979, 
Baughn and Malamy, 2003). FRD couples the two electron reduction of fumarate with NADH or H2, 
using menadione (vitamin K2) and membrane bound dehydrogenase/s, yielding succinate (Macy et 
al., 1975, Reddy and Harris, 1976, Macy et al., 1978). The reduction of fumarate to succinate is likely 
to occur in the cytoplasm, coupled with the cyclic re-oxidation of menaquinol (MQH2) to 
menaquinone (MQ) and oxidation of NADH2 to NAD+ in the periplasm (Kotarski and Salyers, 1984, 
Kröger et al., 1992). This system will be coupled to proton or Na+ export across the inner membrane 
into the periplasm, creating chemiosmotic potential for phosphorylation of ADP (ATP formation) 
(Kröger et al., 1992). An F-type ATPase in B. fragilis may mediate this system (Baughn and Malamy, 
2003), and is likely to be employed by other Bacteroides. More broadly, FRD plays a role in the 
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reductive portion of the tricarboxylic acid cycle (rTCA), permitting redox maintenance (NAD+ 
regeneration) and through reductive carboxylation of succinate, forms α–ketoglutarate, the 
precursor of glutamate, arginine, proline and aspartate (Allison and Robinson, 1970, Macy et al., 
1975, Macy et al., 1978). In Bacteroides exogenous supplementation of porphyrin enabling FRD, 
permits the extraction of more than double the amount of ATP per molecule of glucose than in the 
absence of glucose (Macy et al., 1975, Macy et al., 1978, Sperry et al., 1977). The presence of an 
oxidative portion of the TCA cycle, as demonstrated in B. fragilis (Baughn and Malamy, 2002), might 
obviate the need for external porphyrin supplementation. The absence of the oTCA pathway might 
explain porphyrin auxotrophy of various Prevotella and Porphyromonas spp. (Allison and Robinson, 
1970). 
In the initial report of a b-cytochrome in Prevotella ruminicola, an ‘o type’ (oxidase) was also 
described (White et al., 1962). Soon after, an o-type cytochrome was described in B. fragilis (Reddy 
and Bryant, 1967). It was known that B. fragilis and Clostridium perfringens, as well as other 
‘anaerobes’ tolerated oxygen (Rolfe et al., 1977, Rolfe et al., 1978). It was also known FRD functions 
as a succinate oxidase (Kotarski and Salyers, 1984, Baughn and Malamy, 2003). More recently, under 
low (nanomolar) concentrations of oxygen, it was demonstrated that one of the FRD components 
(FrdC) of B. fragilis appears to couple succinate oxidation to reduction of O2 via a cytochrome bd 
oxidase (CydAB) (Baughn and Malamy, 2004). The oxidation of succinate to fumarate by FRD 
represents a thermodynamic barrier [fumarate/succinate (E’0 = +30mV)], requiring a terminal 
electron acceptor with a more positive (E°’) redox potential than that of fumarate/succinate couple, 
such as electron acceptors used by aerobes (including O2/H2O: E°’=+818mV and NO3-/NO2-: 
E°’=+433mV) (Thauer, 1988). Sulfur, sulfate and thiosulfate would also suffice in some anaerobes as 
a terminal electron acceptors (Thauer, 1988). In P. gingivalis, CydAB may also link the oxidation of 
succinate to fumarate via low concentrations of oxygen (Meuric et al., 2010). However, this model is 
based on studies of Desulfovibrio gigas, and has not been experimentally verified. During haem 
limitation, a slight reduction in FrdB and FrdA were observed for P. gingivalis, although not FrdC 
(Dashper et al., 2009), which is in keeping that FrdC is involved in an electron transport chain 
involving limited oxygen (CydA and CydB) (Meuric et al., 2010, Baughn and Malamy, 2004). 
Interestingly, in P. gingivalis, the F-type ATPase is absent, (Meuric et al., 2010), instead an operon of 
the V-type ATPase is present (Nelson et al., 2003). Since some Prevotella and Porphyromonas spp. 
produce H2S (Sawyer et al., 1962), it is also possible these strains use sulfur, sulfate and thiosulfate 
as electron acceptors in this pathway. 
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1.4 Microbial metabolism and nitroimidazole reduction 
(activation) 
This thesis reviews the history, use and cytotoxicity of metronidazole with reference to other 
nitroimidazoles where relevant. Despite more than 60 years research, the metabolism of 
metronidazole and associated cytotoxicity is not definitively characterised. Nitroimidazoles are 
prodrugs that are reduced (activated) under anaerobic conditions. There is divided opinion regarding 
the enzymes responsible for reduction of nitroimidazole prodrugs. It also remains unclear if 
nitroimidazole reduction (activation) is a primary cytotoxic process, or whether subsequent 
fragmentation of the imidazole ring and formed metabolites alone mediate the cytotoxicity (Church 
et al., 1988, Tally et al., 1978, Church and Laishley, 1995). Lastly, the presence of oxygen reduces the 
effectiveness of nitroimidazole activation, confounding study of these prodrugs. 
For purposes of clarity, in this review the metabolism of metronidazole is divided into the 
synthesis of azomycin, the natural precursor of metronidazole (Section 1.4.1), the structure and use 
of nitroimidazoles (Section 1.4.2), nitroimidazole activation (reduction) and associated primary 
effects on microbial metabolism (Section 1.4.3). The structural basis of metronidazole fragmentation 
and cytotoxicity of reduced fragments of metronidazole are also discussed (Section 1.4.4). Lastly, 
resistance to metronidazole is reviewed (Section 1.4.5). The current understanding of metronidazole 
metabolism is described in detail since the reduction of the nitro group appended to 
deuteroporphyrin adduct characterised in this thesis is predicted to be similar to the reduction of 
metronidazole and other nitroimidazoles.  
 
1.4.1 Biosynthesis of azomycin the biotic precursor of metronidazole 
Metronidazole is a bactericidal synthetic derivative of azomycin, originally detected during 
the 1950s from cultures of Streptomyces spp. (Maeda et al., 1953). Azomycin is largely produced by 
Actinobacteria including Streptomyces (Lancini et al., 1966, Lancini et al., 1968) such as 
Streptomyce eurocidicus (Osato et al., 1955) and Nocardia mesenterica (Nocardiaceae) (Okami et al., 
1954, Maeda et al., 1953). Cultures of Proteobacteria (Pseudomonas fluorescens) also produce 
azomycin (Shoji et al., 1989). In S. eurocidicus, 2-aminoimidazole, the precursor of azomycin, is 
considered to be a metabolic product of L-arginine. The proposed metabolism involves three steps, 
forming 2-aminoimidazole (Fig. 1.10, compound I) before a final oxidation of 2-aminoimidazole to 2-
nitroimidazole (Fig. 1.10, compound II) (Nakane et al., 1977). The reaction is localised to the  
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Figure 1.10: The proposed final step of ‘azomycin’ (2-nitroimidazole, compound II) synthesis in 
S. eurocidicus. The ‘oxygenase’ may be AurF or a homologue. Note that unlike the natural precursor 
azomycin, metronidazole (compound III, shown for reference purposes) contains a hydroxyethyl 
group at position 1, a methyl group at position 2 and a nitro group at position 5 (and not position 2) 
of the imidazole. 
 
mycelium of S. eurocidicus (Seki et al., 1970). In Streptomyces thioluteus, the oxidation of various six-
membered aromatic rings containing nitro groups, for instance p-aminobenzoate to p-nitrobenzoate 
of the antibiotic aureothin, involves the oxygenase AurF in a reaction requiring oxygen (Kawai et al., 
1965, Krebs et al., 2007). 
In Bacillus subtilis (an aerobe) and Escherichia coli (a facultative anaerobe) of the Firmicutes 
and Proteobacteria phyla respectively, it has been suggested that azomycin inhibits ribonucleotide 
reductase (‘RNR’, EC 1.17.4.1) (Saeki et al., 1974). Ribonucleotide reductases are conserved in all 
domains of life, catalysing the reduction of the four ribonucleotide diphosphates (NTPs) to 
corresponding deoxyribonucleotide triphosphates (dNTPs) the precursors of deoxyribonucleotides 
(DNA) that allow DNA synthesis and repair (Torrents, 2014). Inhibition of RNR should prevent DNA 
repair and prevent synthesis of DNA during replication. The possible inhibition of RNR by 
nitroimidazoles is discussed in more detail in Section 1.4.3. It is interesting that azomycin is 
produced by soil dwelling microbes such as Streptomyces, since azomycin presumably inhibits DNA 
replication in bacteria that produce this metabolite. It is possible that during nutrient and/or water 
depletion, azomycin may encourage spore formation in Streptomyces.  
 
1.4.2 The structure and use of nitroimidazoles 
 As indicated by the nomenclature, 5-nitro antibiotics share a nitro functional group (-NO2) at 
the fifth position of a planar 5-membered ring, with a nitrogen (nitroimidazole), oxygen (furan) or 
sulfur (thiazole) at position 1. A variety of side chains may be appended to the imidazole, such as the 
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methoxy-propanol (misonidazole), hydroxy-ethyl (metronidazole), and ethyl-amine (‘metronidazole-
amine’) (Fig. 1.11). The heterocycles are aromatic, sharing a conjugated system of single and double 
bonds, in which a lone pair of electrons from the nitrogen, oxygen or sulfur is delocalised in the ring. 
The nitro group of these prodrugs is required for cytotoxicity [imidazole, 2-imidazole and the amino-
derivative of metronidazole are inactive (see compound V of Fig 1.12 for structural details) (O'Brien 
and Morris, 1971, Ehlhardt et al., 1987). 
Metronidazole was originally used against the anaerobic protozoan Trichomonas vaginalis. It has 
since been used against other protozoa, including Entamoeba histolytica (amoebic dysentry) and 
Giardia lamblia (giardiasis). However, it wasn’t until 1962 during treatment for bacterial vaginitis, 
that it was realised that metronidazole also treated bacterial gingivitis in the same patient (Shinn, 
1962), making in-roads for the eventual use against other nanaerobic bacteria, such as in the 
treatment of a suite of acute and chronic inflammatory bowel diseases. Despite the diversity in 
physiology and life cycles of the nitroimidazole-sensitive organisms listed above, nitroimidazoles 
cross these taxonomic boundaries because these organisms occupy niches with low oxygen tension 
that allow reduction of the nitro group. Under conditions favouring aerobic respiration 
nitroimidazole prodrugs are ineffective; these prodrugs are either not reduced (activated) or oxygen 
prevents full reduction of the nitro group and generation of cytotoxic metabolites. 
Notably, nitroimidazoles have also been demonstrated both in vitro and in vivo to act as 
radiosensitizers for cancerous cells (Asquith et al., 1974, Begg et al., 1974, Mohindra and Rauth, 
1976). In an in vitro model, high concentrations of metronidazole (10 mM) have been shown to 
inhibit colony formation in Chinese hamster ovary cells (Ehlhardt et al., 1988). Introduction of E. coli 
nitroreductase (nfsB) as an expressed transgene in zebrafish, leads to death of targeted cells  
(Curado et al., 2008). NfsB is an oxygen-insensitive nitroreductase, predicted to catalyse the 
 
Figure 1.11: Misonidazole, metronidazole and ‘metronidazole-amine’: a variety of aromatic 
nitroimidazoles sharing the common nitro functional group (-NO2) at position two or five of the 
imidazole. Note that ‘metronidazole-amine’ linked to deuteroporphyrin forms P5. 
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reduction of the nitro group of metronidazole to the amino derivative that whilst non-toxic for 
bacteria, may be toxic for mammals by further non-enzymatic activation with thioesters (Knox et al., 
1993). Mammalian selenoprotein thioredoxin reductase (TrxR) catalyses the 1- and 2-electron 
reduction of various poly-and mono- nitroaromatic compounds (Cenas et al., 2006). Mammalian 
NAD(P)H:quinone reductase (DT-diaphorase) also catalyses the 1-electron reduction of mono-
nitroaromatic compounds (Knox et al., 1993). The reductive activation of nitroaromatic compounds 
such as metronidazole is inhibited by the presence of oxygen which is why these compounds are 
only reduced to cytotoxic intermediates under hypoxic conditions (see in Section 1.4.3). 
Interestingly, nitroimidazoles have a structural similarity to uncouplers of oxidative phosphorylation 
[reviewed in (Terada, 1990)], containing an electron withdrawing (nitro) group, a weak acid 
(hydroxethyl) and a hydrophobic ring (imidazole). It is possible that before reductive activation and 
cleavage, nitroimidazoles oscillate between the inner- and outer-mitochondrial membrane. The 
serial protonation and de-protonation of the hydroxethyl functional group could then dissipate the 
proton gradient. 
 
1.4.3 Primary effects on microbial metabolism of the uptake and reductive 
activation of metronidazole  
A receptor for metronidazole uptake has not been described and uptake is considered a 
passive process. However, nitro group reduction and associated cytotoxicity is correlated with the 
rate of metronidazole uptake (Narikawa, 1986) indicating uptake is not passive. Indeed, the 
oxidative phosphorylation inhibitor, carbonyl cyanide m-chlorophenyl hydrazone (CCCP) slows 
metronidazole uptake in Helicobacter pylori and Clostridium pasteuranium suggesting uptake is 
dependent on a proton gradient (Moore et al., 1995, Church and Laishley, 1995). This gradient is 
probably dependent on electron transport since uptake is also inhibited by potassium cyanide and 
oxygen (KCN) (Moore et al., 1995, Church and Laishley, 1995). The concentration of sucrose is also 
correlated with metronidazole uptake (Church and Laishley, 1995). Inhibitors of glycolysis (sodium 
fluoride, arsenate and iodoacetic acid) also slow uptake of metronidazole (Nseka and Müller, 1978, 
Church and Laishley, 1995). Uptake is rapid in Clostridium spp., Trichomonads and Entamoeba 
(Obrien and Morris, 1972, Church et al., 1988, O'Brien and Morris, 1971); intermediate in 
Fusobacteria spp. and slowest in Bacteroides spp. (Narikawa, 1986). Other than E. coli and 
Enteroccocus faecalis, few facultative anaerobes take up metronidazole (Tally et al., 1978, Müller, 
1983, Narikawa, 1986). 
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Metronidazole is inert until taken up. Reduction of the nitro group of metronidazole occurs by two 
routes, with important ramifications for cell survival. Reduction of the nitro group may lead to 
activation of metronidazole resulting in imidazole fragmentation and cytotoxicity or inactivation of 
the nitro group to the non-toxic amino derivative (see overview in Fig. 1.12). The inactivation of 
metronidazole to the non-toxic amino derivative is associated with metronidazole resistance and is 
also discussed in Section 1.4.5. The reductive activation of metronidazole consumes 4-electrons and 
is proposed to occur in a series of 1- or 2-electron steps, leading to ring-fission and formation of 
transient cytotoxic derivatives (Church et al., 1988, Peterson et al., 1979, Lockerby et al., 1984). It 
has been proposed that the reductive activation of metronidazole exerts a primary cytotoxic effect, 
since metronidazole acts as an alternative electron acceptor, inhibiting the proton motive force and 
diminishing ATP production (Tally et al., 1978, Church et al., 1988). The first step of the reductive 
activation of metronidazole is proposed to form the nitro free radical (Fig 1.12). Subsequent steps in 
the reductive activation are proposed to form the nitroso, nitroso free radical and hydroxylamine 
derivatives. Due to their unstable nature, the intermediates have not been isolated from a biological 
context. Given that intermediates have been poorly studied, it is possible other enzyme/s are 
involved in heterocycle fission. Oxygen has a higher affinity for electrons than metronidazole. In the 
presence of oxygen, the nitroso radical has been suggested to be reduced to form a superoxide 
anion; followed by removal of an electron from the nitroso radical by oxygen, regenerating 
metronidazole in a process called ‘futile cycling’ (Church and Laishley, 1995). The reductive 
inactivation of the nitro group to the stable amino-derivative by nitroreductases occurs in 2-electron 
steps, consuming 6-electrons rendering metronidazole inactive and is oxygen insensitive (Roldán et 
al., 2008). Reductive inactivation of metronidazole is discussed further under metronidazole 
resistance (Section 1.4.5). 
A thermodynamic logic was originally used to describe how metronidazole interferes with 
bacterial physiology, leading to the reduction of the nitro group and formation of cytotoxic products. 
The thermodynamic logic employs the oxidation-reduction potential (E0), or the tendency of a 
chemical to accept electrons to predict the flow of electrons between low redox potential molecules 
and their enzyme carriers. In order to understand the reductive activation of metronidazole and the 
thermodynamic logic of activation, it is useful to outline pertinent aspects of microbial metabolism. 
In nanaerobic bacteria, in the cytosol of giardia and amoeba and in the hydrogenosome of 
trichomonads (Müller, 1986, Edwards and Mathison, 1970), pyruvate is formed during glycolysis, 
with a net production of two molecules of ATP and NADH per saccharide molecule (for example 
glucose). Next fermentation occurs, during which pyruvate is oxidatively decarboxylated. The  
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A) Reductive activation
B) Reductive inactivation
 
Figure 1.12: The reductive activation of metronidazole leading to heterocycle fission, transient 
compound formation and cytotoxicity (A) or reductive inactivation of metronidazole forming the 5-
amino derivative (B). The reductive activation of metronidazole leading to cytotoxic derivative 
formation is hypothesised to occur via 1- or 2-electron steps forming transient intermediate 
compounds II – IV and fission of the heterocycle (marked with dashed lines in compound IV). Note 
compounds II – IV have not been isolated during biological reductive activation of metronidazole (A). 
The presence of oxygen is proposed to regenerate metronidazole in the so-called ‘futile cycle’ (A). 
Reductive activation of the nitro group leading to heterocycle fission (A) may be accomplished by 
redox transfer proteins, such as ferredoxin, acting either alone or in concert with hydrogenase, 
flavodoxin, and effectors of the dissimilatory sulphite pathway. The reductive inactivation of the 
nitro group to the 5-amino derivative (compound V) is proposed to occur in 2-electron steps by 
type I oxygen-insensitive nitroreductases, rendering metronidazole non-toxic (B).  
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oxidation of pyruvate is driven by pyruvate:ferredoxin oxidoreductase (‘PFOR’, EC 1.2.7.1) forming 
acetyl phosphate, liberating carbon dioxide, and in turn reducing ferredoxin. Electrons from reduced 
ferredoxin are coupled to the reduction of low redox potential molecules by hydrogenase 1 
(EC 1.12.1.1), an enzyme which couples hydrogen ions to these electrons, reversibly liberating 
molecular hydrogen (Müller, 1986) (Fig. 1.13). Normally, electrons flow from pyruvate/acetate and 
CO2 couple [E0’ = -700 mV, (Thauer et al., 1977)] through PFOR [containing three iron-sulfur (FeS) 
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Figure 1.13: Generalised schema of metronidazole reductive activation. One proposed metabolism 
involving hydrogenase is based on Church et al., 1988 (see other references in text). Some pathways 
are summarised by dashed arrows. PEP= phosphoenolpyruvate. During glycolysis, pyruvate is formed 
from the catabolism of saccharides such as glucose. During fermentation, electrons from pyruvate 
flow to ferredoxin, mediated by pyruvate:ferredoxin oxidoreductase (‘PFOR’). Reduced ferredoxin 
normally donates electrons to protons, by enzymatic coupling for example with hydrogenase 1 
(‘HYD’). In susceptible species, metronidazole enters cells rapidly (dotted line), competing with 
hydrogen ions (protons) for electrons, so that reducing equivalents are consumed and the nitro 
functional group is reduced, resulting in heterocycle fission. Note that pyruvate may also be 
fermented by lactate dehydrogenase (‘LDH’, EC 1.1.1.27) to lactate. Fermentations culminating in 
butyrate, formate, ethanol and butanol, reflecting metabolism in some Clostridia or facultative 
bacteria, are not shown. Some products of reduced metronidazole are not shown. 
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clusters, the most negative of which is E0’ = -540 mV (Chabrière et al., 1999) to reduced ferredoxin 
(E0’ = -420 mV) and to the proton [2 H+/H2 = -414 mV, (Kaster et al., 2011)]]. Originally, it was 
proposed that PFOR/ferredoxin were the only couple in nanaerobes with a sufficiently low redox 
potential to reduce metronidazole [E0’ = - 470-510 mV (Lindmark and Müller, 1976, Church et al., 
1988, O'Brien and Morris, 1971, Obrien and Morris, 1972, Edwards and Mathison, 1970)]. However, 
there are discrepancies as to the exact nature of metronidazole reduction. Originally, it was 
proposed metronidazole accepts electrons directly from ferredoxin (Lindmark and Müller, 1976, 
Obrien and Morris, 1972). Chen and colleagues next reported that hydrogenase reduces 
metronidazole at a low rate and that purified ferredoxin or flavodoxin from C. pasteuranium reduced 
metronidazole directly (Chen and Blanchard, 1979). Other reports have confirmed expression of 
flavodoxin from C. pasteuranium renders resistant E. coli sensitive to metronidazole (Santangelo et 
al., 1991). Later, metronidazole was demonstrated to be reduced by hydrogenase 1 from 
C. pasteuranium, effectively competing with protons (H+) as an acceptor of electrons (Church et al., 
1988). Metronidazole also competes with sulfite (SO32-) for reducing equivalents originating from 
ferredoxin in the dissimilatory sulfite pathway, as noted in studies of C. pasteuranium (Laishley and 
Krouse, 1978, Lockerby et al., 1984). PFOR inactive mutants of C. perfringens spp. and Trichomonad 
spp. are up to 100-fold more resistant to metronidazole although are still killed (Sindar et al., 1982, 
Čerkasovová et al., 1984, Hrdý et al., 2005). Similarly, a B. fragilis double mutant of PFOR and 
flavodoxin is around 10-fold more resistant to metronidazole, although is still killed (Diniz et al., 
2004) confirming activation of metronidazole can occur independently of PFOR. Other candidates 
that may function in the reductive activation of metronidazole are the poorly characterised oxygen-
sensitive (type II) nitroreductases (Roldán et al., 2008). Lastly, metronidazole is also reductively 
activated by sodium dithioninte [E0’ = - 660 mV, (Mayhew, 1978)] in a reaction consuming 4-
electrons, which is irreversible because it induces ring fission (Chen and Blanchard, 1979).  
Oxidation-reduction potential is typically measured using a hydrogen electrode, describing 
the thermodynamic feasibility of a particular redox reaction. Notably, enzymes such as hydrogenase 
that catalyse the reductive activation of metronidazole described above, exhibit variable reduction 
potentials depending on bound substrate/s and local environment. It is paradoxical that 
metronidazole and other nitroimidazoles have a lower reduction potential than the H+/H2 pair (E0’ =  
-414 mV (Thauer et al., 1977)), yet preferentially accept electrons. Also of note, oxygenated 
nitrogenous intermediates usually accept electrons during anaerobic respiration, although the redox 
potential of these electron acceptors, such as NO2-/NO pair [E0’ = +350 mV, (Thauer et al., 1977)] are 
more positive than metronidazole. The presence of a nitro (-NO2) functional group, similar to nitrite 
(NO2-), apparently confers special properties to metronidazole.  
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There is conflicting evidence as to if and how metronidazole is metabolised by facultative 
anaerobic bacteria. It has been proposed that few facultative anaerobes, other than E. coli, 
E. faecalis and Klebsiella pneumoniae take up metronidazole (Tally et al., 1978, Müller, 1983, 
Narikawa, 1986). Furthermore, it has been reported that even if metronidazole is taken up by 
facultative bacteria such as E. coli, that this molecule is not activated due to the use of NAD+ coupled 
pyruvate-formate lyase (PDH) instead of PFOR during anaerobic cleavage of pyruvate to acetyl-CoA 
(Samuelson, 1999, Charon et al., 1999). However, metronidazole-mediated killing of E. coli is 
documented (Jackson et al., 1984, Tamae et al., 2008). Additionally, the rate and total amount of 
metronidazole taken up by E. coli is higher than for B. fragilis (Chrystal et al., 1980a). However, the 
rate of kill and liberation of acetamide, a major product formed after reduction of metronidazole 
and imidazole fission, is higher in B. fragilis than E. coli (Chrystal et al., 1980a), suggesting 
heterocycle fission and cytotoxic products are less efficiently formed in E. coli. Indeed, the cytotoxic 
concentration of metronidazole for facultative anaerobes is 1-3 orders of magnitude higher than 
corresponding concentrations for nanaerobic bacteria, even under strict anaerobic conditions (Tally 
et al., 1978, Ingham et al., 1980, Jackson et al., 1984, Narikawa, 1986, Yeung et al., 1984, Tamae et 
al., 2008, Lubbe et al., 1999). As mentioned, the reduction of the nitro group to the stable amino-
derivative by nitroreductases renders metronidazole inactive. The NfsA, NfsB and YdjA 
nitroreductases of E. coli are type I oxygen-insensitive (see Fig. 1.12), reducing metronidazole to the 
amino derivative (Roldán et al., 2008). These type I oxygen-insensitive nitroreductases may account 
for higher rates of uptake accompanied by reduced cytotoxic potency in facultative bacteria such as 
E. coli than nanaerobic bacteria. It is likely that type II oxygen-sensitive nitroreductases of facultative 
anaerobes play a role in reductive activation of metronidazole. Pyruvate:flavodoxin oxidoreductase 
(YdbK) from E. coli and related enzymes in facultative bacteria may also reductively activate 
metronidazole, leading to ring fission and cytotoxic derivative formation (Nakayama et al., 2013).  
 
1.4.4 Distribution and metabolism of metronidazole in human and murine 
models 
Metronidazole is rapidly absorbed in humans (Ralph et al., 1974), mostly entering the 
gastrointestinal tract directly through the mucosa, rather than via enterohepatic circulation (through 
the bile duct in bile) possibly due to the molecules’s low molecular weight (Ings et al., 1975). 
Metronidazole is found in all tissues in mice and rats, after oral or intravenous injection. The highest 
concentrations are found in liver, bladder, kidneys, vagina and gastrointestinal tract (Placidi et al., 
1970, Ings et al., 1975, Manthei et al., 1969). The majority of metronidazole in human or murine 
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models is excreted in urine unchanged or as oxidised derivatives (compounds VIII - XII, Fig. 1.14) 
(Ings et al., 1966, Ings et al., 1975, Ralph et al., 1974). High concentrations of unchanged 
metronidazole are detected throughout the gastrointestinal tract of rats, except for the caecum. It is 
likely that this structure, containing the highest load of nanaerobic microorganisms (see Section 
1.1.1 of this thesis for further details) is the major site of nitroimidazole reduction (Ings et al., 1975). 
Reduced products of metronidazole, including acetamide and hydroxyethyl-oxamic acid, are 
detected in urine of conventional rats and not germ-free rats, indicating that the intestinal microbes 
are required to reduce metronidazole (Koch et al., 1979). 
From in vitro studies of the oxidised products of metronidazole, the ‘acid’ and ‘alcohol’ (IX 
and X respectively in Fig. 1.14) have been estimated to account for none-5% and 30-65% 
respectively of the toxicity exerted by metronidazole for Clostridium spp. and Bacteroides spp. 
(Ralph and Kirby, 1975, Haller, 1982, O'Keefe et al., 1982). Determining the reduced intermediates 
and how they might exert cytotoxicity after metronidazole activation (reduction) is challenging, since 
intermediates are short-lived (Church and Laishley, 1995). Nevertheless, following enzymatic or 
chemical nitro group reduction (activation of metronidazole), the imidazole ring is irreversibly 
fragmented, transiently forming reactive intermediates and finally, stable end products. In the urine 
of rats treated with metronidazole, N-(2-hydroxyethyl)-oxamic acid (Koch and Goldman, 1979, Ings 
et al., 1975) (compound VI, Fig. 1.14) and acetamide (Koch et al., 1979) (compound VII, Fig. 1.14) 
were detected. These metabolites are consistent with cleavage of the imidazole between positions 1 
and 2 plus positions 3 and 4; however, they do not account for all of the carbon and nitrogen in 
metronidazole. Together these metabolites account for only 20% of total metronidazole 
administered to rats recovered from urine (Koch et al., 1979, Koch and Goldman, 1979). Importantly, 
while it is not possible to recover all of the metabolised metronidazole, around half of the reduced 
derivatives of total administered metronidazole are unaccounted for in the excreta of humans and 
rodents (Stambaugh et al., 1968, Nilsson-Ehle et al., 1981, Koch et al., 1979, Koch and Goldman, 
1979) (see Fig. 1.14). 
Two in vitro models have been used to study biological reduction of metronidazole. The first, 
an enzymatic model consisting of xanthine oxidase (EC 1.2.3.2) and metronidazole produced similar 
concentrations of N-(2-hydroxyethyl)oxamic acid (compound VI, Fig. 1.14) and acetamide 
(compound VII, Fig. 1.14) to those detected in rat studies. Additional products included N-
acetylethanolamine, n-glycoylethanolamine, ethanolamine, acetate, and glycine (Chrystal et al., 
1980b). In the second model, metronidazole was reduced electrolytically forming at least 12 
products, including ethanolamine, N-acetylglycine, glycine and acetate, in agreement with a 
fragmentation between carbons 2 and 4 of the imidazole ring (Knox et al., 1983). The models of  
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A) Metronidazole or oxidised 
derivatives (~55-65%)
B) Reduced metabolites (~20%)
 
Figure 1.14: proposed metabolites of metronidazole and approximate proportions excreted in urine 
and faeces of mice (Stambaugh et al., 1968), humans (Stambaugh et al., 1968) and rats (Koch et al., 
1979, Koch and Goldman, 1979, Ings et al., 1975) or from C. perfringens (Koch et al., 1979) (see 
references for full compound nomenclature). A portion of metabolised metronidazole was not 
detected in the excreta from murine models or humans, so the metabolites do not add to 100%. 
Note that intermediates in brackets (compounds II-IV) are presumptive and have not been isolated. 
Compounds XI and XII were found conjugated to glucuronide via an ether linkage. The carbons 
linking the hydroxyl functional group appended to metronidazole (I) and oxamic acid (VI) are marked 
with an asterisk for clarity. 
 
metronidazole reduction agree, other than the absence of N-acetylethanolamine, nitrite and a 
possible azo or azoxy dimer, formed by condensation with the nitroso and hydroxylamine derivatives 
in the electrolytic model. None of the reduced electrolytic products of metronidazole have been 
shown to be toxic for Clostridium bifermentans, suggesting reduced products are not taken up or 
Chapter I   Introduction 
36 
that intermediate and not final reduced products mediate toxicity (Knox et al., 1983). As mentioned 
above the amino derivative (V of Fig 1.14) is not toxic for E. coli or B. fragilis (Ehlhardt et al., 1987). 
Conflicting reports exist as to how the ‘intermediate’ reductive products of metronidazole 
mediate cytotoxicity. Specifically, the capacity of hydroxylamine or nitroso ‘intermediate’ products 
(III and IV of Fig. 1.14) to exert cytotoxicity by direct DNA damage is contested (Sigeti et al., 1983, 
Church and Laishley, 1995). Sodium dithionite reduced metronidazole (but not metronidazole) was 
found to form covalent bonds with guanine and cytosine bases of mammalian, bacterial and phage 
DNA (Larusso et al., 1977) however, these covalent links cause no detectable damage to the DNA 
(LaRusso et al., 1978). Other investigators demonstrated the release of radiolabelled thymidine from 
synthetically radiolabelled DNA, in a model in which several nitroimidazoles were electrolytically 
reduced, suggesting that reductive intermediates do damage DNA (Knox et al., 1981). Yet another 
report found only 0.02% of radiolabelled reduced metronidazole associated with DNA from E. coli 
(Malliaros and Goldman, 1991). In exponentially growing cultures of Clostridium bifermentans, 
metronidazole inhibited DNA synthesis and degraded existing DNA while not inhibiting RNA 
synthesis (Plant and Edwards, 1976). In agreement, prior inhibition of protein synthesis by 
chloramphenicol does not alter the bactericidal rate of Bacteroides spp. subjected to metronidazole 
(Tally et al., 1978). Indeed, RNA and protein synthesis by B. fragilis, estimated by incorporation of 
radiolabelled uracil and phenylalanine, continued at linear rates even after 80 min exposure to 
metronidazole (Sigeti et al., 1983). Using radiolabelled thymidine, DNA synthesis was shown to cease 
within 20 minutes after addition of metronidazole to B. fragilis; however, no degradation of 
chromosomal DNA or single/double stranded ‘nicking’ of an endogenous plasmid were detected 
(Sigeti et al., 1983). In contrast, reduced metronidazole and dimetronidazole were found to cause GC 
to CG transversions within plasmids in B. fragilis as well as DNA degradation over a similar period of 
time (Trinh and Reysset, 1998).  
Several reports concur that bacteria containing various DNA-repair defects are more 
susceptible to metronidazole. For instance, E. coli mutants, deficient in recA and lexA, that control 
the ‘SOS’ DNA repair system, were 10-fold more sensitive to metronidazole than parental strains 
(Jackson et al., 1984). E. coli uvrB mediates DNA repair by unwinding DNA in unison with ABC 
exinuclease. E. coli uvrB mutants are also more sensitive to metronidazole (Yeung et al., 1984). 
Double mutants affecting glutamate-cysteine ligase (gshA) and uvrD/recG/recC are also up to 40-fold 
more susceptible to metronidazole (Tamae et al., 2008). A AraC/XylS transcriptional regulator 
involved in DNA repair has been reported to aid survival after metronidazole challenge in B. fragilis 
(Casanueva et al., 2008). Also, B. fragilis recA DNA repair mutants (Steffens et al., 2010) and RecQ 
helicase (Paul et al., 2011) are more sensitive to metronidazole. However, the increased sensitivity of 
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DNA repair mutants does not prove that metronidazole or derivatives directly damage DNA in vivo. 
An alternative hypothesis is that failure to replicate DNA may be an indirect response following 
primary drug toxicity.  
As discussed, metabolites detected in animal models and from those recovered from 
C. perfringens, are complementary. However, these metabolites do not account for all of the carbon 
and nitrogen in metronidazole. It is therefore possible that some of the fragments are liberated, 
causing cytotoxicity. It is known that hydroxylamine cleaves thioesters (Fishbein and Carbone, 1963, 
Knox et al., 1993) as shown in Reaction 2 below and hydroxylamine converts acetyl phosphate into 
acetyl hydroxamate (Chen and Blanchard, 1979). In mammals, hydroxylamine is likely to cleave 
acetyl-coenzyme A, forming acetohydroxamic acid (Fishbein and Carbone, 1963). Also, hydroxyurea 
inhibits RNR, the enzyme catalysing the conversion of RNA to DNA, and is relatively stable, although 
it is susceptible to hydrolysis producing hydroxylamine (Fishbein and Carbone, 1963) (see Reaction 1 
below). As mentioned above, azomycin has been shown to inhibit ribonucleotide reductase and 
associated conversion of ribonucleotide diphosphates (ATP/CTP/GTP/TTP) to corresponding dNTPs 
(deoxyribonucleotide triphosphates), the monomers required for DNA synthesis and repair (Saeki et 
al., 1974). In agreement with observations by Sigeti (Sigeti et al., 1983), an explanation for the 
cytotoxicity of nitroimidazoles is that they fragment, one of the products being hydroxylamine. 
 
 
Reaction 1: Hydrolysis of hydroxyurea. 
 
 
Reaction 2: Cleavage of acetyl-Coenzyme A by hydroxylamine. 
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Released hydroxylamine could then cleave acetyl-CoA, reducing the total ATP pool and/or directly 
inhibit RNR, limiting DNA synthesis and thereby contributing to cell death. The short-lived nature of 
reactive intermediates explains some of the discrepancies in the literature and the difficulties in 
studying these mechanisms. 
The ultimate fate of metronidazole depends on whether it is reductively activated or 
inactivated (summarised in Fig 1.15). If reductively activated, metronidazole competes for reducing 
equivalents generated primarily by ferredoxin-linked processes, preventing maintenance of redox 
state (NAD+/NADH ratios), halting cellular functions such as glycolysis. Following reductive 
activation, transient intermediate compounds are formed and the imidazole ring is fragmented. DNA 
synthesis and repair of existing DNA ceases (Church et al., 1988, Sigeti et al., 1983). The formation of 
hydroxylamine or other transient compounds may mediate these processes, for instance by direct 
inhibition of DNA synthesis or cleavage of thioesters.  
 
A)
B)
 
Fig 1.15: Summary of metronidazole activation and associated cytotoxicity (A) or reductive 
inactivation and loss of cytotoxicity (B). Activation of metronidazole by reduction of the nitro group 
is proposed to fragment the imidazole ring producing transient intermediates such as hydroxylamine 
that inhibit DNA synthesis and repair. Hydroxylamine is proposed to inhibit DNA synthesis and repair 
by preventing the RNR (ribonucleotide reductase) catalysed conversion of NTPs (the four 
ribonucleotide diphosphates ATP/CTP/GTP/TTP) to corresponding dNTPs (deoxyribonucleotide 
triphosphates). 
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1.4.5 Metronidazole resistance 
Resistance to metronidazole is complex. Resistance can manifest due to a reduced rate of 
uptake or by efflux. Mutations in effectors activating (reducing) metronidazole could de-sensitise 
organisms. Reducing the rate of metronidazole activation, for example by re-routing glucose 
fermentation, is another mechanism of metronidazole resistance. Presence of inactivating resistance 
determinants and increased DNA repair efficiency provide additional mechanisms (summarised in 
Fig. 1.16). Notably, several studies have detected considerable decreases in metronidazole 
sensitivity, although complete loss of sensitivity is rare in nanaerobes, consistent with metronidazole 
activation being complex (Sindar et al., 1982). Metronidazole resistance was first detected in clinical 
strains of B. fragilis during the late 1970s (Ingham,1978). Rates of clinical resistance in Bacteroides 
spp. (Löfmark et al., 2005, Gal and Brazier, 2004, Fernández-Canigia et al., 2012, Sadarangani et al., 
2015) and Clostridium spp. (Pelaez et al., 2002, Freeman et al., 2015, Kullin et al., 2016) tend to 
range from absent to 11.6%, depending on the criteria of methods used to assess resistance and also 
the geographical region the isolates originate from. 
Metronidazole uptake is one parameter involved in resistance to this drug. Generalised 
defects in metronidazole transport, accompanied by changes in cell wall and by reduced capsular 
polysaccharide have been described in B. fragilis (Britz and Wilkinson, 1979). E. coli that survived 
high-concentration metronidazole challenge exhibited an elongated filamentous morphology and 
colonies of these cells were anaerogenic (did not produce gas from glucose) (Jackson et al., 1984). 
These colonies were less susceptible to metronidazole and it is possible that the uptake rate of 
metronidazole was lower than wild type as found by others (Tally et al., 1978). Mutants lacking the 
ability to reduce nitrate and chlorate, presumably reducing the rate of metronidazole uptake, are 
also resistant (Yeung et al., 1984). A reduced growth rate is also associated with metronidazole 
resistance in C. perfringens (Sindar et al., 1982), C. difficile (Lynch et al., 2013) and B. fragilis (Gal and 
Brazier, 2004). Bacteroides multidrug efflux (bme) pumps also reduce sensitivity to metronidazole 
(Pumbwe et al., 2006). Deletion of the gene encoding the ferrous transport fusion protein (feoAB) 
also decreases sensitivity to metronidazole (Veeranagouda et al., 2014). 
Changes in type of metabolism or down-regulation of metronidazole activators are also 
associated with resistance. For example, changes in fermentation account for some of the 
documented reports of resistance to metronidazole. The reduction of pyruvate ferredoxin 
oxidoreductase activity and up-regulation of lactate dehydrogenase activity is a strategy common to 
C. perfringens and Bacteroides spp. (Sindar et al., 1982, Narikawa et al., 1991, Diniz et al., 2004, Patel 
et al., 2009, Stanko et al., 2016). Also, down-regulation of flavodoxin in B. fragilis decreases 
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sensitivity to metronidazole (Diniz et al., 2004). In B thetaiotaomicron, the up-regulation of 
rhamnose catabolism regulatory protein (RhaR) results in a similar re-routing and increased 
resistance to metronidazole (Patel et al., 2009). In genomic screens of metronidazole-sensitive and 
resistant C. difficile strains, mutations in a putative nitroreductase (nimB), hemN (porphyrin 
synthesis), thiH (thiamine biosynthesis), glycerol-3- oxidoreductase (glyC) and pyruvate-flavodoxin 
oxidoreductase (nifJ) (Lynch et al., 2013) were associated with resistance, consistent with a reduced 
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Figure 1.16: Summary of resistance mechanisms to metronidazole and other nitroimidazoles. Red 
arrows indicate a change in gene expression that confers resistance. Underlined enzymes indicate 
that loss of function mutants affect sensitivity to metronidazole. Crosses indicate reduced activity or 
uptake. Enzymes are shown in green include pyruvate:ferredoxin oxidoreductase (‘PFOR’), lactate 
dehydrogenase (‘LDH’) and hydrogenase (‘HYD’). Metronidazole efflux is facilitated by Bacteroides 
multidrug efflux pump system (‘bme’). The nim genes, represented by ‘NIM’, are proposed to 
reductively inactivate the nitro group appended to nitroimidazoles to an amino derivative. The 
ferrous transport fusion protein is not shown. Fermentations culminating in butyrate, formate, 
ethanol and butanol, or the dissimilatory sulfate pathway, characteristic of metabolism in some 
Clostridia or other facultative bacteria, are not shown. Only some of the metabolites of reductively 
activated metronidazole are shown. 
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rate of electron transport and alterations in intracellular redox. In Helicobacter pylori, thioredoxin 
reductase, alkyl hydroperoxide reductase and superoxide dismutase are involved in metronidazole 
resistance (Kaakoush et al., 2009). 
Various enzymes inactivate metronidazole, primarily by reductive inactivation of the nitro group to 
the amino derivative. Nitroreductases consist of oxygen-insensitive NAD(P)H pairing (type I) and 
oxygen-sensitive (type II) types (Roldán et al., 2008). Type I nitroreductases are the primary enzymes 
described in metronidazole reductive inactivation, while type II nitroreductases may activate 
metronidazole, leading to imidazole fragmentation (Fig. 1.17). The biological role of nitroreductases 
is unclear, although they may function in redox maintenance, by dissipating excess reducing power 
(Roldán et al., 2008). Early studies of S. faecalis (Nagy and Földes, 1991) and E. coli (Ehlhardt et al., 
1987) indicated they were able to inactivate metronidazole. For example, E. coli reduce around 20% 
of administered metronidazole to the amino derivative (V of Fig. 1.14) (Ehlhardt et al., 1987). The 
oxygen-insensitive major and minor (nsfA and nfsB respectively) flavoprotein nitroreductases of 
E. coli, have been shown to reduce nitrofurans and later metronidazole (McCalla et al., 1978, Curado 
et al., 2008). These nitroreductases, like the nim genes (described below) are dimers, with 
characteristic α+β folds. Mutants of both nfsA/nfsB in E. coli show reduced sensitivity to 
metronidazole, suggesting the third poorly characterised nim gene YdjA is involved in metronidazole 
reductive activation or that another uncharacterised enzyme reduces metronidazole to cytotoxic 
derivatives. 
 
Figure 1.17: Bacterial reduction of nitroaromatic compounds by oxygen-insensitive (type I) and 
oxygen-sensitive (type II) nitroreductases (Roldán et al., 2008). In the presence of oxygen, type II 
nitroreductases are proposed to generate a superoxide anion, regenerating the nitro group. 
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Interestingly, metronidazole has also been demonstrated to be a substrate for thiaminase (EC 
2.5.1.2), an enzyme excreted by Bacillus thiaminolyticus (Alston and Abeles, 1987). Thiaminase from 
B. thiaminolyticus may function to inactivate metronidazole. Additionally, metabolic products of 
thiaminase inhibit pyrophosphokinase in the mollusk Venus mercenariathiamine (Alston and Abeles, 
1987). More recently, 2-nitroimidazole nitrohydrolase (NhhA, EC 3.5.99.9), which forms imidazole-2-
one and nitrite from 2-nitroimidazole (azomycin) was shown to render E. coli resistant to 2-
nitroimidazoles (Qu and Spain, 2011). In the limited number of examined nitroimidazoles, 
metronidazole was not inactivated, although other similar enzyme systems may function to render 
bacteria resistant to metronidazole.  
Some of the nitroimidazole resistance can be ascribed to the ‘nim’ genes, conferring low 
level resistance to metronidazole (Trinh and Reysset, 1998). The nim genes are best characterised in 
Bacteroides and other genera of the Bacteroidetes phylum, although they are also encoded by 
genera of the Clostridia class, Proteobacteria and Archaea (Leiros et al., 2004, Theron et al., 2004, 
Marchandin et al., 2004). Currently nine nim genes are described in the Bacteroides, including nimA-
nimH and nimJ which are chromosomally or plasmid borne (Gal and Brazier, 2004, Husain et al., 
2013). A ‘silent’ nim gene, nimI, is encoded by Prevotella spp. (Alauzet et al., 2010). Of 1,502 isolates 
of the ‘B. fragilis’ group, around 2% were found to carry nim genes (Löfmark et al., 2005). In a study 
of resistant clinical isolates of Bacteroides, nimA, followed by nimB and nimE were most commonly 
identified (Gal and Brazier, 2004). Whether chromosomal or on a plasmid, resistance has been 
shown to be transferable in some Bacteroides spp. (Reysset, 1996) and is transferable by conjugation 
between Bacteroides spp. and Prevotella spp. (Trinh et al., 1996). In B. fragilis, nimA encodes a 5-
nitroimidazole reductase reducing the metronidazole analogue dimetronidazole (1,2-dimethyl-5-
nitroimidazole) to the amino derivative, preventing ring fission and associated toxicity (Carlier et al., 
1997). Presumably, other nim genes encode 5-nitroimidazole reductases, although the exact 
mechanism of nim resistance is not known (Husain et al., 2013) and it has not been demonstrated 
that the ‘nim’ system produced the amino derivative in metronidazole. Structural analysis of NimA 
from Deinococcus radiodurans (from the Bacteroidetes phylum) indicates the protein is a 
homodimer, with two binding sites with weak affinity for nitroimidazoles including metronidazole 
(Leiros et al., 2010). Structural analyses of two nitroreductases from C. difficile indicate they are also 
homo-dimeric, both of which bind flavin mononucleotide (Wang et al., 2016). Interestingly, the 
nim genes share structural homology with the gene encoding CREG, a glycoprotein secreted by 
human embryonal carcinoma cells (Sacher et al., 2005).  
The role of nim genes in metronidazole resistance is controversial. It has been established 
that over-expression of a NimA homologue from B. fragilis induces a three-fold increase in 
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metronidazole resistance in E. coli (Meggersee and Abratt, 2015). Also, overexpression of nimE and 
nimJ on pMCL140 in B. fragilis induces a four-six fold increase in metronidazole resistance (Husain et 
al., 2013). However, several non-nim containing Bacteroides spp., Prevotella spp. and C. difficile and 
other genera within the Clostridia class are resistant to metronidazole or nim-containing isolates 
within these clades are sensitive to metronidazole (Theron et al., 2004, Gal and Brazier, 2004, 
Schaumann et al., 2005, Meggersee and Abratt, 2015, Kullin et al., 2016, Galvão et al., 2011, Alauzet 
et al., 2010, Stanko et al., 2016). Also, expression of the NimA-D proteins does not correlate with 
metronidazole resistance in B. fragilis (Leitsch et al., 2014). The possibility that insertion sequences 
upstream of nim genes may control expression is also contested (Löfmark et al., 2005). Lastly, up to a 
256-fold increase in resistance to metronidazole can be induced in the absence of the nim genes 
(Schaumann et al., 2005, Alauzet et al., 2010), suggesting other factors also feature in metronidazole 
resistance (Schaumann et al., 2005, Alauzet et al., 2010, Husain et al., 2013). An explanation for 
these conflicting results is that very high levels of the Nim proteins are required to confer 
metronidazole resistance or that other factors determine metronidazole resistance. 
 
1.5 The rationale underpinning deuteroporphyrin-nitroimidazole 
adducts and selection of candidates for characterisation 
  
Current broad spectrum antibiotics may eliminate pathogens, although they also tend to 
have considerable off-target action, which may destabilise microbial communities. Secondly, uptake 
by non-target organisms may reduce availability of the antibiotic for target pathogen/s. Lastly, 
antibiotic use promotes drug resistance in bacteria (Jernberg et al., 2010, Jakobsson et al., 2010). 
These reasons provided impetus for the design of porphyrin-nitroimidazole adducts, designed to be 
narrow spectrum antibiotics for P. gingivalis.  
The design of nitroimidazole-porphyrin adducts was based on several criteria. P. gingivalis 
was targeted because it is implicated in periodontitis (elaborated in Section 1.1.1). At the time 
porphyrin-nitroimidazole adducts were designed, P. gingivalis was considered one of a few bacteria 
in the human oral cavity that required porphyrin for growth yet was unable to synthesise this 
molecule. Typically in bacterial growth media hemin is used to satisfy this porphyrin growth 
requirement. Hemin is the chloride salt of the iron-oxidised form of haem (consisting of 
protoporphyrin IX with a ferric iron conjugated to a chloride ligand, see Fig. 1.18). P. gingivalis does 
encode three genes of the porphyrin biosynthetic pathway, a coporphyrinogen oxidase (hemN), 
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protoporphyrinogen oxidase (hemG) and ferrochelatase (hemH) (Nelson et al., 2003, Naito et al., 
2008)], see Section 1.3.1 for details of the porphyrin biosynthetic pathway). Ferrochelatase inserts 
Fe2+ into freebase (metal-free) porphyrins, such as protoporphyrin IX, forming haem b.  
A series of growth curves and binding studies demonstrated recognition of porphyrin by P. gingivalis 
was independent of the central metal ligand and of a protein carrier (DeCarlo et al., 1999, Hunter et 
al., 2002, Paramaesvaran et al., 2003). These studies also identified some of the structural variations 
of the porphyrin macrocycle that P. gingivalis recognises, imports and that also stimulate growth 
(Fig. 1.18). The vinyl groups of protoporphyrin IX (PPIX, at positions 3 and 8 of the macrocycle) are 
heat labile, may undergo reversible hydration and be photo-oxidised, forming photoprotoporphyrin 
and isophotoprotoporphyrin (Smith, 1976). Since growth stimulation of P. gingivalis with 
deuteroporphyrin IX (DPIX) was identical to PPIX (DeCarlo et al., 1999, Hunter et al., 2002, 
Paramaesvaran et al., 2003), DPIX was chosen due to these instabilities of the vinyl groups of PPIX. 
Unlike haem b, DPIX does not feature in the porphyrin biosynthetic pathway. As a freebase 
porphyrin without the vinyl groups normally present on ‘biotic porphyrins’, it was envisaged that 
other bacteria in the human oral cavity would be less likely to recognise and import DPIX. 
Metronidazole or nitro- containing derivatives were chosen to link to DPIX, because nanaerobic 
microorganisms such as the porphyromonads are sensitive to these molecules. Together, it was 
anticipated that the recognition of DPIX portion of the DPIX-nitroimidazole adduct would facilitate 
the Trojan-horse style delivery of the toxic nitroimidazole molecule, killing P. gingivalis and few 
other bacteria during periodontitis in the human oral cavity (Fig. 1.19). 
 
 
Substituent C2 C3 C7 C8
-H - Y - Y
-CH3 Y Y Y Y
-CHCH2 N Y N Y
-SO3H - Y - Y
-CHOHCH2OH - Y - Y
 
Figure 1.18: Porphyrin macrocycle numbering, in accord with the international Union of Pure and 
Applied Chemistry (IUPAC) scheme and tolerated substituents at the ‘northern aspect’ (carbons 2, 3, 
7 and 8) of the porphyrin macrocycle. Porphyrins that stimulate or do not stimulate the growth of 
P. gingivalis are marked ‘Y’ and ‘N’ respectively. Data summarises work from DeCarlo, 1999, Hunter 
et al., 2003 and Paramaesvaran et al., 2003. 
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Nitroimidazole sensitive Porphyrin auxotroph
1) Abiotic porphyrins (ie. DPIX) 
recognised and imported 
2) Nitroimidazole sensitive
P5
B
P. gingivalis
Metronidazole
A
P. gingivalis
 
Figure 1.19: The rationale of synthesising deuteroporphyrin-nitroimidazole adducts and expected 
outcome after administering metronidazole (A) or porphyrin-nitroimidazole adduct ‘P5’ (B) in the 
human oral cavity during periodontitis. Unlike metronidazole, P5 is expected to kill P. gingivalis in 
the human oral cavity with minimal ‘by-stander’ damage for other bacteria.  
 
A library of porphyrin adducts, their organic synthesis and preliminary characterisation were 
documented (Yap et al., 2009, Dingsdag et al., 2015). These porphyrin-nitroimidazole adducts 
consisted mostly of amide or lysine linkages, with a variety of nitroimidazoles. Porphyrin-
nitroimidazole adducts are regioisomers. Separated Isomers of P5 have no difference in toxicity for 
P. gingivalis (Yap et al., 2009). Two candidates, amide linked (‘P5’) and lysine-linked (‘P8’) are 
characterised in this thesis (see fig. 1.20 for the structure of these adducts). P5 and P8 were studied 
because early biological characterisation indicated they had a similar potency to metronidazole and 
in preliminary assays, P5 was selective for P. gingivalis.  
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Figure 1.20: The structure of porphyrins, nitroimidazoles and deuterpporphyrin-nitroimidazole 
adducts used in this thesis. The lysine linkage between metronidazole-amine and deuteroporphyrin 
of P8 is highlighted in grey and the tert-butyloxycarbonyl group (BOC) is highlighted in green. 
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2.0 PREFACE TO CHAPTER II 
 
Chapter II is comprised of three parts: in the first section the response of anaerobic, human-
isolated bacteria to amide- (‘P5’) and lysine-deuteroporphyrin (‘P8’) nitroimidazole adducts is 
explored with growth curve and viable count assays (aim I). Based on this preliminary in vitro 
evidence, in which none of the four examined bacterial strains were killed by P5 or P8, a plaque 
growth model and a rat alveolar bone loss (periodontitis) model are also explored, to examine the 
specificity of adducts for P. gingivalis in complex bacterial communities (aim II). Parts of the first 
section of this Chapter have been published (Dingsdag et al., 2015). 
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2.1 INTRODUCTION 
Single species growth curves give insight into the kinetics of uptake and processing of 
deuteroporphyrin-nitroimidazole adducts and metronidazole. While informative, such experiments 
are an inefficient approach to define specificity of deuteroporphyrin-nitroimidazole adducts. A 
dental plaque growth curve provides the opportunity to challenge complex bacterial populations 
under defined conditions and the capacity to evaluate specificity of adducts. It is expected that if 
adducts are specific for P. gingivalis, the total populations of bacteria (or yield of bacterial DNA) in 
adduct treatments would be similar to non-treated controls, unlike the metronidazole treatment, 
which should have a broader spectrum (Fig. 2.1). Deuteroporphyrin IX (DPIX) is included as a control 
with metronidazole in these experiments and throughout this thesis. DPIX is a strong growth 
stimulant for P. gingivalis. In contrast, metronidazole rapidly kills this bacterium. Including DPIX and 
metronidazole together indicates whether the DPIX growth stimulation overcomes the bactericidal 
effect of metronidazole reductive activation. 
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Figure 2.1: Expected yield of bacterial DNA after incubation with treatments, if adducts were specific 
for P. gingivalis (A) and expected yield of DNA if adducts were not specific for P. gingivalis (B). 
‘M’ = metronidazole.  
 
Growth experiments are subject to experimental conditions, including inoculum 
concentration and phase of bacterial growth, the type and concentration of nutrients and pH. On 
this basis, a periodontal bone loss model is explored, using P. gingivalis ATCC 33277, a pathogenic 
strain, capable of inducing bone loss in murine models (Evans et al., 1992, Rajapakse et al., 2002, 
Polak et al., 2009). The rat oral cavity is dominated by Gram-positives, such as Rothia 
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(Actinobacteria) and Streptococcus (Firmicutes) (Manrique et al., 2013). Proteobacteria, 
Cyanobacteria, Bacteroidetes, Acidobacteria and Planctomycetes associated sequences are detected 
at low abundance (Manrique et al., 2013). In order to aid colonisation of P. gingivalis, kanamycin was 
co-administered. Kanamycin is a bactericidal aminoglycoside produced by Streptomyces 
kanamyceticus (Umezawa et al., 1957). Kanamycin prevents protein synthesis by inhibiting 
translocation of tRNA when N-acetyl-diPhe-tRNA is on the acceptor site and deacylated tRNA at the 
donor site of the bacterial 30S ribosome (Misumi and Tanaka, 1980) which is not present in 
eukaryotes. P. gingivalis spp. encode a kanamycin acetylase, inactivating kanamycin by acetylation 
(Kato et al., 1995). It is also possible that as with aminoglycoside uptake by Bacteroides, that 
kanamycin transport occurs poorly under anaerobic conditions because uptake is dependent on 
nitrate and oxygen (Bryan et al., 1979). Kanamycin predominantly targets facultative anaerobes 
(Davies et al., 1964, Waitz et al., 1972) and is expected to broadly kill members of the Proteobacteria 
and Actinobacteria. In both metronidazole and adduct treatments, a reduction in P. gingivalis and 
associated bone loss was expected with respect to untreated control. Populations of anaerobic 
bacteria in the rat oral cavity were expected to remain constant after P5 and P8 treatment, unlike 
the metronidazole treatment, in which it was anticipated anaerobic bacteria would be killed. 
 
2.2 METHODS 
2.2.1 Single Bacterial Strain Growth Curves and Kill Curves 
Bacteria (Porphyromonas gingivalis ATCC 33277, Fusobacterium nucleatum ATCC 25586, 
Prevotella melaninogenica ATCC 25845, Bacteroides fragilis ATCC 25285 and Tannerella forsythia 
ATCC 43037) were prepared in enriched brain heart infusion broth (eBHI) in an anaerobic chamber 
[Don Whitley Scientific, CO2 (5%), H2 (10%) and N2 (85%)] at 37 °C. Strict anaerobic conditions were 
maintained with a platinum-palladium-based catalyst (Don Whitley Scientific) which was regularly 
changed to remove O2 introduced during entry into the chamber. Annotox reagent (Don Whitley 
Scientific) was also frequently changed to absorb volatile compounds, such as hydrogen sulphide. 
eBHI medium contained brain heart infusion (37 g L-1, Oxoid, pH 7.7), yeast extract (5g L-1, Oxoid) and 
L-cysteine (0.5 mg L-1, Fluka), which was autoclaved before the addition of filter sterilised menadione 
(2 mg L-1, Sigma), fetal bovine serum (FBS, 5% v/v) and N-acetylmuramic acid (NAM, 10 mg L-1, 
Sigma). Porphyrins, adducts and metronidazole derivatives were prepared as 5 mM stock solutions 
in DMSO (Sigma) for dilution into growth medium. To control the possible inhibition of bacterial 
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growth by DMSO, all cultures contained levels of this solvent equivalent to the highest concentration 
used in the experiment (1% v/v). 
Bacterial strains were first grown in eBHI with haemin (5 mg L-1, Fluka) to an OD600 ≈ 1.0. 
Bacteria were diluted 1/2000 into fresh eBHI medium. At OD600 ≈ 1.0 bacterial cultures were 
sampled for viable count on eBHI agar and were diluted 1/2000 into fresh eBHI medium with 
treatments at a final concentration of ≈5 × 105 cfu ml-1. At various times after addition of bacterial 
inolcula, viable bacteria were enumerated by plating in duplicate onto eBHI agar. Plates were 
incubated under completely anaerobic conditions at 37°C for 96 hours before counting. Data show 
mean values and standard error of the mean from two or three experiments for growth curves and 
kill curve assays respectively.  
 
2.2.2 Plaque-derived bacterial growth curves 
Subgingival plaque scrapings were taken from the upper molars (teeth 1-3), emulsified into 
pre-reduced phosphate buffered saline (PBS, pH 7.0, Sigma) and immediately transfered into an 
anaerobic chamber. Bacterial inoculum was adjusted to a final concentration of ≈ 1×108 cfu ml-1 in 
PBS, determined by optical density (600nm, OD600 DiluPhotometer, Implen GmbH), and were 
verified in triplicate by viable count on solid blood agar containing (4%) enriched BHI medium. 
Bacterial inoculum was introduced at a final concentration of ≈ 1×106 cfu ml-1 (1/100 dilution) into 
enriched BHI broth without haemin. Treatments were prepared from concentrated stock in DMSO, 
and were added to growth medium at a final concentration of 50 µM. Controls included 1% (v/v) 
DMSO (equivalent to the final concentration in other treatments) and 50 µM: deuteroporphyrin IX 
(DPIX), metronidazole plus DPIX and metronidazole. In each experiment, treatments were carried 
out in duplicate, and experiments were repeated twice from each donor. 
 
2.2.3 DNA Extraction 
500 µl aliquots were sampled from duplicate treatments at times indicated in text following 
established protocols (Nadkarni et al., 2009). Bacterial were pelleted at 13 000 rpm for 5 minutes at 
4°C, before removal of supernatant, and suspensed in mutanolysin (200 units, Sigma-Aldrich), 
lysozyme (400 µg, Sigma-Aldrich), proteinase K (400 µg, Qiagen) and diethylpyrocarbonate (DEPC, 
20mM, Sigma-Aldrich), made up to 200 µl with sodium phosphate buffer (10 mM, pH 6.7). Samples 
were vortexed during a 40 minute incubation at 56°C, before the addition of sodium dodecyl 
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sulphate (1% v/v, Sigma-Aldrich) and RNAse (400 µg, Sigma-Aldrich). Samples were then incubated 
at 37°C for 10 minutes. ‘Buffer AL’ (200 µl, Qiagen) was added to the samples, and they were 
incubated at 70°C for 10 minutes. Extracted DNA was eluted into 60 µL AE buffer. DNA was purified 
with the QIAamp DNA Mini kit (Qiagen). Purified DNA was electrophoresed in 1% agarose (Promega) 
in the presence of gelred (0.5×, Biotium). 
 
2.2.4 Real time polymerase chain reaction 
Real time polymerase chain reaction (qPCR) was performed as described previously 
(Nadkarni et al., 2002). For estimations of total bacteria, each reaction contained 300nM of 16S 
rRNA gene bacterial domain-specific forward (5’-TCCTACGGGAGGCAGCAGT) and reverse (5’-
GGACTACCAGGGTATCTAATCCTGTT) primers, 175nM of the fluorogenic probe (5’-6-FAM-
CGTATTACCGCGGCTGCTGGCAC-TAMRA, IDT) and 30nM ROX (SOLIS BioDyne) with Firepol (SOLIS 
BioDyne) buffer made of to 20 µl with 18ΩM dH20. Reaction conditions included an initial 95 °C for 
20 minutes followed by 40 cycles of 95 °C for 20 seconds and 60 °C for 1 minute using an Mx3005p 
(Agilent). Conditions for the estimation of P. gingivalis abundance were identical to the total 
bacterial estimations, except forward (5’-TCGGTAAGTCAGCGGTGAAAC), reverse (5’-
GCAAGCTGCCTTCGCAAT) primers and probe (5’-6-FAM-CTCAACGTTCAGCCTGCCGTTGAAA-TAMRA) 
amplified a P. gingivalis specific 16S rRNA amplicon (Martin et al., 2002). The fluorescent emission of 
FAM, was corrected by ROX. 10-fold dilutions of P. gingivalis ATCC 33277 genomic DNA of known 
concentration was used to construct a standard curve for the conversion of threshold cycle (Ct) to 
cfu ml-1 following an established methodology (Nadkarni et al., 2002). Amplicons were assessed by 
agarose electrophoresis (1% agarose, Promega) in the presence of gelred (0.5×, Biotium) or by melt 
curve analysis. Linear acrylamide, DMSO, bovine serum albumin and betaine were provided by 
Sigma-Aldrich and were used at a final concentration of 10 µg 20 µL-1, 300 mM, 2 ng 20 µL-1 and 100 
mM respectively. 
 
2.2.5 Periodontitis model in F344 rats 
10 Female F344 rats (5 per cage) were allowed unlimited access to drinking water with 
kanamycin sulfate [1.7 mM (1mg/ml), Sigma-Aldrich] for two weeks. Porphyromonas gingivalis ATCC 
33277, grown to an optical density of 1.2 – 1.5 in BHI medium supplemented with haemin (5 mg L-1), 
was pelleted and emulsified into anaerobically equilibrated carboxymethyl cellulose (2% w/v) 
buffered with PBS, for daily introduction (≈5×1010 cfu made up to a final 100 µl volume) into the oral 
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cavity of rats over the two-week period. Autoclaved chow was available ad libitum and bedding was 
replaced bi-weekly. Bacterial purity and concentration was assessed daily in duplicate on solid 
medium. Bacteria were sampled by a subgingival scrape of front incisors with a wooden tooth pick. 
Approval of animal procedures was granted by Westmead Hospital Animal Ethics Committee 
(protocol 4185.12.11). 
 
2.3 RESULTS 
2.3.1 Single Species Growth Curves 
 In order to confirm a previous result in which P. gingivalis was challenged with P5 (Yap, 
2009) and to establish rate of kill kinetics for plaque growth curves, anaerobic bacteria were profiled 
in enriched BHI. In enriched BHI, P5 (3 µM) and P8 (4 µM) killed P. gingivalis with a similar 
concentration to that of metronidazole (3 µM) (Fig. 2.2A). F. nucleatum was rapidly killed by 20 µM 
metronidazole (˂30 minutes), whilst equimolar P5 and P8 did not affect F. nucleatum (Fig. 2.2B and 
Fig. 2.3B, Table 2.1). F. nucleatum was unable to grow in 2 µM metronidazole (Fig. 2.2B). Like 
F. nucleatum, B. fragilis was unaffected by adducts in enriched BHI medium, but no growth was 
detected in the presence of 7 µM metronidazole (Fig. 2.2D and Table 2.1). P. melaninogenica was 
less sensitive to metronidazole than F. nucleatum, with 8 µM metronidazole preventing growth and 
20 µM metronidazole taking 2.5 hours to kill 5 × 105 cfu mL-1 of this bacterium (Fig. 2.3C). P8 
significantly increased the doubling time of P. melaninogenica, with recovery between 24-48 hours 
similar to the optical density of untreated controls (Fig. 2.2C, Fig. 2.3C and Table 2.1). In relation to 
the DMSO control, P5 (20µM) slowed the doubling time of P. melaninogenica slightly (Fig. 2.2C and 
Table 2.1). 
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Table 2.1: Doubling times of bacteria grown in enriched BHI medium. The reported doubling times 
are for P. gingivalis grown in 4 µM DPIX. Other bacteria were assayed in DMSO alone (1% v/v) or 
20 µM DPIX, P5 and P8 with DMSO (1% v/v). 
Bacterium DMSO DPIX P5 P8
P. gingivalis 165.9 164.2 N/A N/A
F. nucleatum 78.8 69.9 81.3 85.2
P. melaninogenica 75.7 59.2 87.6 229.4
B. fragilis 68.1 68.8 63.3 64.3
T. forsythia 446.9 501 2007.5 1047.2
TD (min
-1
)
 
 
The doubling time of T. forsythia was delayed significantly by P5 (20 µM) and to a lesser 
extent by P8 (20 µM) whereas 2.5 µM metronidazole prevented growth of T. forsythia (Fig. 2.2E and 
Table 2.1). Notably, in enriched BHI growth medium the doubling time of P. gingivalis and B. fragilis 
in the presence of DPIX was identical to the DMSO control (Fig. 2.2A, Fig. 2.2D and Table 2.1), 
suggesting that there are sources of porphyrin in enriched BHI or that the medium contains other 
nutrients (see discussion). 
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Figure 2.2: Bacterial growth curves in enriched BHI medium. Growth of P. gingivalis (A), 
F. nucleatum (B), P. melaninogenica (C), B. fragilis (D) and T. forsythia (E). Concentrations of 
treatments in growth curves are indicated micromoles. DPIX=deuteroporphyrin IX, 
M=metronidazole. 
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Figure 2.3: Bacterial kill curves in enriched BHI medium. Concentrations of treatments in kill 
curves are indicated in brackets. Growth of P. gingivalis (5 µM, A); F. nucleatum (20 µM, B); 
and P. melaninogenica (20 µM, C). DPIX=deuteroporphyrin IX, M=metronidazole. 
 
2.3.2 Human subgingival bacterial plaque growth assays 
 
Table 2.2: Details of patients who donated plaque for growth curves and real time PCR assays1. 
Patient Age Sex Antibiotic use (previous six months)
A 66 M N
B 80 M N
C 24 M N
D 34 F N
 
1The sample from patient D consisted of subgingival plaque stored cryopreserved in glycerol 
(20% v/v) from a patient with chronic periodontitis.  
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Doubling times of bacteria from subgingival plaque of patients A-D varied from 24.3-52.7 
minutes (Table 2.3). In all patients, the doubling time of bacteria in the metronidazole treatment 
was similar or decreased slightly than the DMSO controls (average TD of 37.6 and 30.8 minutes 
respectively, Table 2.3). The lag phase was longest and growth in metronidazole was the most 
delayed from plaque of patient D, with periodontitis (Table 2.3 and Fig. 2.4). In all patients, P5 
increased the doubling time of subgingival bacteria in respect to the DMSO control by around 20% 
(Table 2.3), an affect more pronounced by the P8 adduct (50.7%, Table 2.3) which delayed initiation 
of exponential growth by 2.5-5 hours (Fig. 2.4). The average doubling time of nanaerobes originating 
from the oral cavity (P melaninogenica, F. nucleatum and P. gingivalis) in enriched BHI (with 1% 
DMSO) was 74.2 minutes (Table 2.1). Doubling times of subgingival plaque under the same growth 
conditions were around 1.4-3 fold lower than these three nanaerobes, more consistent with 
doubling times of facultative anaerobes. Doubling times imply facultatively anaerobic bacteria 
dominate the subgingival plaque samples. 
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Figure 2.4: Growth of subgingival plaque in eBHI medium from patients A-D (A – D) in treatments 
(50µM) or DMSO control (1% v/v). M=metronidazole, DPIX=deuteroporphyrin IX. 
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Table 2.3: Doubling times of subgingival plaque bacteria from patients A-D grown in enriched BHI 
medium. Subgingival plaque bacteria were grown in the presence of treatments (50µM) or DMSO 
control (1% v/v). 
Patient DMSO DPIX DPM M P5 P8
A 43.4 60 40.5 40.8 42.5 27.9
B 30.1 22.5 28.4 27 42.7 134.5
C 24.3 26 33.2 20.1 48.8 123.3
D 52.7 54.0 52.7 35.2 52.8 20.0
Average 37.6 (±6.4) 40.6 (±9.6) 38.7 (±5.3) 30.8 (±4.5) 46.7 (±2.5) 76.4 (±30.4)
TD (min
-1)
 
 
The fate of subgingival plaque bacteria deposited into enriched growth media will vary from 
lysis, loss of viability or replication. The bacteria with the lowest doubling times are those most likely 
to be detected by an increase in the optical density after the lag phase (around 4 hours). It is 
expected that changes in the number of individual species of subgingival bacteria are complex. 
Nevertheless, by analysing bacterial number (estimated by 16 ribosomal copy number), it should be 
possible to detect reductions in nanaerobic bacteria, known to be most susceptible to 
metronidazole, during challenge with this compound for comparison with the number of bacteria 
after challenge with P5. For example, if nanaerobic bacteria consist of 20% of the subgingival plaque 
bacteria, real-time PCR has the sensitivity to detect the reduction of these bacteria after challenge 
with a lethal concentration of metronidazole. In viable count assays (Fig. 2.3), it was established that 
in enriched BHI medium, 20 µM metronidazole was sufficient to kill the majority of susceptible 
nanaerobes within 30 minutes. As such, 30 minutes and 2 hours were selected as reference points 
for analysis of the number of subgingival plaque bacteria by real time PCR. At these times, 
nanaerobes were expected to be killed by metronidazole. Real time PCR indicated total bacteria in 
the P5 treatment were typically similar or slightly higher than metronidazole treatment at 2 hours 
(Fig. A1), which was a similar pattern to that observed at 0.5 hours (data not shown). When 
enumerating bacteria on blood agar, dark brown/black colonies, consistent with the colony 
morphology of Prevotella and Porphyromonads, were observed, although at relatively low frequency 
(approximately 1-5 × 104 cfu mL-1). Consistent with colony count observations, based on the rapid 
growth of DMSO treatment samples and the relatively high number of bacteria remaining at 2 hour 
time point in the metronidazole treatment, it was concluded that insufficient nanaerobes were 
present to determine the specificity for adducts in the subgingival plaque of the four examined 
patients. This problem was exacerbated by rapid growth of presumably facultative bacteria, which 
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by examination of the total bacteria present, made it difficult to detect the fate of anaerobic 
bacteria. It was decided that an in vivo approach to determine the specificity of adducts may be 
more informative, so a rat plaque model was pursued. 
 
2.3.3 Rat Plaque Model 
During administration of P. gingivalis, inflammation was observed in the gingiva of rats, most 
prominent between the incisors of the mandible. Over the two-week period, no signs antisocial 
behaviour, changes in weight or in grooming were observed. The daily consumption of kanamycin by 
each rat was approximately 13-14 mg (65-70 mg kg-1 per day). Three weeks after conclusion of 
P. gingivalis and kanamycin administration, total bacteria and P. gingivalis population were 
compared by qPCR (Fig. A1 and Table A1). Each sample contained around 106 bacteria (0.6-1.4 ng 
genomic DNA) (Table A1). None of the samples contained detectable levels of P. gingivalis, a result 
verified by agarose gel electrophoresis (data not shown), despite the sensitivity of this assay being 
around 10 bacterial cells (20 fg genomic DNA). While the standard curve indicated the assay had 
excellent sensitivity, the samples may have contained substances that inhibited PCR or DNA may 
have been lost during extraction. Since the total bacterial population was low, acrylamide, a known 
carrier of DNA, was used to prevent loss of DNA during extraction. No significant increase in total 
DNA was detected, with serial dilutions of P. gingivalis genomic DNA mixed with acrylamide, in 
respect with non-treated controls (data not shown). PCR facilitators, DMSO, betaine and BSA did not 
significantly increase the concentration of amplified DNA (data not shown).  
Since none of the rats exhibited gross anatomical changes, and as introduction of ‘foreign’ 
Gram-negative nanaerobes into the rat oral cavity is notoriously difficult (Manrique et al., 2013) and 
the anatomy and bacterial composition differs from human counterparts, pursuit of this model was 
discontinued. 
 
2.4 DISCUSSION 
In single species growth curves, metronidazole killed examined anaerobic bacteria (five 
strains). P5 and P8 had a similar potency for P. gingivalis to that of metronidazole. In contrast, all of 
the other anaerobic bacteria tested grew in the presence of P5 and P8 in concentrations 
approximately ten fold higher than in concentrations of metronidazole that prevented growth. To 
facilitate comparisons between fastidious T. fosythia and other nanaerobes, enriched BHI medium 
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was chosen. In enriched BHI, F. nucleatum was unaffected by P5, whereas in CDC medium it was 
previously demonstrated that growth of this organism was delayed (Yap et al., 2009). Compared 
with CDC medium used previously (Yap et al., 2009), enriched BHI facilitated an increased growth 
rate and higher final biomass of P. gingivalis and F. nucleatum. It is possible that these results are 
due to increased fitness of these strains in enriched BHI medium, however, the growth of 
P. gingivalis and B. fragilis in DPIX was similar to DMSO carrier control, indicating enriched BHI 
contains sources of porphyrin (for example from fetal bovine serum) or other nutrients (such as 
succinate). If there are sources of porphyrin in enriched BHI, adducts may be competing with these 
porphyrins for uptake via porphyrin uptake pathways. The results also suggest the effectiveness of 
porphyrin adducts will be impacted by local concentration of nutrients (including porphyrin). 
The assessment of bacterial growth by optical density and real time PCR gave an overview of 
the response of complex subgingival bacterial communities to adducts and metronidazole. The fate 
of bacteria deposited in enriched BHI medium ranges from lysis, loss of viability or replication. 
Subgingival bacteria that are able to replicate in eBHI growth medium will have different nutrient 
requirements and different doubling times. Based on the number of black/brown pigmented 
colonies, consistent with the colony morphology of Porphyromonas and Prevotella, it was estimated 
that these clades together consisted of 1-5% of total inoculated bacteria.  
The average doubling time of nanaerobes of the oral cavity (P melaninogenica, F. nucleatum 
and P. gingivalis) in enriched BHI medium was 74.2 minutes. Doubling times of subgingival plaque 
under the same growth conditions were around 1.4-3 fold lower than for these nanaerobes, 
consistent that subgingival plaque was dominated by facultative anaerobes. Even though Prevotella 
and porphyromonads were presumptively identified on blood agar, it was likely these genera were 
being outcompeted by other bacteria with more lower doubling times. It is possible the DNA 
extraction method, based on chemical-lysis of cells, may not have isolated DNA from all microbes in 
growth curve samples. However, the chosen DNA extraction method had previously been verified 
against a range of facultative nanaerobes and anaerobic bacteria. Also, in all growth curves at 2 
hours, the concentration of DNA was above the 106 cfu mL-1 inoculum, indicating the extraction of 
bacterial DNA was effective. In order to examine the fate of presumably outcompeted nanaerobic 
bacteria, it would have been possible to slow the growth of facultative bacteria with antibiotics. 
Alternatively, the number of nanaerobic genera such as Porphyromonas could have been estimated 
by real time PCR using oligonucleotide primers specific for this clade. However, single species growth 
curves indicated sources of porphyrin or other nutrients might be obscuring the response of 
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nanaerobic bacteria to adducts. It was decided instead that a periodontal bone loss model may be 
more informative. 
The total bacteria detected three weeks after kanamycin and P. gingivalis administration, 
assessed by 16S rDNA real time PCR, equated to 106 cfu per sample. Based on the sampling 
procedure, a subgingival scrape of the front mandible incisors, the detected population of bacteria 
(DNA) was in the expected range. As mentioned above, the DNA extraction method had already 
been optimised for the extraction of DNA from oral bacteria. Nevertheless in an attempt to increase 
sensitivity of extraction and amplification, a DNA carrier and three PCR facilitators were used, none 
of which increased the detection of total bacterial genomic DNA. It is presumed that the disruption 
of oral microbes by kanamycin caused the observed inflammation, which may have inhibited the 
colonisation of P. gingivalis. It is more likely however, that the disruption caused by kanamycin was 
insufficient and that an antibiotic cocktail and a physical insult (tooth ligature) was required. 
Alternatively, a two-week induction period may have been insufficient or co-administration of other 
bacteria was required with P. gingivalis to allow colonisation and bone resorption (Kesavalu et al., 
2007). The rat oral cavity is dominated by facultative bacteria. If P. gingivalis colonisation was 
successful, there was no guarantee that the populations of native nanaerobes in the rat oral cavity 
would also increase. Rather than introduce P. gingivalis, a foreign anaerobic bacterium to an animal 
model, it was decided that it may be more informative to select a model replete with anaerobic 
bacteria, sensitive to nitroimidazoles, allowing interrogation of the specificity of adducts. 
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3.0 PREFACE TO CHAPTER III 
 
Studies using single species growth rates and by viable count determinations, as reported in 
Chapter II, revealed some pharmacokinetic properties of P5 and P8. Neither an ex vivo plaque model 
nor an in vivo rat P. gingivalis-induced periodontal bone loss model successfully interrogated the 
specificity of deuteroporphyrin-nitroimidazole adducts for P. gingivalis among complex microbial 
communities.  
For reasons outlined in Chapter II, a human ex vivo distal colon culture model was 
considered a more suitable than the rat oral cavity to determine the specificity of deuteroporphyrin-
nitroimidazole adducts, since it is dominated by nanaerobic nitroimidazole-sensitive Bacteroidetes 
(including Porphyromonas) and Clostridia (of the Firmicutes phylum). As a reference point, growth 
curves of 23 strains from dominant bacterial phyla originating from the human gastrointestinal tract 
are grown in brain heart infusion medium. Interesting findings relating to Bacteroides are further 
characterised. Using B. fragilis mutants, light-based biochemical, in silico analyses coupled with high 
performance liquid chromatography mass spectrometry, a schema is proposed for the metabolism 
of P5. The specificity of P5 is also compared with metronidazole by Illumina sequencing of the 16S 
ribosomal DNA of human bacteria challenged with these compounds in an ex vivo distal colon 
culture model. 
 
 
 
 
 
 
 
 
 
 
Chapter III   The metabolism of a deuteroporphyrin-nitroimidazole adduct by nanaerobic Bacteroidetes 
91 
3.1 INTRODUCTION 
 There are several ways to analyse complex bacterial populations, all of which have 
deficiencies. To overcome deficiencies inherent in each method, a combination of molecular and 
more traditional culture-based approaches are used in Chapter III. For example, bacteria may be 
analysed by using primers targeting conserved regions that flank variable portions of the universally 
conserved 16S rDNA. Bacteria may then be identified by sequencing the amplified variable region/s 
and comparing with databases of known 16S rDNA sequences. Misrepresentation of the types of 
bacteria in a given community in such analyses may be introduced from the DNA extraction, PCR 
primers and amplification conditions, sequencing platform and also post sequencing analyses. 
Specifically, a DNA extraction method may under represent different groups of bacteria. ‘Universal’ 
16S rDNA primers are designed to target conserved regions of the bacterial ribosomal DNA on the 
basis of a ‘best fit’ consensus. Thus, the 16SrDNA template is less likely to be amplified as it diverges 
from the primers, introducing bias in the types of template (or bacterial clades) that are amplified 
(Lee, et al., 2012). Empirical testing, coupled with an in-silico examination of primer-template 
specificity helps determine the degree to which divergence from the primers (or consensus 
conserved region) will allow a given template 16S rDNA molecule (or bacterial group) to amplify 
(Klindworth et al., 2012, Schirmer et al., 2015). As a taxonomic group of bacteria diverges from the 
‘universal primers’, it is less likely to be amplified, thus no 16S rDNA primers are truly universal (Lee, 
et al., 2012, Tremblay et al., 2015). The nine variable regions in the 16S rDNA give variable 
resolution, so the region/s chosen will inform resolution, which again may be interrogated by in 
silico analyses. Lastly, new bacterial phyla, are continually being detected/characterised and added 
to 16S rDNA databases, such as the non-photosynthetic anaerobic clade Melainabacteria, relatives 
of the Cyanobacteria recently found in the mammalian gut (Di Rienzi et al., 2013).  
Several ‘next generation’ sequencing technologies, including 454 pyrosequencing and 
Illumina platforms (see Fig. 3.1) are commonly used to survey complex bacterial consortia targeting 
the 16S rRNA gene or total genomic DNA. For 16S rRNA gene surveys, 454 pyrosequencing was the 
dominant platform since it was released first (in 2005) and also because of the originally longer 
sequencing capacity over competing technologies (Mardis, 2008, Degnan and Ochman, 2012). The 
nature of error introduced by sequencing platforms may result from insertions, deletions and base 
substitutions. The most prominent source of error inherent to 454 and Illumina platforms depends 
on the sequencing strategy, although in both technologies error results primary due to substitutions 
(Tremblay et al., 15). The Illumina ‘MiSeq’ platform has the capacity to sequence ≈250 bp amplicons 
from both ends of the same sequence generally known as ‘paired end’ sequencing. Paired-end  
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Figure 3.1: Solid phase amplification used in Illumina sequencing [from (Metzker, 2010)]. First, a 
‘library’ is prepared, during which the 5’ and 3’ ends of single stranded DNA molecules are appended 
to linkers (represented by red or blue rectangles) during PCR amplification. Linkers that are 
complementary to a flow cell (hexagonal base), adhere and form a bridge. Next, DNA molecules are 
amplified and the template plus newly synthesised reverse strand are linearised. This process 
proceeds iteratively until thousands of clonal DNA molecules are synthesised. Finally, nucleotides 
modified with a 3’ blocker and a fluorescent tag are added, along with primers. The 3’ block allows 
only one nucleotide to be incorporated per DNA sequence (adenine, thymine, cytosine or guanine). 
After the addition of each nucleotide, an image is taken, to determine which was incorporated. To 
allow incorporation of new modified nucleotides (ie. thymine), DNA sequences are chemically ‘de-
blocked’ until the DNA molecule is fully sequenced. 
 
sequencing increases the fidelity of 16S rDNA sequencing if the amplicon is small enough, since each 
base is sequenced twice (Tremblay et al., 15). As noted, 454 pyrosequencing sequences longer 
amplicons, however, the accuracy of base calling falls after approximately 350 bp, such that some 
sequences do not reliably reflect the original DNA template (Gilles et al., 11). The quality of base 
calling using Illumina Miseq sequencing also falls as the DNA molecule is sequenced from the 5’ to 3’ 
end (Nelson, 2014). The highest fidelity base calling of paired end Illumina sequencing is achieved by 
near-full or full-length overlap of the amplicon being sequenced, currently limiting this technology to 
the variable region 4 (V4) of the 16S rDNA which is approximately 254 bp (Kozich et al., 2013).  
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Both Illumina and 454 platforms provide a metric for the confidence of each base call against 
the parental sequence (similar to a Phred score associated with Sanger sequencing). For applications 
such as genome sequencing, a ten-fold coverage of the majority of target DNA is achieved, so that 
the fidelity (determined by the quality score, or ‘q score’) isn’t as important. However, for 
sequencing portions of a single gene such as the 16S rDNA, sequencing fidelity is important, as DNA 
molecules are sequenced once or twice. A q score of 20 to 30 corresponds to a predicted 99-99.9 % 
accuracy in base calling respectively (Ewing and Green, 1998). Genus level associations are currently 
accepted at 97% cut-off. A q-score less than or equal to 20, starts to impinge on the quality of 
binning sequenced DNA into taxonomic groups (Kozich et al., 2013). Notably, Illumina technologies 
are known to inflate the OTU number of sampled microbes from human faeces compared with 
longer reads (454 pyrosequencing Titanium technology), which is in part due to decreases in 
accuracy as a given molecule is sequenced (Claesson et al., 2010). After consideration of these 
technologies, Illumina Miseq paired-end sequencing of the V4 region was chosen to analyse complex 
bacterial populations, since this methodology provides the highest theoretical fidelity for one region 
of the 16S rDNA and gives the closest approximation to shotgun sequencing of environmental 
samples (Tremblay et al., 15). 
In order to establish the specificity of deuteroporphyrin-nitroimidazole adducts, a human ex 
vivo distal colon culture model is used in Chapter III. The main advantage of an ex vivo distal colon 
culture model is that bacterial inhabitants of human distal gut are largely nitroimidazole-sensitive 
Bacteroidetes (including Porphyromonas) and Clostridia (a Class of nanaerobes of the Firmicutes 
phylum, see also Table 3.1 for a phylogeny of these bacteria). Since human faecal bacteria are 
generally amenable to culturing (Goodman et al., 2011, Rea et al., 2011, Maurice et al., 2013), 
human faeces provides a largely nitroimidazole-sensnitve bacterial population for challenge with P5 
or metronidazole. Selective growth medium permit quantification of viable bacteria, instead of using 
DNA molecules as a proxy for the number or type of bacteria in a given sample. If bacteria are 
culturable, selective growth media may overcome some of the issues of 16S rDNA copy number, PCR 
amplification-bias, amplification of DNA from non-viable bacteria and/or errors associated with next 
generation sequencing mentioned above. Gentamicin is an aminoglycoside, produced primarily by 
Micromonospora spp. (such as M. purpurea, an Actinobacteria). Bacteria residing in the human gut, 
such as Prevotella and Fusobacterium tend to grow in high concentrations of gentamicin, while 
Bacteroides tend to be even more resistant to gentamicin (Finegold and Sutter, 1971). The vast 
majority of Bacteroides also hydrolyse esculin into esculetin and dextrose (Livingston et al., 1978). 
Taken together, gentamicin kills Proteobacteria and Firmicutes, whilst members of the Fusobacteria 
and non Bacteroides members of the phylum Bacteroidetes (including Prevotella and 
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Porphyromonas) tend to be inhibited by bile. Of the remaining bacteria that grow on solid medium 
with bile and gentamicin, esculin hydrolysis may be detected by the black precipitant formed from 
esculetin and ferric ammonium citrate, providing presumptive identification of Bacteroides. Indeed, 
all 160 Bacteroides strains tested in vitro blackened ‘Bacteroides Bile Esculin’ (BBE) agar, other than 
two of seven Bacteroides vulgatus strains (Livingston et al., 1978). The recipe used for BBE agar is 
similar to recipe optimised for brain heart infusion gentamicin bile ‘BHIGB’ agar in Chapter III, 
although with 75% less bile (see Table A2 for optimisation of bile and gentamicin concentrations).  
 
3.2 METHODS 
3.2.1 Medium Preparation and Growth Curves 
All bacterial growth curves were carried out using brain heart infusion medium (BHI), unless 
otherwise noted, in an anaerobic chamber at 37 °C in an atmosphere containing CO2 (5%), H2 (10%) 
and N2 (85%). Strict anaerobic conditions were maintained with a platinum-palladium-based catalyst 
(Don Whitley Scientific) which was regularly changed to remove O2 introduced during entry into the 
chamber. Annotox reagent (Don Whitley Scientific) was also frequently changed to trap volatile 
gasses. BHI contained brain heart infusion (37 g L-1, Oxoid, pH 7.7), yeast extract (5g L-1, Oxoid), L-
cysteine (0.5 mg L-1, Fluka), and when supplemented, haemin (5 mg L-1, Fluka) was included before 
autoclaving. Menadione (2 mg L-1, 0.22 µM filtered, Sigma) was added after autoclaving. Bacteria 
were first grown in BHI with haemin to OD600 ≈ 1.0 (or Faecalibacterium prausnitzii ≈ 0.8, Veillonella 
parvula and Parvimonas micra; ≈ 0.6). Bacteria were diluted 1/100 into fresh growth medium 
without haemin. At OD600 ≈ 1.0, bacteria were again diluted 1/2000 into fresh BHI medium without 
haemin at a final concentration of ≈5×105 cfu ml-1 and growth was monitored (by optical density at 
600nm). This procedure limited porphyrin carryover, while allowing growth of porphyrin-requiring 
strains (Prevotella and Porphyromonas) as described previously (Paramaesvaran et al., 2003). For 
each growth curve, bacterial purity and concentration was confirmed in duplicate on BHI containing 
4% sheep blood. Bacteroides thetaiotaomicron VPI 5482 was prepared in the same medium for 
viable counts and was enumerated in duplicate for each treatment on solid BHI supplemented with 
4% sheep blood. Adducts or metronidazole were defined as bactericidal when no growth (turbidity) 
occurred at a given concentration after 96 hours. Bacterial strains (23 for growth curves and four 
additional strains used in validating BGBHI agar) were available from our culture collection; 
purchased from American Type Culture Collection (Bacteroides thetaiotaomicron ATCC 29148 (VPI 
5482), Bacteroides vulgatus ATCC 8484 and Clostridium difficile ATCC 43255); or from Deutsche 
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Sammlung von Mikroorganismen und Zellkulturen (F. prausnitzii DSM 17677 and 
Eubacterium rectale DSM 17629).  
Bacteroides fragilis ADB77 (ΔthyA1) contains a deletion of the thymidylate synthase gene 
(thyA1), requiring thymine supplementation for growth (Baughn and Malamy, 2002). B. fragilis 
ADB247 and ADB260 are derived from B. fragilis ADB77, with small deletions from frdC (of 
transmembrane helices 2-5, ΔfrdC) or frdB (iron-sulfur coordination sites, ΔfrdB) (Baughn and 
Malamy, 2003). Since mutants have portions deleted from their genomes, antibiotic or other 
selective agent is not required, although B. fragilis ADB77 and derivative mutants require thymine 
for growth. Mutant B. fragilis ADB77 and mutant derivatives ADB247 and ADB260 were grown as 
described (Baughn and Malamy, 2002), by passaging from BHI(S) with supplemented haem into a 
minimal medium (‘glucose minimal medium’, ‘AMM gluc’). At an OD600 of 0.5, strains were diluted 
1/2000 into fresh AMM gluc medium. Bacterial purity and concentration was confirmed in duplicate 
on BHI(S) supplemented with haemin. Strains were not complemented, since under identical 
conditions, it was previously shown that mutants were complemented by vector plasmids carrying 
the frd operon (Baughn and Malamy, 2003). 
BGBHI agar was based on the original composition developed by Livingston et al, (Livingston 
et al., 1978) in which brain heart infusion (37g L-1, pH 7.7), esculin (0.5g L-1, Sigma), ferric ammonium 
citrate (0.25g L-1, Sigma), L-cysteine (0.5mg L-1), oxgall (‘bile’, 5g L-1, Difco) and gentamicin (100 mg L-
1, Sigma) were autoclaved, before the addition of menadione (2 mg L-1). 
Concentrated stock solutions of porphyrin/nitroimidazoles (<10mM) were dissolved in 
molecular grade DMSO (Sigma) before sterilisation with 0.22 µm non-pyrogenic cellulose acetate 
filters (Corning). In each assay, concentrated stock solutions were diluted 1/100 into growth medium 
so that each treatment contained 1% DMSO. Treatments were titrated in 1-2 µM intervals between 
0.5-20 µM. Pyrex growth tubes and caps were soaked in detergent and bleach between 
experiments, before autoclaving and extensive washing to remove residual porphyrin. 
Deuteroporphyrin IX-Cl2 (511.2 g mol-1) was provided by Frontier Scientific, metronidazole (171.2 g 
mol-1) by Sigma and ‘metronidazole-amine’ (1-(2-Aminoethyl)-2-methyl-5-nitroimidazole 
dihydrochloride monohydrate, 169.1 g mol-1) by Santa Cruz Biotechnology. P5 (663.5 g L-1) was 
synthesised as described previously (Yap et al., 2009). Unless stated otherwise, error incorporates 
standard error of the mean from two experiments containing duplicate treatments. The MIC is 
defined as the absence of growth after 96 hours incubation in growth medium. 
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3.2.2 Human ex vivo distal colon culture model growth curves, DNA 
extraction and Illumina Sequencing 
One portion of fresh human faeces (100 mg) was immediately emulsified into 4900 µL 
anaerobically equilibrated warm PBS, before transfer into an anaerobic chamber. The second 
portion of faeces (200 mg) was immediately stored at -80°C for DNA extraction. Viable counts were 
made on BHI agar with 4% sheep blood or on BGBHI, before introduction into BHI broth at 1 × 106 
cfu ml-1 with 20 µM treatments (see below) or DMSO carrier control (1%). The viable count of 
Bacteroides was estimated on BGBHI agar at 5 and 10 hours for comparison with the count obtained 
on BGBHI immediately before inoculation. At 10 hours, a 1 mL sample was stored -80 °C for DNA 
extraction and sequencing of 16S rDNA. Four ex vivo distal colon experiments were performed from 
one donor. Statistical analyses of viable counts were performed using unpaired, non-parametric t-
test (GraphPad Prism, v.6).  
For DNA extraction, 1 mL samples were defrosted on ice, and bacteria were isolated 
(14,000 g, 10 minutes, 4°C). DNA was extracted from bacterial pellets or faeces (200 mg) using 
QIAamp Fast DNA Stool MiniKit (QIAGEN), following the manufacturer’s protocol with the following 
amendments. 1) After a 10 minute incubation at 95C, lysozyme (800 µg, Sigma-Aldrich) and 
mutanolysin (400 U, Sigma-Aldrich) were added and samples were incubated for 1 hour at 56 °C. 2) 
All remaining supernatant lysate (~800 µL) was added to buffer AL (800 µL) with proteinase K (15 µL, 
QIAGEN) for a one hour incubation at 70°C. The standard protocol was followed until 3) samples 
were eluted into 100 µL ‘TAlowE’ buffer (10mM Tris, 0.5mM EDTA, pH 7.5). One extraction blank 
was included for each growth curve experiment. An average of 282 (±50) ng µL-1 genomic DNA, 
assessed by absorbance (Nanophotometer, Implen) was isolated from the four faecal inoculum 
samples. 
Genomic DNA was diluted to ≈10 ng µL-1 and sent to Ramaciotti Centre for Genomic Analysis 
(UNSW, Australia) for PCR amplification and sequencing of the V4 region [with 515f (5’-
GTGCCAGCMGCCGCGGTAA) and 806r (5’-GGACTACHVGGGTWTCTAAT) corresponding to positions 
533-786 of Escherichia coli 83972] of the 16s rRNA gene (300-350bp) using a mate pair dual 
sequencing strategy as described elsewhere (Caporaso et al., 2012). An illumina Miseq instrument 
using V2 chemistry had an average PhiX 6.21% and a cluster density of 1072±44. Sequences were 
demultiplexed and paired end reads were joined into contigs using Mothur (Schloss and Westcott, 
2011) leaving 9,391,212 sequences. Sequences were processed with Mothur (v. 1.36) following the 
‘Illumina SOP’ (http://www.mothur.org/wiki/MiSeq_SOP). Sequences were removed if they 
exceeded 275 bp, contained any ambiguous base calls or more than 8 homopolymeric runs or did 
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not map to regions 13862-23444 of the 50,000 column SILVA reference alignment (r 119, (Pruesse et 
al., 2007). Sequences flagged as chimeric using the Mothur implementation of UCHIME (Edgar et al., 
2011) were removed and sequences were amalgamated (‘preclustered’, diffs=2) into one sequence 
if they differed by less than 4 bases (Huse et al., 2010). Sequences were classified using the naïve 
Bayesian algorithm against the Mothur-formatted Greengenes reference 16S ribosomal database 
(‘gg_13_8_99’, with 202,421 bacterial and archaeal sequences) using an 80% pseudobootstrap value. 
Sequences were clustered into OTUs (3% similarity threshold). The number of quality filtered reads 
within a sample were converted to a percentage of the total reads within that sample. The average 
and standard error of the mean were calculated for remaining taxa within each sample type. Taxa 
that were less than 0.5% average abundance in all samples are not shown. Metastats, which uses a 
Student’s t-test (White et al., 2009) was used within Mothur to assess statistical significance of OTUs 
binned at 0.05 dissimilatory threshold (approximating genus level).  
 
3.2.3 Micro-broth Dilution for Antibiotic Susceptibility, DNA Extraction and 
nim-Gene Amplification 
Clostridum difficile were isolated from the stools of 100 symptomatic patients presenting to 
Westmead Hospital, Australia during July - October 2015. Strains were PCR-ribotyped and evaluated 
by Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spectrometry (MALDI-TOF MS, 
Bruker MALDI Biotyper using MALDI Biotyper Automation Control, software version 2.0.43.8) 
following established protocols in a clinical laboratory (Stubbs et al., 1999, Schmitt et al., 2012). 100 
strains were collected from 42 males and 58 females, which were characterised into 25 ribotypes. In 
an anaerobic chamber, strains were plated on pre-reduced BHI agar (1.5% w/v)]. Under strictly 
anaerobic conditions, strains were rapidly transferred to the Institute of Dental Research. After a 24 
hour incubation, strains were inoculated into BHI growth medium in an anaerobic chamber. At an 
OD600 of ≈1.0, strains were stored at -80°C in a final concentration of 10% (v/v) glycerol. 1 mL of the 
C. difficile cultures was retained at -80°C for DNA extraction following the protocol outlined in the ex 
vivo human faecal model. 
In an anaerobic chamber, metronidazole (0.07 – 17.12 µg mL-1) and P5 (0.52 – 66.35 µg mL-1) 
were introduced in two-fold serial dilutions ranging from 0.4-100 µM into 96 well micro titre plates 
with BHI growth medium. At the same time, C. difficile strains were streaked onto BHI agar. After 24 
hour incubation on BHI agar, C. difficile were introduced at a final concentration of 5×105 cfu mL-1 
into micro titre plates containing metronidazole and P5. After a 48 hour incubation of C. difficile 
Chapter III   The metabolism of a deuteroporphyrin-nitroimidazole adduct by nanaerobic Bacteroidetes 
98 
strains with treatments, the optical density was recorded (570 nm, Benchmate microplate reader, 
Bio rad). The concentration of metronidazole or P5 that prevented growth (OD570<0.01) after a 48 
hour incubation was defined as the MIC. For each 96-well plate, growth of C. difficile, sterility of 
media and metronidazole/P5 were verified in triplicate. Antimicrobial breakpoints were established 
based on guidelines from the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 
2016). All media and 96-well plates were equilibrated for 24 hours in the anaerobic chamber before 
use. Strictly anaerobic conditions were maintained by frequent exchange of a platinum-palladium 
catalyst (Don Whiteley Scientific) and anotox (Don Whiteley Scientific).  
PCR screening for the nimA-H genes (458 bp) was carried out using extensively validated nim 
primers (nim5: 5’-ATGTTCAGAGAAATGCGGCGTAAGCG and nim3: 5’-GCTTCCTTGCCTGTCATGTGCTC) 
(Trinh and Reysset, 1996, Husain, 2013, Meggersee and Abratt, 2015). PCRs were performed with 0.2 
µM primers, approximately 1 ng genomic DNA with HotStarTaq Master Mix (1x, QIAGEN) made up to 
a final volume of in 25 µL. The cycling protocol for nimA-H consisted of 95°C for 15 min, followed by 
35 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 1 min and a final 10 minute extension at 72°C. PCR 
screening for the nimJ was carried out using previously validated primers (615-616nimJ-qRT-F: 5’-
TGACAAGGCTTCGTTCTGTG and 615-616nimJ-qRT-R: 5’-GTCGAAACGAATCATCAGCA) (Husain et al., 
2013, Meggersee and Abratt, 2015). The cycling protocol for nimJ was identical, other than the use 
of a 55°C annealing temperature for 31 cycles (Husain et al., 2013, Meggersee and Abratt, 2015).  
 
3.2.4 Fumarate Reductase and Succinate Dehydrogenase Enzyme Assays 
B. thetaiotaomicron VPI-5482 was grown anaerobically and passaged in BHI medium as 
described for growth curves, before introduction into fresh growth medium with 20 µM haem, DPIX, 
P5 or DMSO (1% v/v) carrier in 50 mL Falcon tubes. During exponential phase of growth, Falcon 
tubes were tightly capped and bacteria were harvested at 10,000 g for 15 minutes at 4 °C. Cell 
pellets were washed with chilled buffer A and the washed pellet was made up to 5 ml with chilled 
pre-reduced buffer A (Macy et al., 1975). Buffer A consisted of potassium phosphate (50 mM), NaCl 
(150 mM), sucrose (100 mM) and sodium thioglycolate (10 mM), pH 7.0) as previously described 
(Macy et al., 1975). Cells were lysed via a French press (80 psi, Avestin) and aliquots were snap 
frozen by liquid nitrogen for storage at -80°C. All steps were carried out in an anaerobic chamber, 
except centrifugation and lysis. 
Enzyme activity assays were carried out in quartz cuvettes with a 1 mL reaction volume. 
Reagents were prepared in an anaerobic chamber, before cuvettes were tightly sealed and removed 
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for recording assays. Enzyme activities were assayed in 50 mM potassium phosphate, pH 7.6, with 
5 mM MgCl2 (Macy, 1975). Fumarate reductase activity was measured by recording the fumarate-
dependent increase in absorbance of the low potential electron donor safranin O (200 µM, E°-
290 mV), indicated by increase in absorbance at 521 nm. Immediately prior to each fumarate 
reductase assay, fresh sodium dithionite (5 mM, E°-660 mV) was added to reduce safranin O stock 
(5 mM) to a starting absorbance of A521≈0.01. Fumarate reductase activity is expressed in µmol 
safranin oxidised min-1 mg-1 protein in the presence of 10 mM sodium fumarate (using Ɛ = 27.8 cm-1 
mM-1). Succinate dehydrogenase activity was determined by measuring the succinate-dependent 
reduction of methylene blue (44 µM, E°10 mV) as indicated by a decrease in absorbance at 667 nm 
(Baughn, 2003). Succinate dehydrogenase activity is expressed in µmol methylene blue reduced min-
1 mg-1 protein in the presence of 3 mM sodium succinate (using Ɛ = 25.0 cm-1 mM-1). Assays were 
initiated by the addition of cell lysate and were monitored for 10 minutes at 23 °C (Beckman DU800). 
Error incorporates mean ±SEM from two experiments prepared from one cell extract. 
 
3.2.5 Chemical and Biological Reductive Activation of P5, Purification of 
Products and Liquid Chromatography and High Performance Mass 
Spectrometry of  
Sodium dithionite is used to model the biological reductive activation of nitroimidazoles 
(LaRusso et al., 1978). In an anaerobic chamber, porphyrin or nitroimidazole stock (10-40mM) in 
DMSO were made up to final volume with 10 equivalents (100-400mM) sodium dithionite (1M stock 
in anaerobically equilibrated PBS, 0.22 µM filtered). After a 5 minute incubation, an aliquot was used 
for B. thetaiotaomicron or C. difficile dithionite growth curves or at indicated concentrations. 
Treatments for growth curves were treated or non-treated with sodium dithionite, including DMSO. 
Extraction of the reduced products of P5 was based on an established porphyrin extraction 
method (McConville and Charles, 1979, Granick et al., 1972), in which porphyrins are partitioned into 
ethyl acetate with acetic acid (at pH 3.5, ‘fraction 1’) and a subsequently free-base porphyrins are 
purified in hydrochloride acid (at pH 1-2, ‘fraction 2’). B. thetaiotaomicron VPI-5482 was grown in 
defined ‘AMM Gluc’ medium (Baughn and Malamy, 2002) to OD600≈0.5, before dilution 1/2000 into 
AMM Gluc with P5 (20 µM). After 48 hours, pH was adjusted to 3.5 with acetic acid (≈70 mL per 500 
mL) and the culture autoclaved (‘dry cycle’, 15 minutes, 121 °C), to assist release of protein bound 
porphyrin during extraction.  
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P5, P5-reductively activated by dithionite and DPIX or P5 metabolised by B. thetaiotaomicron 
were diluted 1/10 in methanol for liquid chromatography coupled mass spectrometry (LC-MS). Low-
resolution measurements were obtained in positive mode from 150-1500 m/z on an LCQ Deca XP 
Plus mass spectrometer coupled in-line with PDA detection (Surveyor PDA Plus). Chromatography 
was performed on a C18 column (2.1 mm x 100 mm, Phenomenex Luna) using a Surveyor HPLC 
pump and auto sampler. Sample (1 µL) was injected and separated using a binary gradient of 0.1% 
formic acid in water against acetonitrile. The column eluent was directed through the flow cell of the 
PDA and into the electrospray source of the mass spectrometer. High resolution measurements 
were obtained using a Q-Exactive Plus mass spectrometer coupled to a U3000 UHPLC pump and 
auto sampler. A C18 BEH UHPLC column (2.1 mm x 100 mm, Waters) was employed on this system 
due to the differences in pumps. Chromatographic conditions and mass spectrometric detection 
were otherwise identical. Slight differences in retention times of ions between systems are due to 
slight changes in the employed systems.  
LC-MS data was analysed with Xcalibur (Thermo, v. 3.0.63) and ChemBioDraw Ultra (Perkin 
Elmer, v. 13.0.2.3021). The absorbance at 400 nm in chromatograms, corresponding to the Soret 
absorption region of porphyrins is shown because it is the most intense region. Q-band absorbance 
signatures were used to verify retention time of possible porphyrin compounds (data not shown). 
Parental ions and fragments were examined manually 0.5 minutes before and after retention times 
of tetrapyrrole absorbance peaks (at 400 nm). The base peak, or ion that had the highest intensity 
was assigned an abundance of 100%. LC-MS is not necessarily quantitative, though the ionisation 
efficiency relative to the base peak is reported graphically. Ions were examined from the base peak 
abundance to 6 orders of magnitude in the lower range. At predicted retention times, peaks were 
also inspected using Xcalibur ion detection system. For example, to confirm that P5 was metabolised 
in relevant samples, searches were made manually and via Xcalibur for [m/z + H+] = 663.3043. 
Specific search strategies are further elaborated in text. Where possible, structures and formulae 
consistent with ions were manually solved and depicted using ChemBioDraw Ultra. Specific  
 
3.2.6 In Silico Analysis of Fumarate Reductase 
For fumarate reductase, BLASTP searches were conducted using 
B. thetaiotaomicron ATCC 29148 frdC (230 residues), frdA (647 residues) and frdB (251 residues). 
Curated hits were binned at the genus resolution or the next highest available taxonomic 
classification. Hits with an average homology of ≥60% of the total frdCAB operon are shown. 
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3.3 RESULTS 
3.3.1 The response of single species and more complex bacterial populations 
of bacteria to P5 
In Chapter II, the maximal growth of P. gingivalis ATCC 33277 was observed in enriched BHI 
medium with and without porphyrin supplementation. These results suggested that porphyrin or 
other nutrient sources in enriched BHI growth medium were obscuring the porphyrin-based maximal 
growth of P. gingivalis. To determine whether sources of porphyrin in enriched BHI growth medium 
were obscuring the growth stimulation of other bacteria, growth curves were repeated in non-
enriched BHI media. The doubling times of P. gingivalis ATCC 33277 and W83 in the presence of 20 
µM DPIX doubled and the final optical density was close to double the DMSO control treatment by 
96 hours (Fig 3.1 and Table 3.2). Growth of Bacteroides spp. (n=5) and Prevotella spp. (n=2) also 
doubled when 20 µM DPIX was supplemented into media (average 1.9-fold) (Fig. 3.1 and Table 3.2). 
Surprisingly, relative to the DMSO control, the doubling time decreased 1.5-fold in Bacteroides spp. 
grown with DPIX amide linked-nitroimidazole adduct P5 at 20 µM (Fig. 3.1, Table 3.1 and Table 3.2). 
At 20 µM, P5 is more than 3-fold the concentration of metronidazole that suppresses growth of 
these Bacteroides spp. (Fig. 3.1, Table 3.1 and Table 3.2). 
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Figure 3.1: Growth of Bacteroidetes in BHI medium. B. thetaiotaomicron VPI 8482 (‘Bt’), B. fragilis 
(‘Bf’), B. vulgatus (‘Bv’), B. thetaiotaomicron ATCC 29741 (‘B’), B. uniformis (‘Bu’), Porphyromonas 
gingivalis W83 (‘Pw’), P. gingivalis ATCC 33277 (‘Pg’), Prevotella melaninogenica (‘Pm’) and 
P. intermedia (‘Pi’). 
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Further, P5 decreased the doubling time of Prevotella spp. two-fold when titrated below 
inhibitory concentrations. Since metronidazole in the presence of DPIX killed Bacteroides spp., the 
responses of other major bacterial phyla of the human gastrointestinal tract were surveyed. P5 and 
DPIX were assayed at 20 µM, which approaches the solubility limits in BHI growth medium. In 
contrast to the Bacteroidetes, DPIX or P5 did not support the growth of other major clades of the 
human gut, including representatives from the Firmicutes (n=8), Fusobacteria (n=1), Actinobacteria 
(n=3) and Proteobacteria (n=2) (Fig. 3.2, Fig. 3.3 and summary in Table 3.1). Growth of facultative 
bacteria in these clades in the presence of metronidazole was similar to DMSO carrier control (Table 
3.2). Nanaerobes within the Clostridia class (n=5), were consistently more sensitive to P5 (MIC: 1-2 
µM, mean 1.6 µM) than metronidazole (MIC: 3-11, µM mean 5.6 µM; see Fig. 3.2 and Table 3.1), 
with the exception of Veillonella parvula, which was not killed by P5 at 20 µM. Fusobacterium 
nucleatum grew in the presence of 20µM adduct, 10-fold the concentration of metronidazole 
required to kill this bacterium. 
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Figure 3.2: Growth of Firmicutes and Fusobacteria in BHI medium. Veillonella parvula (‘Vp’), 
Parvimonas micra (‘Pm’), Clostridium perfringens (‘Cp’), C. difficile (‘Cd’), Faecalibacterium prausnitzii 
(‘Fp’), Eubacterium rectale (‘Er’) and Fusobacterium nucleatum (‘Fn’). 
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Figure 3.3: Growth of Proteobacteria and Actinobacteria in BHI medium. Streptococcus mutans 
(‘Sm’), Lactobacillus rhamnosus (‘Lr’), Bifidobacterium dentium (‘Bd’), Actinomyces odontolyticus 
(‘Ao’), Actinomyces naeslundii (‘An’), Serratia marcescens (‘S’) and Escherichia coli (‘Ec’). 
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Table 3.1: Summary of minimum inhibitory concentrations (in µM) or growth stimulation (+) of 
bacterial strains in BHI growth medium with metronidazole (‘M’), DPIX and P5. The absence of 
growth stimulation is indicated by (-). Below inhibitory concentrations, P5 stimulated growth of 
bacteria marked with an asterisk (*).  
Physiology Phylum Family Strain M DPIX P5
Bacteroides fragilis  ATCC 25285 <5 + +
Bacteroides thetaiotaomicron VPI-5482 (ATCC 29148) <7 + +
Bacteroides thetaiotaomicron ATCC 29741 <7 + +
Bacteroides vulgatus ATCC 8482 <5 + +
Bacteroides uniformis ATCC 8492 <7 + +
Porphyromonas gingivalis W83 <0.5 + <0.5
Porphyromonas gingivalis ATCC 33277 <0.5 + <0.5
Prevotella melaninogenica ATCC 25845 <2 + <3*
Prevotella Intermedia ATCC 25611 <1 + <3*
Fusobacterium nucleatum ATCC 25586 <2 - >20
Veillonellacaeae Veilonella parvula  ATCC 10790 <9 - >20
Parvimonas micra  ATCC 33270 <11 - <1
Clostridium perfringens  ATCC 13124 <6 - <2
Clostridium difficile VPI-10463 (ATCC 43255) <3 - <2
Faecalibacterium prausnitzii  A2-165 (DSM 17677) <5 - <2
Eubacterium rectale A1-86  (DSM 17629) <3 - <1
Streptococcus mutans  ATCC 25175 >20 - >20
Lactobacillus rhamnosus  ATCC 7469 >20 - >20
Bifidobacteriaceae Bifidobacterium dentium  ATCC 27534 >20 - >20
Actinomyces odontolyticus  ATCC 17982 >20 - >20
Actinomyces naeslundii  ATCC 12104 >20 - >20
Serratia marcescens  ATCC 274 >20 - >20
Escherichia coli ATCC 25922 >20 - >20
Nanaerobic
Facultative Actinobacteria
Enterobacteriaceae
Actinomycetaceae
Fusobacteriaceae
Lactobacillaceae
Bacteroidetes
Fusobacteria
Proteobacteria
Firmicutes
Bacteroidaceae
Porphyromonadaceae
Prevotellaceae
Clostridiaceae
 
 
Next an ex vivo faecal growth curve model was used to determine if the results obtained in 
single species growth curves held in complex bacterial populations. In this model, bacterial inocula 
were diluted to be within concentrations of metronidazole and P5 known to be lethal, as determined 
in Chapter II in enriched BHI growth media and confirmed in BHI growth media (Fig 3.4). Changes in 
viable Bacteroides were assessed with BHI medium containing gentamicin and bile (‘BHIBG’), a 
selective medium for Bacteroides, that are resistant to these molecules (Livingston et al., 1978). On 
BHIBG, Bacteroides hydrolyse esculin forming a dark precipitate with iron-citrate surrounding 
colonies (Livingston et al., 1978). By 10 hours, metronidazole and metronidazole with DPIX 
eliminated 97.9% and 97.5% respectively of inoculated Bacteroides, confirming escape of 
nitroimidazole-mediated death occurred only when DPIX was tethered to a nitroimidazole, as in P5 
(P<0.05, Fig. 3.5A). Also after a 10 hour incubation with P5, viable Bacteroides were around double 
(1.9 fold) DMSO control and were higher than DPIX (17.6%), indicating not only did P5 enhance 
growth, but that depletion of other clades (such as Clostridia) advantaged the Bacteroides 
(Fig. 3.5A). Illumina sequencing of the 16S rDNA gene (V4 region) confirmed that by 10 hours, the 
Bacteroides population were enhanced by P5 (2.4 fold increase over DMSO, OTU1 P=0.0009 and  
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Table 3.2: Summary of bacterial doubling times (TD) of strains in BHI growth media with 
metronidazole (‘M’), DPIX and P5. Doubling times are calculated in 20 µM DPIX, metronidazole and 
P5 except for Parvimonas micra and Prevotella spp. which were grown in the presence of 12 µM and 
2 µM DPIX respectively. 
Physiology Phylum Family Strain DMSO DPIX M P5
Bacteroides fragilis  ATCC 25285 128 64 NA 65
Bacteroides thetaiotaomicron VPI-5482 155 78 NA 77
Bacteroides thetaiotaomicron ATCC 29741 111 72 NA 74
Bacteroides vulgatus ATCC 8482 138 74 NA 120
Bacteroides uniformis ATCC 8492 145 68 NA 139
Porphyromonas gingivalis W83 295 162 NA NA
Porphyromonas gingivalis ATCC 33277 398 198 NA NA
Prevotella melaninogenica ATCC 25845 345 139 NA 155
Prevotella Intermedia ATCC 25611 332 206 NA 201
Fusobacterium nucleatum ATCC 25586 110 103 NA 88
Veillonellacaeae Veilonella parvula  ATCC 10790 205 218 NA 226
Parvimonas micra  ATCC 33270 308 264 NA NA
Clostridium perfringens  ATCC 13124 29 35 NA NA
Clostridium difficile VPI-10463 50 51 NA NA
Faecalibacterium prausnitzii  A2-165 97 95 NA NA
Eubacterium rectale A1-86 92 95 NA NA
Streptococcus mutans  ATCC 25175 70 73 73 108
Lactobacillus rhamnosus  ATCC 7469 112 92 86 102
Bifidobacteriaceae Bifidobacterium dentium  ATCC 27534 114 155 155 155
Actinomyces odontolyticus  ATCC 17982 128 180 128 272
Actinomyces naeslundii  ATCC 12104 177 227 156 156
Serratia marcescens  ATCC 274 46 47 46 47
Escherichia coli ATCC 25922 41 41 41 41
TD (min
-1
)
Nanaerobic
Bacteroidetes
Bacteroidaceae
Porphyromonadaceae
Prevotellaceae
Fusobacteria Fusobacteriaceae
Firmicutes
Clostridiaceae
Facultative
Lactobacillaceae
Actinobacteria
Actinomycetaceae
Proteobacteria Enterobacteriaceae
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Figure 3.4: Kill curve of B. thetaiotaomicron VPI 5482 with 20 µM treatments or DMSO (1% v/v). 
B. thetaiotaomicron (≈5×105 cfu ml-1) was introduced into each treatment at time O. The doubling 
time for B. thetaiotaomicron in DMSO, DPIX and P5 were 136.4, 85.2 and 77.4 min-1 respectively. The 
lower limit of detection was 20 cfu mL-1. 
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OTU4 P=0.0002) and that metronidazole and metronidazole plus DPIX eliminated the majority 
(97.7% and 98.2% respectively) of inoculated Bacteroides (Fig. 3.5B and Table 3.3). In contrast, 
Clostridia were eliminated by metronidazole and by P5, with the exception of Lachnospiraceae 
(predominantly OTU5, P=0.007, Fig. 3B and Table 3.3). Interestingly, overgrowth of bacteria 
insensitive to metronidazole was reduced in the P5 treatments. For example, Streptococci (OTU2) 
dominated the metronidazole treatment (68.4%, P=0.0002), a 5-fold increase over DMSO control 
(12.9%), whereas P5 resulted in a 2-fold increase (25.5%, ns, see also Table 3.3). 
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Fig. 3.5: Ex vivo distal colon culture model with (A) Viable Bacteroides recovered at five hours (blue) 
and 10 hours (grey) as a percent of inoculated Bacteroides (‘100%’ at 0 hours), (mean±SEM, n=4). (B) 
Major changes in bacterial families based on 16S rDNA sequencing at 10 hours (mean±SEM, n=4). 
Bacterial families with >±5% variance between metronidazole and P5 treatments are shown (see 
Table 3.3 for full 16S rDNA sequencing results). 
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Table 3.3: Ex vivo faecal culture model Illumina sequencing of the 16S rDNA (V4 region) of 
10,864,916 quality filtered sequences. The absolute total was calculated from all quality filtered 
(10,864,916) sequences. The average (‘Av.’) and SEM were also calculated within each of the seven 
treatment groups from four experiments. Phylum summing less than 0.5% of the total sequences are 
summarised as ‘Other’ including: Unclassified (8661 sequences), Fusobacteria (107 sequences), 
Planctomycetes (6 sequences), Acidobacteria (3 sequences), OD1 (3 sequences), Chloroflexi (1 
sequence) and OP11 (1 sequence). 
Taxa Av. SEM Av. SEM Av. SEM Av. SEM Av. SEM Av. SEM
Bacteroidetes 27.0 0.7 13.6 1.9 16.1 2.1 0.6 0.3 0.8 0.5 32.7 3.5
Bacteroidaceae 23.6 0.6 13.1 1.8 15.3 1.8 0.5 0.3 0.7 0.5 31.7 3.5
Porphyromonadaceae 0.9 0.2 0.4 0.1 0.7 0.3 0.0 0.0 0.0 0.0 0.9 0.2
Rikenellaceae 1.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Firmicutes 63.8 1.0 84.0 2.5 81.3 3.2 76.3 11.2 71.5 10.2 55.7 8.0
Bacilli 0.6 0.0 13.5 3.4 10.3 2.4 73.9 10.9 70.0 9.8 33.0 4.4
Enterococcaceae 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.9 0.3 0.2 7.4 7.2
Streptococcaceae 0.4 0.0 12.9 3.5 9.6 2.5 72.5 11.0 69.7 9.8 25.5 7.9
Turicibacteraceae 0.2 0.1 0.5 0.3 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0
Clostridia 59.0 1.5 63.4 4.5 64.1 4.2 2.0 1.0 1.2 0.4 22.3 6.9
Unclassified family 1.0 0.2 8.0 5.7 7.2 6.0 0.4 0.3 0.1 0.1 0.0 0.0
Clostridiaceae 1.1 0.4 2.2 1.0 1.2 0.8 0.1 0.0 0.0 0.0 0.0 0.0
Lachnospiraceae 30.5 1.9 39.8 2.0 43.5 5.1 1.2 0.5 0.8 0.3 20.1 7.0
Ruminococcaceae 25.4 3.6 12.7 1.1 11.5 1.9 0.4 0.1 0.2 0.1 0.3 0.1
Veillonellaceae 1.0 0.1 0.5 0.1 0.5 0.1 0.0 0.0 0.0 0.0 1.9 0.3
Erysipelotrichi 1.5 0.3 7.0 2.6 6.8 2.1 0.1 0.0 0.0 0.0 0.4 0.2
Erysipelotrichaceae 1.5 0.3 7.0 2.6 6.8 2.1 0.1 0.0 0.0 0.0 0.4 0.2
Unclassified class 2.6 0.9 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.1 0.1 0.0
Proteobacteria 7.1 0.4 0.7 0.4 1.3 0.6 21.2 11.6 26.3 10.2 10.9 5.4
Betaproteobacteria 1.0 0.0 0.1 0.0 0.2 0.1 5.0 1.4 4.9 1.4 1.1 0.3
Alcaligenaceae 1.0 0.0 0.1 0.0 0.2 0.1 5.0 1.4 4.9 1.4 1.1 0.3
Deltaproteobacteria 1.1 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1
Desulfovibrionaceae 1.1 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1
Gammaproteobacteria 5.0 0.5 0.5 0.3 1.0 0.6 16.2 12.6 21.4 11.3 9.6 5.4
Enterobacteriaceae 0.0 0.0 0.4 0.4 0.8 0.6 14.4 13.2 19.5 12.2 9.3 5.5
Pasteurellaceae 5.0 0.5 0.1 0.0 0.1 0.0 1.8 0.6 2.0 0.9 0.3 0.1
Actinobacteria 0.5 0.2 1.6 0.4 1.3 0.5 1.9 0.8 1.4 0.5 0.7 0.4
Bifidobacteriaceae 0.2 0.1 0.8 0.4 0.5 0.2 1.9 0.8 1.4 0.5 0.7 0.4
Coriobacteriaceae 0.3 0.2 0.8 0.6 0.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0
Other 1.6 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0
P5Inocula DMSO DPIX DPM M
 
 
3.3.2 The metabolism of P5 by Bacteroides 
After establishing the growth enhancing effect of P5 for Bacteroides and Prevotella, it was 
hypothesised that these genera might incorporate a metabolite or metabolites of P5 into a b-
cytochrome to enabling fumarate reductase activity. The homology of the fumarate reductase 
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operon within the Bacteroides and Prevotella genera was 87.5% (78 strains) and 75.6% (107 strains) 
respectively (Fig. 3.8). In B. fragilis FRD forms a three-component operon, frdC, frdA and frdB 
encoding the b-cytochrome, iron sulphur cluster protein and flavoprotein respectively. As previously 
described, doubling times for parental B. fragilis ADB77 were around 8.3 h-1 in the absence of a 
porphyrin source, compared to 2.3-2.4 h-1 when the growth medium was supplemented with haem, 
DPIX, or P5 (Fig. 3.6 and Table 3.4) (Macy et al., 1975, Baughn and Malamy, 2003). Whether grown 
with porphyrin supplementation or not, mutants derivatives of ADB77, which were deficient in b-
cytochrome formation, B. fragilis ADB247 (ΔfrdC) and ADB260 (ΔfrdA), had similar doubling times 
(averaging 8.1-8.2 h-1 Fig. 3.6), similar to those reported (Macy et al., 1975, Baughn and Malamy, 
2003). These results confirmed that in a defined growth medium, these genes were essential for 
incorporation of exogenous porphyrin into a b-cytochrome. Under identical conditions, it was 
previously shown that mutants complemented by vector plasmids carrying the frd operon, restored 
fumarate reductase activity (Baughn and Malamy, 2003). 
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Figure 3.6: Growth of parental B. fragilis ADB77 (A) or derivative mutant strains B. fragilis ADB247 
(frdC, B) and B. fragilis ADB260 (frdA, C) in defined medium. Data is from one representative 
experiment repeated twice. Haem, DPIX and P5 were assayed at 20 µM.  
 
Next, the activity of FRD and SDH, using a lysate of B. thetaiotaomicron grown with P5 were 
compared with porphyrins that are known to form a b-cytochrome (DPIX and haem) or with no 
added porphyrin control (DMSO). No FRD or SDH activity were detected in a lysate of 
B. thetaiotaomicron grown without added porphyrin (DMSO control), indicating B. thetaiotaomicron 
was unable to form a detectable b-cytochrome in BHI medium (Table 3.5). In contrast, FRD activity 
similar in B. thetaiotaomicron lysate grown in the presence of haem or DPIX, which was 
approximately 0.3-fold higher than the activity of B. thetaiotaomicron grown with P5 (Table 3.5). 
SDH activity was similar in B. thetaiotaomicron lysate grown in the presence of haem or DPIX, which 
was 15-fold higher than the activity of B. thetaiotaomicron grown with P5 (Table 3.5). 
Next, using serial 10-fold serial dilutions of porphyrins, it was demonstrated that haem, 
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Table 3.4: Doubling times of parental B. fragilis ADB77 or derivative mutant strains 
B. fragilis ADB247 and B. fragilis ADB260 in the presence and absence of porphyrins. 
Treatment ADB77 ADB247 ADB260
DMSO 8.3 8.1 8.1
DPIX 2.3 8.2 8.3
Haem 2.3 8.0 7.9
P5 2.4 8.7 8.3
Td (h-1)
 
 
DPIX and PPIX, all increased doubling time of B. thetaiotaomicron above 20 pM (>2.4 × 104 molecules 
cell-1) in BHI medium (Fig. 3.7 and Table 3.6). Above 2 nM (>2.4 × 106 molecules cell-1) P5, enhanced 
growth rate than DMSO control (Fig. 3.7). Growth stimulation by P5 at nanomolar concentrations is 
compatible with P5 forming a b-cytochrome. Finally 10-fold serial dilutions of B. thetaiotaomicron 
were prepared in BHI growth medium ranging from 5 × 105 cfu to 5 cfu containing 20 µM 
metronidazole or P5. None of the cultures of B. thetaiotaomicron grew in 20 µM metronidazole, 
whereas all grew in P5 (not shown). These results demonstrate that regardless of the concentration, 
B. thetaiotaomicron is not killed by P5. Possible interpretations of this data are considered in the 
discussion.  
 
Table 3.5: Fumarate reductase and succinate dehydrogenase activity of cell free extracts of 
 B. thetaiotaomicron grown with (DPIX, haem, P5) or without a source of porphyrin (DMSO). Error 
incorporates mean ±SEM from two independent experiments prepared from one cell extract. ND=no 
activity detected 
DMSO Haem DPIX P5
FRD ND 6.2 ±0.1 7.6 ±0.8 4.6 ±0.4
SDH ND 4.9 ±0.1 4.0 ±0.2 0.3 ±0.1
Enzyme Activity [µmol min-1 (mg protein)-1]
 
 
Table 3.6: Doubling time of B. thetaiotaomicron VPI 5482 titrated with 0.02 nM - 20 µM treatments 
(equating to 2.4×103-10 molecules per inoculated bacterium). The concentration of treatments is 
indicated in nmoles. The doubling time of B. thetaiotaomicron in DMSO was 116.1 min-1. 
Treatment 20000 2000 200 20 2 0.2 0.02
DPIX 69.4 66.3 68.3 66.3 65.4 78.8 116.1
PPIX 67.3 64.6 65.4 67.3 70.6 83.7 116.1
Haem 64.6 63.8 68.3 65.4 68.3 86.7 116.1
P5 75.0 63.8 70.6 69.4 86.7 100.0 116.1
Treatment Concentration (nM)
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Figure 3.8: Growth of B. thetaiotaomicron VPI 5482 titrated with 0.02 nM - 20 µM treatments 
(equating to 2.4×103-10 molecules per inoculated bacterium) or with DMSO. The concentration of 
treatments is indicated in nmoles. Concentrations below 2 pM for P5 or below 20 pM for 
metronidazole (‘M’) are not shown because growth in these treatments were identical to DMSO 
treatment. Note that from 20 pM – 20 µM growth of B. thetaiotaomicron in DPIX, PPIX and haem 
(haem) was saturated. Note that 20 µM treatment was corrected by blanks and that this treatment 
was otherwise identical to the 2 µM treatment. 
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Figure 3.8: Homology searches (BLASTP) using B. thetaiotaomicron VPI 5482 FrdC (D), FrdA (C) and 
FrdB (B) fumarate reductase complex proteins. The average homology from gastrointestinal bacteria 
for the entire fumarate reductase complex is also summarised (A, hits ≥60% are shown). When 
genus identification was not available, next highest available taxonomic rank was presented.  
 
3.3.3 The Structural Metabolism of P5 by Bacteroides thetaiotaomicron 
         Sodium dithionite is commonly used to chemically inactivate nitroimidazoles, causing nitro 
group reduction and heterocycle fragmentation. To validate this method, the growth of C. difficile 
(Fig. 3.9) and B. thetaiotaomicron (Fig. 3.10) was compared with metronidazole and P5 alone or with 
these compounds after chemical reduction by pre-incubation with sodium dithionite. C. difficile was 
unable to grow in the presence of lethal concentrations of metronidazole or P5 (10 µM, Fig 3.9). 
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When metronidazole and P5 (10 µM) were pre-incubated with sodium dithionite, growth of 
C. difficile was identical to the DMSO treatment (Fig 3.9) validating this method. Similar results were 
obtained for B. thetaiotaomicron with a lethal concentration of metronidazole (20 µM). Pre-
treatment of metronidazole with sodium dithionite permitted identical growth to the DMSO control, 
whereas in the absence of sodium dithionite, growth was totally inhibited (Fig. 3.10). Maximal 
growth of B. thetaiotaomicron occurred with P5 and with dithionite treated P5 (Fig. 3.10). There was 
a slight increase in the growth of B. thetaiotaomicron (Fig. 3.10). Interpretations for this result are 
discussed below. Altogether, these results provide strong evidence toxicity associated with P5 is 
related to the nitro group reduction.  
 
0.001
0.01
0.1
1
10
0 20 40
O
D
 (6
0
0
n
m
)
Time (h)
DMSO
DMSO-
DPIX
DPIX-
A
0 20 40
Time (h)
M
M-
B
0 20 40
Time (h)
P5
P5-
C
 
Figure 3.9: Growth of C. difficile in the presence of DMSO, DPIX (10 µM), metronidazole (‘M’, 10 µM) 
or P5 (10 µM). Treatments with a minus sign (-) were chemically reduced with sodium dithionite as 
described in methods before introduction into growth medium. Doubling times of DMSO or 
reductively activated metronidazole and P5 were 53, 54 and 54 min-1 respectively. 
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Figure 3.10: Growth of B. thetaiotaomicron in the presence of DMSO, DPIX (20 µM), metronidazole 
(‘M’, 20 µM) or P5 (20 µM). Treatments with a minus sign (-) were incubated with sodium dithionite 
(chemically reduced as described in text) before introduction into growth media. Doubling times of 
DMSO, P5 or reductively activated metronidazole and P5 were 130, 74, 127 and 69 min-1 
respectively. 
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As described in the thesis introduction, the nitro group appended to a nitroimidazole may be 
reductively activated, leading to ring fragmentation and cytotoxicity. A possible alternative fate is 
that the nim system reductively inactivates the nitro group, forming an amino derivative. Two 
controls were used to help decipher how B. thetaiotaomicron was metabolising P5. P5 chemically 
reduced with dithionite was used as the first control, to model the biological reductive activation of 
P5, leading to ring fragmentation. The metabolism of DPIX by B. thetaiotaomicron was also 
examined. This control was included to help determine if P5 or derivatives were metallated and also 
whether metabolite/s of P5 were further processed by B. thetaiotaomicron. Since tetrapyrroles 
exhibit characteristic absorbance around 400 nm and also in the q-band region, ions at retention 
times within peaks that had these unique signatures were interrogated. 
In a previous study, low resolution LC-MS technology demonstrated metronidazole 
fragments into several species [at least 26 products (Knox et al., 1983)]. Data obtained with a high 
resoluton LC-MS was more complex (>100 ions). In order to stratify ions, structures consistent with 
the possible fragmentation of P5 were solved (Figs. 3.12A and 3.12B), also see summary in Fig. 3.15). 
Importantly, an ion with [m/z + H+] = 510.2502 (which was similar to the calculated ion of 510.2505, 
for C30H31N5O3 + H+), was consistent with a similar structure to DPIX (Fig. 3.12C). This ion was 
detected with a relative abundance of approximately 0.04% (Fig. 3.12C and also Fig. 3.17).  
In an examination of DPIX metabolised B. thetaiotaomicron, hundreds of ions were also 
observed. Three main ions, consistent with DPIX or the addition of ethyl and methyl groups to DPIX, 
were detected (Fig. 3.13). The genome of B. thetaiotaomicron encodes three candidate enzymes 
that may add methyl or ethyl groups including tetrapyrrole methylase family-like protein (BT_2273), 
tetrapyrrole methylase family protein/MazG (BT_4350) and magnesium protoporphyrin O-
methyltransferase (BT_4355). In DPIX metabolised by B. thetaiotoamicron, no ions consistent with 
iron metallated DPIX [m/z + H+] = 565.1538) or magnesium metallated DPIX ([m/z + H+] = 533.2039) 
were detected. Possible explanations for the absence of a metallated derivative of DPIX are 
discussed below. Notably, these data further support the notion that B. thetaiotaomicron is able to 
metabolise abiotic porphyrins.  
Next, using dithionite treated P5 and B. thetaiotaomicron metabolised-DPIX controls to 
inform analyses, the metabolism of P5 by B. thetaiotaomicron following incubation in defined 
growth medium was examined. Many of the ions detected at these retention times in 
B. thetaiotaomicron metabolised P5 were shared in dithionite-incubated P5 treatment (see 
examples of these ions and possible structures in (Figs. 3.14A - 3.14B). No ions were detected 
consistent with P5 ([m/z + H+] = 663.3043), indicating all of the P5 was taken up and metabolised by 
B. thetaiotaomicron. Secondly, no ion consistent with the amino derivative of P5 ([m/z + H+ =  
Chapter III   The metabolism of a deuteroporphyrin-nitroimidazole adduct by nanaerobic Bacteroidetes 
116 
 
 
Figure 3.11: HPLC traces with absorbance at 400 nm on the y-axis and retention time on the x-axis. 
A representative blank (A) is shown for samples (B), (C) and (D). A representative blank (E) pertains 
to remaining samples. P5 (B) is shown for reference, and (C) is P5 incubated (chemically reduced) 
with sodium dithionite. (F) and (G) are ethyl acetate extract and final HCl extract from 
B. thetaiotaomicron–metabolised P5 after 48 hour incubation respectively. The final HCl layer from 
B. thetaiotaomicron–metabolised DPIX after 48 hour incubation is shown as a reference (D).  
 
633.3301, for C36H40N8O3 + H+) was detected, indicating the absence of a nim system. An ion with 
[m/z + H+] = 510.2502, which was similar to ion detected in the dithionite-P5 treatment of 
abundance ~0.01%, was consistent with a derivative with a similar structure to DPIX (see summary 
Fig. 3.15 and Fig. 3.17). This ion is a possible candidate for b-cytochrome formation. Also, a 
prominent ion of around 10% ‘abundance’ ([m/z + H+ = 553.2919, calculated for C32H36N6O3 + H+, 
Fig. 3.14A) was also shared in P5-dithionite control. This ion also contained a possible methyl 
derivative ([m/z + H+ = 567.3080, calculated for C33H38N6O3 + H+, Fig. 3.14A) of abundance ~1%.  
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Fig. 3.12A: LC-MS from sodium dithionite incubated P5 (chemically reduced) from 200-900 m/z. 
Where possible, formula and structures consistent with major detected ions (boxed) are shown. 
^Possible doubly charged ion, often formed from the parental ion of tetrapyrroles. 
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Fig. 3.12B: LC-MS sub-set (of Fig 3.12A) from sodium dithionite incubated P5 from 500-650 m/z. 
Formula and structures consistent with major detected ions (boxed) are shown. Note the new scale 
of y-axis. 
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Fig. 3.12C: LC-MS sub-set (of Fig 3.12B) from sodium dithionite incubated P5 from 500-520 m/z. 
Formula and structures consistent with major detected ions (boxed) are shown. Note the new scale 
of y-axis. 
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Fig. 3.13: LC-MS of an extract of DPIX metabolised by B. thetaiotaomicron from 200-900 m/z. 
Formula and structures consistent with major detected ions (boxed) are shown ^Possible double-
charged ions are indicated. 
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Fig. 3.14A: LC-MS from an ethyl acetate extract of P5 metabolised by B. thetaiotaomicron from 200-
900 m/z. Where possible, formula and structures consistent with major detected ions (boxed) are 
shown. ^Possible doubly charged ion, often formed from the parental ion of tetrapyrroles. 
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Fig. 3.14B: LC-MS sub-set (500-700 m/z) from an ethyl acetate extract of P5 metabolised by 
B. thetaiotaomicron (Fig. 3.14A). Formula and structures consistent with major detected ions 
(boxed) are shown. Note the new scale of axes. 
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Various searches for m/z consistent with iron or magnesium metalation of these ions failed to 
identify candidates. Again, enzymes encoded by B. thetaiotaomicron (BT_2273, BT_4350 and 
BT_4355) may enable this metabolism, supporting the notion that this bacterium may metabolise 
abiotic porphyrins. Mass spectrometry is further discussed below and the major ions with possible 
structures are summarised in Fig. 3.15. 
Since P5 was around 100-fold less stimulatory than PPIX, haem and DPIX in growth curve 
titrations, the possibility that only selected metabolites of P5 are used to form a b-cytochrome is 
discussed below. Together with suppression of growth of mutants, these experiments disclosed that 
P5 was reduced by Bacteroides spp. and confirm P5 is a prodrug, exerting cytotoxic activity for 
C. difficile by nitro group reduction. 
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Figure 3.15: Potential structures of dithionite reduced P5, B. thetaiotaomicron metabolised P5 and 
DPIX derived from high resolution mass spectrometry. Mass spectrometry is not a structural 
technique, so some of the functional groups may be oriented slightly differently than proposed, such 
as methyl and ethyl additions to carboxylic acids of DPIX. Dotted lines indicate structures consistent 
with distinct ions, rather than fragments of parent ions.  
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3.3.3 Antibiotic Susceptibility and nim Gene Presence 
In growth curves, susceptible Clostridia were approximately 3-fold more susceptible to P5 
than metronidazole. A possible explanation for increased sensitivity to P5 is that these Clostridia 
encode a nim derivative with different specificities for P5 and metronidazole. The expression of the 
nim genes may then enable more efficient reductive inactivation of metronidazole than the nitro 
group appended to P5. Conversely, expression of nim genes may also enable the Bacteroides to 
overcome nitro group reduction of P5 and not of metronidazole. In a PCR screen of 23 bacterial 
strains used in Chapter III for nimA-I, no product was detected (data not shown). A second PCR 
screen for nimJ also failed to detect amplicons (data not shown). 
To determine if differences in susceptibility more broadly reflect clinical isolates of 
C. difficile, 100 strains collected in a clinical setting were evaluated. The MIC of 100 strains of 
C. difficile ranged from 0.8-50 µM for metronidazole and P5. The average MIC for metronidazole 
(8.7±0.9 µM) was slightly higher than P5 (7.1±0.7 µM, Fig. 3.16). Based on EUCAST breakpoints, 10% 
of the strains (n=10) were considered resistant to metronidazole (>2 µg mL-1) growing in ≥23.4 µM 
metronidazole (EUCAST, 2016). P5 does not have an established EUCAST breakpoint, although at 
equimolar concentrations, 8% (n=8) of the strains were resistant to P5, growing in ≥23.4 µM P5. 
Strains within ribotypes 49, 6, 43, 103 and 17, classified resistant to metronidazole (MIC ≥23.4 µM), 
were 7.9, 5.0, 3.6, 2.0 and 1.8-fold more susceptible to P5 respectively (Fig. 3.16 and Table 3.7). One 
strain identified as ribotype 31 was two-fold more resistant to P5 than metronidazole (Table 3.7). 
 DNA was extracted from the strains of C. difficile, yielding between 10-70 ng µL-1 genomic 
DNA per extract. PCR amplification with oligonucleotide primers nimA-H and nimJ yielded no PCR 
products (data not shown). Having found that the nim genes were not present, it was concluded that 
increased sensitivity to P5 was caused by other factors than the nim genes. This is further elaborated 
in the discussion.  
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Figure 3.16: MIC of 100 C. difficile strains grown in BHI medium. 
 
 
 
Table 3.7: the MIC of 100 C. difficile strains within each PCR-ribotype group.  
PCR-Ribotype Strains (n) Metronidazole P5
MIC Fold Change 
(Metronidazole/P5)
1 2 9.4 4.7 2.0
2 21 5.7 5.0 1.1
6 2 31.3 6.3 5.0
10 1 12.5 6.3 2.0
12 8 5.9 6.1 1.0
14 18 7.3 7.4 1.0
17 2 28.1 15.6 1.8
18 6 9.9 8.6 1.2
20 6 9.9 12.5 0.8
27 4 3.9 4.3 0.9
31 1 25.0 50.0 0.5
43 2 28.1 7.8 3.6
49 1 25.0 3.1 8.0
51 2 4.7 4.7 1.0
56 1 3.1 1.6 2.0
70 6 9.4 6.0 1.6
76 1 12.5 12.5 1.0
78 4 5.1 4.9 1.0
103 1 25.0 12.5 2.0
106 1 12.5 12.5 1.0
126 1 1.6 3.1 0.5
220 4 5.1 3.5 1.4
251 3 4.2 7.3 0.6
404 1 6.3 6.3 1.0
412 1 6.3 3.1 2.0
Average MIC (µM)
 
Chapter III   The metabolism of a deuteroporphyrin-nitroimidazole adduct by nanaerobic Bacteroidetes 
124 
3.4 DISCUSSION 
P5 was demonstrated to stimulate growth of Bacteroides spp. and below minimal inhibitory 
concentrations, Prevotella spp. In contrast to these genera of the Bacteroidetes, DPIX or P5 did not 
support the growth of other major clades of the human gut, including representatives from the 
Firmicutes, Fusobacteria, Actinobacteria and Proteobacteria. Nanaerobes within the Clostridia class, 
were consistently more sensitive to P5 than metronidazole. The possibility that the nim genes were 
inactivating the nitro-group to the amino derivative is unlikely, since nim genes were not detected in 
any of the 23 strains bacteria used in Chapter III or in 100 clinical strains of C. difficile.  
Metronidazole resistance in clinical isolates of C. difficile is not well understood and 
problematically strains may revert from resistant to susceptible after freeze-thawing (Lynch et al., 
2013). Several investigators have failed to identify nim genes from clinical strains of C. difficile 
(Meggersee and Abratt, 2014, Meggersee and Abratt, 2015), Bacteroides spp. (Eitel et al., 2013, 
Kullin et al., 2016) or from complex bacterial populations of the oral cavity (Koukos et al., 2016). 
Many investigators have concluded the presence of nim genes does not necessarily convey 
resistance to metronidazole (Schaumann et al., 2005, Katsandri et al., 2006, Leitsch et al., 2014, 
Meggersee and Abratt, 2015, Kullin et al., 2016). There are several alternative explanations as to the 
increased sensitivity to P5. In C. difficile, mutations in coproporphyrinogen III oxidase (hemN) are 
associated with metronidazole resistance (Lynch, 2013). Clostridia do not use protoporphyrin, rather 
these bacteria oxidise coproporphyinogen III, forming coproporphyrin III, before iron is inserted and 
carboxylation to generate haem b [(Dailey, 2015), also see thesis section 1.3.1 for further details). It 
is possible P5 or metabolites interfere with iron-metalation or another aspect of porphyrin 
biosynthesis in C. difficile, accounting for increased sensitivity to P5 in respect to metronidazole. It is 
also possible P5 or metabolites modulate the regulation of hemN, inducing a change in the 
physiological response of C. difficile to P5, for example by increased rate of uptake. It is also possible 
the nitro group of P5 is more efficiently reductively activated by C. difficile. 
In defined medium, doubling times of B. fragilis were 3-4 fold lower when supplemented 
with a porphyrin source, including P5. Doubling times of derivative mutants, defective in b-
cytochrome formation, were similar regardless of porphyrin supplementation. The FRD activity from 
a lysate of B. thetaiotaomicron grown with P5 was around 66% the levels detected from a lysate of 
haem and DPIX. Also, growth of Prevotella spp. was enhanced when P5 was titrated below minimal 
inhibitory concentrations. The homology of the fumarate reductase (FrdCAB) was similar between 
the Bacteroides and Prevotella clades. Together, these results indicate P5 is metabolised by 
Bacteroides spp. and Prevotella spp. with at least one metabolite of P5 forming a functional b-
cytochrome.  
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The surprising survival of Bacteroides challenged with P5 could be ascribed to enhanced 
regeneration of ATP and NAD+ through FRD activity. However, B. fragilis mutants, unable to derive 
ATP or NAD+ from P5, but susceptible to reductive activation of P5, were not killed by P5. The 
increased doubling times of Bacteroides spp. (B. vulgatus and B. uniformis) grown with P5 
supplementation rather than DPIX, together with a slight reduction in doubling time in the presence 
of chemically reduced P5 (inactive) versus P5 (active nitroimidazole) all confirm that reductive 
activation of the nitro group on P5 is a metabolic challenge for Bacteroides. Nevertheless, P5 
supplementation consistently decreased the doubling time Bacteroides by 2-3 fold, indicating 
metabolic derivatives of P5 may be suitable for incorporation into the b-cytochrome. Since 
increasing the relative concentration of metronidazole to B. thetaiotaomicron killed this bacterium, 
though P5 did not, it is possible that Bacteroides limit uptake of porphyrins, taking up sufficient P5 to 
form a b-cytochrome, whilst at the same time effectively limiting uptake of the toxic nitro-group. It is 
also possible that the rate of reductive activation of P5 may be lower than metronidazole or the 
formation of FRD and associated regeneration of ATP and NAD+ mitigate the toxic effects of 
nitroimidazole reduction. The activity of the FRD formed in B. thetaiotaomicron exposed to P5 was 
around half that of DPIX and haem controls. Yet in growth curves with serial dilutions of 
DPIX/haem/PPIX, maximum growth of B. thetaiotaomicron was reached at 20 nM, whereas 100-fold 
more P5 (2 µM) was required to reach maximal growth. One possibility is that only a limited range of 
derivatives formed during reduction of P5 form a functional b-cytochrome (Fig. 3.17). The three 
subunits of the magnesium chelatase were detected in almost all examined Bacteroides (results not 
shown). Ions consistent with magnesium metalation were not found, possibly related to removal of 
magnesium during the extraction procedure (Granick et al., 1972). 
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Fig: 3.17: proposed metabolism of P5 by Bacteroides, involving a series of electron transfers, 
represented by arrows. A) P5 is proposed to be first reduced, by hydrogenase (HYD) or 
pyruvate:ferredoxin oxidoreductase (PFOR). A metabolite/s of P5 is then proposed to function as 
source of porphyrin for b-cytochrome formation, permitting fumarate reductase activity (FRD). 
Magnesium chelation of the possible metabolite of P5 is not shown. Some pathways are summarised 
by dashed arrows. Enzymes (in green) include LDH=Lactate dehydrogenase, PFOR, HYD. 
PEP=phosphoenolpyruvate and MQ=menaquinone. B) A metabolite of P5 that may enable FRD 
activity. See main text for references and details. 
 
An ex-vivo distal colon culture model was chosen for this study to explore the effect of P5 in 
complex human-derived bacterial populations of the distal colon, since such a model ameliorates 
confounders such as uptake by the host, allowing a direct evaluation of the impact of P5 activity. 
Broadly, since growth of members within the Bacteroidetes, Firmicutes, Proteobacteria and 
Actinobacteria was perturbed in the ex vivo distal colon culture model or strains were killed in single 
species growth curves, these results indicate cell surface receptors, that recognised P5, a metal free 
porphyrin with a ‘bulky’ nitroimidazole appendage, have a previously unappreciated flexibility, 
apparently independent of the metal ligand and vinyl groups of the porphyrin macrocycle. Also in 
this model, P5 reproducibly killed Clostridia while promoting growth of Bacteroides. Based on the 
high homology to the Bacteroides FRD, it is likely that growth of other members of the 
Bacteroidetes, such as Paraprevotella, and even saccharolytic Porphyromonas with metabolic 
fermentations similar to Bacteroides rather than proteolytic Porphyromonas (used herein for growth 
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curves), will also be stimulated. As with Prevotella, it is predicted that the response of these bacteria 
will depend on the concentration of P5, whereby below the minimal bactericidal nitroimidazole 
concentration, growth may be stimulated, whereas at higher concentrations, growth may be 
inhibited. 
Scant reports indicate bacteria are able to subsist on antibiotics as a sole carbon source 
(Dantas et al., 2008), however, to the best of our knowledge P5 is the first molecule reported to both 
stimulate growth of one clade (the Bacteroides) via formation of a b-cytochrome and suppress 
growth of another major clade (the Clostridia), of the human gut. On a molar basis, P5 is more 
potent for susceptible Clostridia than metronidazole and P5 supports the formation of a functional 
b-cytochrome stimulating growth of B. thetaiotaomicron at nanomolar concentrations (≥2.4 × 106 
molecules per cell). Use of metronidazole alone or with vancomycin, during a suite of diseases 
including colitis or toxic megacolon in which C. difficile is involved, is problematic, since off-target 
bacteria may be killed, including the Bacteroides. Destabilisation of the gastrointestinal microbiota 
may also encourage overgrowth of facultative bacteria. P5 presents an alternative strategy, where it 
is envisaged that the killing of Clostridia with concomitant growth stimulation of Bacteroides, will aid 
restoration of microbial populations to pre-diseased states, helping to prevent relapse of C. difficile 
infection and overgrowth of facultative bacteria. 
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4.1 THESIS DISCUSSION 
A deuteroporphyrin-nitromidazole adduct (‘P5’), designed to deliver nitroimidazoles into 
P. gingivalis unexpectedly enhanced the growth of the related and also nitroimidazole sensitive 
Bacteroides and Prevotella spp. Whilst not designed for this purpose, P5 consists of a 
deuteroporphyrin base, tethered to a nitroimidazole through an amide linkage. By comparison with 
DPIX and untreated controls in growth curves and rate of kill assays, P5 was used as a proxy to infer 
the rate of porphyrin uptake and other aspects of porphyrin metabolism. For example, in single 
species growth curves and an ex vivo distal human faecal model (Chapter III), P5 killed the majority 
of Clostridia and the growth of Bacteroides and Prevotella spp. was stimulated and the growth of 
some Proteobacteria plus Actinobacteria was slowed. These results highlight a previously 
unappreciated flexibility in the types of porphyrin that are recognised by membrane receptors and 
taken up by several clades of human-associated bacteria. Indeed, recognition and uptake appear to 
be independent of the vinyl groups (highlighted in blue, Fig. 4.1) of the porphyrin macrocycle. 
Secondly, assuming metals are not inserted enzymatically or non-enzymatically before uptake, 
recognition of P5 and perhaps other tetrapyrroles, also appears to be metal independent. In 
agreement with these results, a literature review highlighted that porphyrin auxotrophy was broader 
than previously appreciated in members of the Bacteroidetes. These results broadly agree that many 
Firmicutes (Bacilli and Clostridia), Fusobacteria and Actinobacteria, take up porphyrin analogues, 
such as P5, regardless of whether they synthesise haem b or not (summarised in Fig. 4.2). 
The growth stimulation of the Bacteroides, which for B. thetaiotaomicron was linear from 
2 nM - 2µM (or 2.4 × 106-9 molecules of P5 per cell), that the growth of two mutant B. fragilis, 
incapable of forming a b-cytochrome, were not stimulated by P5 (or DPIX control) and that the FRD 
activity of cell free lysate was similar for P5 and porphyrin controls, provide evidence that 
Bacteroides incorporate a metabolite/s of P5 into a cytochrome. Since the growth of examined 
 
 
Figure 4.1: Haem b (A) and P5 (B).  
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Prevotella spp. was also stimulated, and the fumarate reductase of this clade has a high homology to 
that of Bacteroides, it is likely Prevotella also form a b-cytochrome from a metabolite/s of P5. It is 
likely that the uptake of P5 by Bacteroides was delayed, possibly due to an active mechanism to limit 
porphyrin uptake, although it is also possible that recognition and uptake of P5 is impaired, relative 
to unconjugated porphyrins. 
The metabolism of P5 by B. thetaiotaomicron was probed with liquid chromatography mass 
spectrometry. The products of P5 reduced by sodium-dithionite, were used to study nitroimidazoles 
and their reduction (Church et al., 1988, Lockerby et al., 1984). Several of the ions (and possible 
corresponding formulas) of sodium dithionite-reduced P5 were consistent with the fragments 
formed from the ‘electrolytic’ and enzymatic reduction of metronidazole, producing structures 
consistent with the fragmentation at carbons 2 and 4 of the imidazole ring (Chrystal et al., 1980, 
Knox et al., 1983). Also, many of the ions observed in sodium dithionite-reduced P5 were observed 
in a porphyrin-based extraction of B. thetaiotaomicron incubated with P5. A primary ion, consistent 
with the formation of 2-amino-N-methyl-2-oxoacetamido-ethyl-amino-3-oxopropyl derivative from 
DPIX-metronidazole-amine at position 13 of the porphyrin macrocycle was observed, which is similar 
to the fragmentation of metronidazole to n-(2-hydroxyethyl) oxamic acid. Several sequential 
fragments of 2-amino-N-methyl-2-oxoacetamido-ethyl-amino-3-oxopropyl side chain were also 
detected as were ions consistent with fragmentations of the DPIX-nitroimidazole linker, forming 3-
amino-3-oxopropyl and 2-aminoethyl-amino-3-oxopropyl side chains. A metronidazole-amine 
control was not included because mass spectrometry below a mass to charge ratio of approximately 
200 has an insufficient accuracy to elucidate formulae consistent with ions. 
Interestingly, in the B. thetaiotaomicron metabolised P5, several ions were detected that 
were consistent with the sequential addition of two methyl (–CH3) functional groups to the 
porphyrin macrocycle. Ions consistent with the addition of two methyl functional groups were also 
detected in a control culture of B. thetaiotaomicron incubated with DPIX, and these ions were not 
observed in dithionite-reduced P5. These results strongly indicate that B. thetaiotaomicron has a 
broader flexibility than previously recognised for the types of abiotic tetrapyrroles incorporated into 
its metabolism other than a b-cytochrome. Also, modification of P5 is consistent with loss of toxicity 
when nitroimidazoles are reduced (Knox et al., 1983). Mass spectrometry is not a structural 
technique, although by the fragmentation signature of the parent ion (how a larger, or parent ion 
fragments into constituent ions by mass spectrometry of the parental fragment or ms/ms), and from 
the biology of other microbes, it is possible that these -CH3 groups are appended to one or both of 
the carboxylic acids (positions 13 and 17 of the porphyrin macrocycle). For example, pheophytins 
and chlorophyll a contain a 16-carbon chain appended to the carboxyl group at position 17 of the 
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macrocycle (Fig. 4.3). One possibility, shown in Fig. 4.2, is that B. thetaiotaomicron appends a long 
chain hydrocarbon to the carboxylic acid at position 17 of the macrocycle. The addition of a long 
chain hydrocarbon would decrease the polarity of the molecule, which might be why it was not 
detected in the final fraction of the B. thetaiotaomicron incubated DPIX extract. Alternatively, it is 
also possible B. thetaiotaomicron appends only four methyl groups at this position. The smaller ion, 
which was a fragment of a parent ion, but a distinct ion, could be the result of addition of –CH3 to 
the methyl group at position 8 of the macrocycle and to the carboxylic acid at position 13 or 17 of 
the macrocycle, for example by Mg-protoporphyrin IX methyl transferase. It is also possible this 
fragment was generated by the extraction procedure, for example from autoclaving the 
B. thetaiotaomicron culture. 
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Figure 4.2: Potential structures of dithionite reduced P5, B. thetaiotaomicron metabolised P5 and 
DPIX derived from high resolution mass spectrometry. Mass spectrometry is not a structural 
technique, so some of the functional groups may be oriented slightly differently than proposed, such 
as methyl and ethyl additions to carboxylic acids of DPIX. Dotted lines indicate structures consistent 
with distinct ions, rather than fragments of parent ions.  
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Figure 4.3: chlorophyll a, synthesised for example by Cyanobacteria (A). DPIX (B) with carbons 8, 13 
and 17 labelled, is shown for reference purposes. 
 
Interestingly, in single species growth curves, the majority of examined Clostridia (five 
strains) were around three-fold more sensitive to P5 than metronidazole. It is possible that like 
metronidazole, P5 competes with sulfite (SO32-) for reducing equivalents originating from ferredoxin 
in the dissimilatory sulfite pathway, as described in Clostridium spp. (Lockerby et al., 1984, Laishley 
and Krouse, 1978). It is also possible P5 perturbs the growth of members within the Clostridia by 
disrupting porphyrin biosynthesis or function of another pathway. In the same vein, in Chapter II, P8 
was observed to delay the growth of several bacteria insensitive to nitroimidazoles. It is possible that 
P8 perturbs the formation of a b-cytochrome in these organisms, including Actinomyces spp. and 
Faecalibacterium spp., both of which have relatively high amino acid homology (47% and 42% 
respectively) to the B. thetaiotaomicron fumarate reductase operon (see Appendix Table A4). 
In Chapter III, findings from single species growth curves were confirmed by selective 
culturing of Bacteroides and by Illumina sequencing of the 16S rDNA in a human ex vivo faecal 
culture model. In this model, faecal bacteria were diluted more than 5 orders of magnitude (from 
≈5 × 1011 to ≈1 × 1066 cells per mL-1) to be within lethal concentrations of P5 and metronidazole. 
Strikingly, across the four replicates, there was a remarkable preservation of bacterial genera 
comparing the inoculum to the DMSO and DPIX treatments, even though bacteria underwent 
several divisions over the course of the 10 hour period (from the initial ≈1 × 106 cells mL-1 to the 
endpoint total of ≈5 × 109 cells per mL-1). These results agree with similar models (Freter et al., 
1983b). Intriguingly in this model, growth stimulation by DPIX was not as beneficial as P5, yet DPIX 
has a greater stimulatory capacity for Bacteroides in single species growth curves. One interpretation 
is that Bacteroides are outcompeted by members of the Clostridia, in a proteinaceous broth such as 
BHI medium. The faecal culture model does not preserve spatial distribution of gut bacteria, but it 
could be inferred that in the gut, members of the Clostridia more efficiently metabolise 
proteinaceous nutrients than Bacteroides. As mentioned in the thesis introduction (Section 1.1.1), 
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E. coli and examined Clostridium spp. (see Chapter III) have similar rapid growth rates in BHI 
medium. Broad removal of the Clostridia class by P5 leads to overgrowth of Bacilli (mostly 
streptococci, consisting of 26% of the total population) and a 19-fold increase of Proteobacteria 
(mostly Gammaproteobacteria including E. coli), relative to DMSO control (see Table 3.3, 
Chapter III). Interestingly, removal of remaining Clostridia (Lachnospiraceae) and Bacteroides by 
metronidazole, facilitated growth of Streptococci, which dominated this treatment (70% of the total 
bacterial population) and also E. coli (21% of this treatment). These results agree that there is a 
reciprocal relationship between E. coli and more dominant clades. In the presence of bile and P5, a 
control not shown in Chapter III (see Appendix Table A3 for this control), the removal of the 
remaining Lachnospiraceae, although not Bacteroides, returned E. coli to levels observed in 
metronidazole control (22%), suggesting Lachnospiraceae may exert control over E. coli. As 
suggested by others, this relationship could be mediated by H2S (Freter et al., 1983a). However, it is 
paradoxical that E. coli populations maintain residence in the gut, or grow in this model, unless they 
also occupy a unique nutrient niche or provide a nutrient for other bacteria. If such a relationship 
exists, it is most likely with members within the Clostridial class. On the basis of these results, it is 
anticipated that the depletion of Clostridia with P5 rather than metronidazole, will reduce the 
available nutritional and spatial niche for overgrowth of non-target organisms, such as Streptococcus 
spp. or E. coli.  
Consistent with structural studies of metronidazole metabolism and microbiological analyses 
in murine models (Placidi et al., 1970, Mikelsaar and Siigur, 1992), a remarkable concentration of 
metronidazole is required to displace nanaerobes residing in the gut. Based on the bactericidal 
concentration of metronidazole in BHI medium established in Chapters II and III, ranging from 1-11 
µM for 5 × 105 viable bacterial cells, extrapolated for 3 × 1012 total bacterial cells in the gut of rats, 
the minimum concentration of metronidazole is around 65 mg. However, these calculations 
oversimply the metabolism of metronidazole (see Appendix for calculations of required 
metronidazole). For example, more than half of the administered metronidazole is oxidised and 
excreted (see further details in section 1.4.1). Also, as established in Chapter III, when displaced 
from the human distal gut and diluted into BHI growth medium, the numbers of bacteria within each 
genera were remarkably stable. The stability of bacterial genera in the ex vivo distal colon culture 
model indicate that the number and type of bacteria are also likely to be relatively stable over short 
periods of time and it is possible that the quantity of metronidazole required during health is 
probably larger than that required during a dysbiotic state. On the basis of ten-fold serial dilutions of 
metronidazole and porphyrins presented in Chapter III, the minimum concentration of 
metronidazole required to elicit an effect would be 65 mg per day and around ten-fold lower for P5  
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Table 4.1: Estimated bioactivity of compounds based on extrapolations of the growth of 
B. thetaiotaomicron in BHI medium. The calculations are based on a rat weighing 200g. For P5, this 
equates to a 2.3 gram dose in a 70 kg human. See the thesis appendix for full details of these 
calculations. 
Compound
Minimally active 
concentration (nM)
Molecules bacterial 
cell
-1 Mass rat
-1 
(mg)
DPIX 0.02 2.409 × 104 0.065
Metronidazole 20 2.409 × 10
7 65.19
P5 2 2.409 × 106 6.519
 
 
to stimulate the growth of Bacteroides (Table 4.1). Interestingly, the calculated concentration of 
metronidazole is close to that established by Mikelsaar et al. However, as demonstrated in 
Chapter III, the removal of the Clostridia is probably required to open a spatial and nutritional niche 
to facilitate the growth of the Bacteroides, requiring a much higher concentration of P5. 
In an initial exploration of the response of rat gastrointestinal bacteria to P5, 
pyrosequencing established there was a surprisingly high variation (2-3 fold) in the populations of 
bacterial clades of rats housed in one cage (see Table 6.8 of Appendix Chapter VI). Appendix 
Chapter VI established this variability, indicating that at least a 10 to 100-fold change in anaerobic 
populations would be required to assess the effect of metronidazole and P5. The pyrosequencing 
technology used in Chapter VI, with longer reads than Illumina technology, will not be available for 
future studies. One advantage of the Illumina technology is ‘sequencing depth’, which depending on 
the number of samples, increases the number of sequences per sample, allowing more accurate 
enumeration of lower abundance population clades. 
In order to determine to the extent that in vitro activity of P5 determined in Chapters II and 
III reflects biological changes in vivo, rats were also dosed with high concentrations of P5, DPIX and 
metronidazole (Appendix Chapter VI). To achieve relatively large quantities of required P5, the 
previous synthesis described in (Yap et al., 2009) was ‘up-scaled’ to produce gram quantities. 
Regardless of treatment regime, the weight of rats was similar. Strikingly, the caecal volume of the 
metronidazole-treated rats doubled over a period of 5 days (Appendix Chapter VI). No other 
differences in gross anatomy of rats were observed. Anatomical changes at a finer resolution were 
next examined. In relation to the carrier control, the large intestine of the metronidazole, DPIX and 
P5 treatments all exhibited an increase in lymphoid follicles, particularly adjacent to the crypts. The 
metronidazole treatment also exhibited goblet cell hyperplasia and an increase in infiltrating 
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leukocytes. These promising results call for further exploration into the microbiology and also the 
response of the host. 
 
 
4.2 FUTURE DIRECTIONS 
4.2.1 Assessing P5 in a murine model of human C. difficile IBD 
Unfortunately, time constraints prevented fully testing the hypothesis that results garnered 
in vitro reflect those in vivo. Planned future studies depend on the demonstration that P5 functions 
in a rat model to at least limit growth of members within the Clostridia and either have no effect on 
Bacteroides or facilitate the growth of this clade directly and/or by removal of Clostridia spp. P5 
functioning in this way is dependent on many factors, including how P5 is taken up (Ings et al., 1975). 
Pending success, translational and basic lines of investigation would be warranted. A C. difficile 
model of human colitis would be explored in a murine model and the derivatisation of P5 to increase 
potency for Clostridia or to improve stimulation of Bacteroides, would be considered. The possibility 
of using P5 to examine basic aspects of bacterial populations and their function are also considered 
below.  
 As gram quantities of P5 are required to assess the response of nitroimidazole-sensitive 
microbes of the gastrointestinal tract, the logistical challenges of upscaling synthesis must first be 
overcome. The planned study would extend the study described in Appendix Chapter VI, to 
determine if (and where) changes in total bacteria, Clostridia and or Bacteroides occur after a five 
day concentrated dose of metronidazole, P5, carrier and DPIX controls. It would be possible to 
determine to what extent changes in bacterial communities reflect function of these populations.  
Finally, a planned future study will focus on the host response during Clostridial-insult by 
examining epithelial integrity (crypt morphology, tight junction integrity), overlying mucus layer and 
alteration of cells lining the mucosa, including goblet cells, colonocytes and (in the small intestine) 
Paneth cells. The presence of inflammatory markers (including RegIIIγ, interleukins 11, 17 and 25) or 
transcript of these markers would be used as a metric to determine to what extent the removal of 
Clostridia dampened active inflammation, as would metrics such as animal weight and faecal 
consistency. Microbial screens would be carried out with qPCR and next generation sequencing 
methodologies to assess changes associated with bacterial genera in illeal and colonic tissue.  
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4.2.2 The use of P5 to glean insight into gut development and function 
The removal of microbes from animal hosts has illuminated various principles, such as the 
stimulation of host development. An extension of this approach involves the addition of one or two 
bacterial species back into the gut, to demonstrate trade and stimulation. Another approach to 
answer basic questions involves the removal of specific bacteria or a clade of bacteria and examining 
the outcome for the host and resident microbes. For example, if it was possible to largely sterilise 
the gut of Clostridia with P5, would this affect host development, for example by reducing total 
available butyrate for colonocytes? Would it be possible to confirm that H2S controls populations of 
E. coli in vivo and that Lachnospiraceae mediate this interaction? Would a reduction in Clostridia 
impinge upon or aid the growth of Bacteroides and other clades, such as E. coli? 
 
4.2.3 Derivatisation of P5 to improve potency for Clostridia or improve 
growth of Bacteroides 
It was noted in Chapter III that P5 stimulated the growth of B. thetaiotaomicron less 
efficiently (2 nM) than other porphyrins (200 pM: DPIX, PPIX and Fe-PPIX). In Bacteroides, 
magnesium chelatase inserts magnesium into the PPIX-methyl ester. To increase efficacy, P5 could 
be derivatised to P5-methyl ester and/or magnesium could be inserted. Whilst this may help 
Bacteroides to metabolise P5, it may also modify solubility of the drug in the stomach, since the 
inner pyrrolic hydrogens would not be available for protonation. It would also be possible to 
increase the solubility of P5 by addition of urea linkers between nitroimidazole and DPIX. 
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5.1 RESULTS PERTAINING TO CHAPTER II 
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Figure A1: A representative standard curve used to convert fluorescent intensity of real time PCR 
amplified 16S rDNA to the corresponding bacterial viable count [(A), from growth curve of sample C]. 
Total bacteria detected from plaque curves of patient A (B), patient B (C), patient C (D) and patient D 
(E) from DNA extracted at 2 hours. 
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Figure A2: qPCR standard curves generated with Bacteria domain-specific primers and probe for 16S 
rDNA gene (A) and P. gingivalis 16S rRNA gene specific primers and probe (B). 
 
Table A1: qPCR fluorescent output and corresponding concentration of total genomic DNA in 
controls and from two rat groups using 16S rDNA specific primers and taqman probe. 
CT DNA (pg µl
-1 )
DNA elution buffer 37.25 (±0.49) 0.003 (± 0.0010)
qPCR no template control 38.27 (±0.48) 0.002 (± 0.0005)
DNA reagent negative 38.20 (±0.74) 0.002 (± 0.0008)
Group 1 22.64 (±0.39) 23.35 (±4.40)
Group 2 24.25 (±0.52) 10.00 (±1.93)
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5.2 RESULTS PERTAINING TO CHAPTER III 
 
Table A2: Growth of bacterial cultures streaked on BHI agar media with gentamicin (100 mg L-1) or 
with gentamicin and bile (titrated at 5, 10, 15, 20 g L-1). For bacteria that grew after 4 days on 
gentamicin BHI Esculin Agar, growth was assessed as excellent (++), impaired (+), scant (~) or non-
existent (-) at the four bile treatment concentrations. Esculin hydrolysis (indicated by a dark halo 
surrounding colonies) was not assessable for strains that failed to grow on gentamicin BHI agar 
(denoted N/A).  
 
Gentamicin BHI 
Bile Esculin Agar
Family Strain Growth
Esculin 
Hydrolysis
Bile       
(5/10/15/20 g L
-1
)
Porphyromonas gingivalis W83 + - -
Porphyromonas gingivalis ATCC 33277 + - -
Prevotella melaninogenica ATCC 25845 - N/A -
Prevotella Intermedia ATCC 25611 - N/A -
Bacteroides fragilis  ATCC 25285 ++ + ++
Bacteroides thetaiotaomicron ATCC 29148 ++ + +/+/+/~
Bacteroides thetaiotaomicron ATCC 29741 ++ + +/+/+/~
Bacteroides vulgatus ATCC 8482 ++ - ~/-/-/-
Bacteroides uniformis ATCC 8492 ++ + ++/++/++/+
Bacteroides eggerthii  ATCC 27754 ++ + ++/++/++/+
Fusobacterium nucleatum ATCC 25586 + - -
'Leptotrichia buccalis' - N/A -
Veillonellacaeae Veilonella parvula  ATCC 10790 ~ - -
Parvimonas micra  ATCC 33270 - N/A -
Clostridium perfringens  ATCC 13124 + - -
Clostridium difficile ATCC 43255 ~ - -
Enterococcaceae Enterococcus faecalis  ATCC 29212 ~ + -
Serratia marcescens  ATCC 274 - N/A -
Escherichia coli ATCC 25922 - N/A -
Bifidobacteriaceae Bifidobacterium dentium  ATCC 27534 - N/A -
Coriobacteriaceae Eggerthella lenta  ATTC 43055 - N/A -
Enterobacteriaceae
Gentamicin BHI 
Esculin Agar
Porphyromonadaceae
Prevotellaceae
Bacteroidaceae
Fusobacteriaceae
Clostridiaceae
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Table A3: Illumina sequencing of the ex vivo faecal culture model (V4 region 16S rDNA) at 10 hours. 
The absolute total was calculated from 10,864,916 sequences that passed quality filtering. The 
average (‘Av.’) and SEM were calculated within each of the seven treatment groups from four 
experiments. Phylum summing less than 0.5% of the total sequences are summarised as ‘Other’ 
including: unclassified (8661 sequences), Fusobacteria (107 sequences), Planctomycetes 
(6 sequences), Acidobacteria (3 sequences), OD1 (3 sequences), Chloroflexi (1 sequence) and OP11 
(1 sequence). P5(B) treatment group consisted of P5 (20 µM) plus bile (‘oxgal’, 5gL-1). 
Taxa Av. SEM Av. SEM Av. SEM Av. SEM Av. SEM Av. SEM Av. SEM
Bacteroidetes 27.0 0.7 13.6 1.9 16.1 2.1 0.6 0.3 0.8 0.5 32.7 3.5 47.1 5.9
Bacteroidaceae 23.6 0.6 13.1 1.8 15.3 1.8 0.5 0.3 0.7 0.5 31.7 3.5 46.5 5.9
Porphyromonadaceae 0.9 0.2 0.4 0.1 0.7 0.3 0.0 0.0 0.0 0.0 0.9 0.2 0.3 0.1
Rikenellaceae 1.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1
Firmicutes 63.8 1.0 84.0 2.5 81.3 3.2 76.3 11.2 71.5 10.2 55.7 8.0 28.5 6.8
Bacilli 0.6 0.0 13.5 3.4 10.3 2.4 73.9 10.9 70.0 9.8 33.0 4.4 3.6 2.8
Enterococcaceae 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.9 0.3 0.2 7.4 7.2 0.1 0.1
Streptococcaceae 0.4 0.0 12.9 3.5 9.6 2.5 72.5 11.0 69.7 9.8 25.5 7.9 0.1 0.0
Turicibacteraceae 0.2 0.1 0.5 0.3 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 3.4 2.9
Clostridia 59.0 1.5 63.4 4.5 64.1 4.2 2.0 1.0 1.2 0.4 22.3 6.9 20.0 4.9
Unclassified family 1.0 0.2 8.0 5.7 7.2 6.0 0.4 0.3 0.1 0.1 0.0 0.0 0.0 0.0
Clostridiaceae 1.1 0.4 2.2 1.0 1.2 0.8 0.1 0.0 0.0 0.0 0.0 0.0 2.6 2.5
Lachnospiraceae 30.5 1.9 39.8 2.0 43.5 5.1 1.2 0.5 0.8 0.3 20.1 7.0 6.3 1.7
Ruminococcaceae 25.4 3.6 12.7 1.1 11.5 1.9 0.4 0.1 0.2 0.1 0.3 0.1 0.1 0.0
Veillonellaceae 1.0 0.1 0.5 0.1 0.5 0.1 0.0 0.0 0.0 0.0 1.9 0.3 11.1 1.8
Erysipelotrichi 1.5 0.3 7.0 2.6 6.8 2.1 0.1 0.0 0.0 0.0 0.4 0.2 4.8 1.4
Erysipelotrichaceae 1.5 0.3 7.0 2.6 6.8 2.1 0.1 0.0 0.0 0.0 0.4 0.2 4.8 1.4
Unclassified class 2.6 0.9 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.1 0.1 0.0 0.0 0.0
Proteobacteria 7.1 0.4 0.7 0.4 1.3 0.6 21.2 11.6 26.3 10.2 10.9 5.4 22.0 13.2
Betaproteobacteria 1.0 0.0 0.1 0.0 0.2 0.1 5.0 1.4 4.9 1.4 1.1 0.3 0.1 0.1
Alcaligenaceae 1.0 0.0 0.1 0.0 0.2 0.1 5.0 1.4 4.9 1.4 1.1 0.3 0.1 0.1
Deltaproteobacteria 1.1 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.2 0.0
Desulfovibrionaceae 1.1 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.2 0.0
Gammaproteobacteria 5.0 0.5 0.5 0.3 1.0 0.6 16.2 12.6 21.4 11.3 9.6 5.4 21.7 13.2
Enterobacteriaceae 0.0 0.0 0.4 0.4 0.8 0.6 14.4 13.2 19.5 12.2 9.3 5.5 21.6 13.2
Pasteurellaceae 5.0 0.5 0.1 0.0 0.1 0.0 1.8 0.6 2.0 0.9 0.3 0.1 0.0 0.0
Actinobacteria 0.5 0.2 1.6 0.4 1.3 0.5 1.9 0.8 1.4 0.5 0.7 0.4 2.5 1.1
Bifidobacteriaceae 0.2 0.1 0.8 0.4 0.5 0.2 1.9 0.8 1.4 0.5 0.7 0.4 2.2 1.2
Coriobacteriaceae 0.3 0.2 0.8 0.6 0.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1
Other 1.6 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0
P5 P5(B)Inocula DMSO DPIX DPM M
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Figure A3: Estimations of viable Bacteroides and total bacteria per gram human faeces (from the ex 
vivo distal colon culture model donor) over seven days on bile and gentamicin containing BHI agar 
(‘BGBHI’) and BHI blood agar (‘BA’) plates. Over seven days, viable Bacteroides averaged 19% of total 
bacteria recovered on BHI blood agar (‘BA’) plates. Each bar incorporates the mean from triplicate 
plate counts. 
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Figure A4: growth curves of ex vivo distal colon culture model. Bacterial growth was estimated by 
optical density at 600 nm, with the mean and SEM from four experiments. The average total 
bacterial inoculum was 1.95±0.72 × 106 cfu ml-1, 15% of which were Bacteroides 
2.97±0.51 × 105 cfu ml-1, assessed on culture medium as described in Chapter III. Doubling times for 
DMSO, DPIX, DPIX and metronidazole, M and P5 were 42.8, 37.5, 54.0, 54.0 and 50.0 min-1 
respectively. The optical density of treatments containing gentamicin and bile was not recorded.  
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Table A4: Summary of BLASTP homology searches to the Bacteroides thetaiotaomicron ATCC 29148 
fumarate reductase. ‘FRD units’ indicates how many of the three genes were present in a given 
taxon and ‘average hits’ refers to the average number of taxa (bacterial strains) within each clade. 
Bacterial clades with representatives that were examined with in this thesis with growth curves are 
in bold font. The highest resolution is given when genus descriptions were not available. 
Taxon FRD units Average Homology (%) Average Hits
Bacteroides 3 87.2 78
Paraprevotella 3 80.5 3
Phocaeicola 3 77.0 1
Prevotella 3 75.6 107
Barnesiella 3 73.3 2
Coprobacter 3 73.2 2
Alloprevotella 3 72.9 3
Parabacteroides 3 70.2 8
Tannerella 3 70.0 10
Porphyromonas 3 69.9 32
Paludibacter 3 69.7 1
Dysgonomonas 3 69.7 5
Proteiniphilum 3 68.7 1
Porphyromonadaceae 3 68.0 2
Bacteroidetes 3 67.6 2
Alistipes 3 65.5 18
Mucinivorans 3 65.3 1
Niastella 2 64.0 1
Sporocytophaga 2 63.8 3
Fibrobacter 2 63.8 2
Thermophagus 3 63.7 1
Anaerophaga 3 63.5 2
Geothrix 2 63.0 1
Haloferula 2 62.5 1
Marinilabilia 3 62.3 1
Rikenella 3 62.0 1
Actinobaculum 2 62.0 1
Rubritalea 2 62.0 1
Alkaliflexus 3 61.7 1
Saccharicrinis 3 61.7 2
Geofilum 3 61.0 1
Enhygromyxa 2 61.0 1
Halothece 2 60.5 1
Serinicoccus 2 60.0 2
Sanguibacteroides 3 59.7 1
Butyricimonas 3 59.7 2
Zavarzinella 2 59.5 1
Sunxiuqinia 3 59.2 1
Draconibacterium 3 59.0 2
Methylacidiphilum 2 59.0 4
Odoribacter 3 58.7 4
Aphanocapsa 2 58.5 2
Sandaracinus 2 58.5 2
Persicobacter 3 58.0 1
Prolixibacter 3 58.0 1
Ornithinimicrobium 2 58.0 1
Granulicoccus 2 58.0 1
Fulvivirga 3 56.8 1
Methylophaga 2 56.3 7
Flavobacteriales 3 55.8 3
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Calculations extrapolated from in vitro potency of metronidazole and 
porphyrins 
 
The minimum inhibitory concentration of metronidazole required to kill 5 × 105 viable 
bacteria in BHI medium ranged from 1-11 µM. If it is taken that 10 µM (1.172 ng mL-1) metronidazole 
is required to kill 5 × 105 cells mL-1: 
5 × 105 bacterial cells / 1.172 ng metronidazole 
1 bacterial cell / 2.344 pg metronidazole 
 
If it is taken that the rat caecal volume is 3 mL, with 1 × 1012 bacterial cells per ml, we have 
3 × 1012 bacterial cells: 
1 bacterial cell / 2.344 pg metronidazole 
3 × 1012 bacterial cells / [(2.344 pg metronidazole) × (3 × 1012)] 
3 × 1012 bacterial cells / 7.032 g metronidazole 
 
Culture conditions (in vitro) are expected to provide conditions more favourable for carbon 
and nitrogen acquisition, as well as the maintenance of membrane polarity and integrity. Cultured 
bacteria may therefore be more resistant to metronidazole than bacteria residing in the rat gut. 
Also, metronidazole may be inactivated by non-target bacteria or metabolised by the host. Ignoring 
factors that may impede the efficacy of metronidazole in rats, based in vitro efficacy of 
metronidazole, 7 grams of metronidazole are required to kill the majority of anaerobic bacterial 
inhabitants in rats. 
The molecular weight of metronidazole is 171.15 g mol-1. Thus, to deliver 7.032 g 
metronidazole in 200 µL, would require a stock solution of 35.16 g mL-1. In water, metronidazole 
solubility approximates 10 mg ml-1, whilst in DMSO the concentration approaches 30 mg ml-1.  
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Extrapolations of the minimum concentration of DPIX required for in vivo 
growth stimulation of Bacteroides 
 
For deuteroporphyrin IX, the in vitro concentration required to promote excellent growth of 
Bacteroides approximates 2 nM, (around 3-log lower than the concentration of metronidazole 
required to kill susceptible bacteria). If it is taken that 2 nM (6.022 ×1011 molecules ml-1) DPIX is 
required to stimulate growth of 5 × 105 cells ml-1: 
5 × 105 bacterial cells / 6.022 × 1011 molecules of DPIX 
1 bacterial cell / 1.204 × 106 molecules of DPIX 
 
If it is taken that the rat caecal volume is 3 mL, with 1 × 1012 bacterial cells per ml, we have 3 × 1012 
bacterial cells: 
3 × 1012 bacterial cells / [(1.204 × 106 molecules of DPIX) × (3 × 1012)] 
3 × 1012 bacterial cells / 3.613 × 1018 molecules of DPIX required 
 
In a rat weighing 200g, a 3.613 × 1018 molecule dose of DPIX equates to: 
3.502 mg of DPIX (17.51 mg kg-1) 
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APPENDIX CHAPTER VI 
 
INITIAL INVESTIGATIONS INTO THE RESPONSE OF RAT 
GASTROINSTESTINAL BACTERIA TO THE DEUTEROPORPHYRIN-
NITROIMIDAZOLE ADDUCT P5 
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6.0 PREFACE TO APPENDIX CHAPTER VI 
 
In Chapter III, P5 was found to behave like biotic porphyrins, stimulating the growth of 
Bacteroides spp. (five strains) and below growth inhibitory concentration, Prevotella spp. (two 
strains) in brain heart infusion medium. None the facultative bacteria (seven strains) or the 
nanaerobe F. nucleatum were killed by P5. In contrast, P5 retained nitroimidazole qualities for 
nanaerobic Clostridiales (five strains tested), which were killed by P5. Findings were confirmed by 
Illumina sequencing and viable counts of an ex-vivo human faecal culture model, in which the 
growth of Bacteroides was stimulated and capacity to kill Clostridia was retained by P5. Notably, in 
faecal growth curves, DPIX only slightly stimulated growth of Bacteroides, suggesting by reference to 
the P5 treatment, that removal of Clostridia was required to open a nutritional niche for the 
Bacteroides. The possible formation of a b-cytochrome using a metabolite/s of P5 in Bacteroides, 
which would link products of glycolysis to the terminal respiration of fumarate was described. 
Together with in silico data and a re-examination of the literature, the previously unappreciated 
aspect of porphyrin auxotrophy of Prevotella and Porphyromonas was noted, and it was suggested 
Prevotella also incorporate metabolites of P5 into a b-cytochrome, enabling fumarate reductase 
activity.  
In appendix Chapter VI, a rat gastrointestinal model is used to test the predicted metabolism 
of P5 based in vitro results outlined in Chapter III. It is found that high concentrations of P5 (and 
metronidazole) are required to kill susceptible nanaerobes. The synthesis of P5 is up-scaled and a 
preliminary investigation of the biology of rats is examined after administering high doses of 
metronidazole and P5. 
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6.1 INTRODUCTION 
In Chapter III, the effects of P5 observed in single species growth curves reflected those 
detected by Illumina sequencing in a human faecal growth curve model. While the bacterial 
populations were remarkably stable, such a model ignores spatial distributions of bacteria in the 
gastrointestinal tract, pH and concentration gradients of nutrient/waste products. Specifically, how 
mucosal bacterial populations will respond to P5, or what extent the availability of molecules such as 
menadione impinge upon fumarate reductase activity in the Bacteroides. The choice of the rat 
gastrointestinal tract to examine the ecological effects of P5 is based on several criteria. Clone 
libraries with few sequences suggest the types of bacteria in the faeces of laboratory rats at the 
genera level is similar to humans, sharing Bacteroidetes (Porphyromonas, Prevotella and 
Bacteroides), Firmicutes (Lactobacilli, Clostridium, Ruminococcus, Lachnospira and Enterococcus), 
Actinobacteria (Corynebacterium, Actinomyces and Eubacterium) and Proteobacteria (Sutterella and 
Escherichia) (Inoue and Ushida, 2003, Brooks et al., 2003). Secondly, as in humans, Bacteroidetes 
and Firmicutes dominate the rat gut, which was established by Ley et al., 2008 (see Introduction). 
Anaerobic genera of these clades are sensitive to nitroimidazoles and the number of viable bacteria 
per gram of stool (>5 × 1011) is similar to human counterparts. The gross anatomy in rats is similar to 
humans, other than an enlarged caecum. Lastly, inbred laboratory rats, such as specific ‘pathogen 
free’ Fischer 344 rats have identical housing, diet and genetics, all of which should reduce biological 
confounders in assessing the ecological effects of P5 or metronidazole. 
Some of the advantages and disadvantages of analysing complex bacterial populations are 
discussed in Chapter III (see introduction to Chapter III). In appendix Chapter VI, the primary reason 
for selecting 454 pyrosequencing for analysing complex bacterial populations from rat 
gastrointestinal tracts is that this technology has the capacity to sequence longer reads than Illumina 
paired-end Miseq platform (see Fig. 6.1 for an overview of this technology). Secondly, it is known 
that shorter but more numerous paired end reads (Illumina technology) technology inflate the OTU 
number of sampled microbes from human faeces compared with longer reads (454 pyrosequencing 
Titanium technology) (Claesson et al., 2010), which is in part due to decreases in accuracy as a given 
molecule is sequenced. Regions V3-V4 of the 16S rDNA molecule were chosen, using the same 
primer set for total estimations of bacterial populations, allowing direct comparisons between qPCR 
and 454 pyrosequencing data sets. Sequencing technologies are prone to error (as detailed above 
and in the introduction of Chapter III). Mothur was chosen for analysis, following a conservative 
methodology for reducing error associated with next generation sequencing. For example, to reduce 
inflated estimates of bacterial diversity, reads that were similar to each other (within 4 nucleotides 
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Fig 6.1: An overview of 454 pyrosequencing [from (Metzker, 2010)]. Template DNA is PCR amplified 
with universal primers appended to unique DNA adapters. DNA molecules are denatured, and 
captured onto beads under conditions that favour one sequence per bead. Single DNA molecules are 
then PCR amplified and typically deposited into wells for sequencing. As a specific nucleotide is 
incorporated (A, T, C or G) by polymerase, pyrophosphate is released. Pyrophosphate is converted to 
ATP by ATP sulfurylase. ATP in turn acts as a substrate for luciferase mediated conversion of luciferin 
to oxyluciferin and release of light. The emitted light is correlated to which nucleotide (A, T, C or G) 
was added, in an iterative process. The unique DNA adapter, which identifies the sample the 
sequence originates from, may then be coupled to the sequence of the DNA molecule.  
 
or ~1% of the entire read length) were merged into one read (Huse S.M. et al., 2010). Secondly, 
sequences were screened for putative chimeras, again reducing arbitrarily inflated estimates of 
bacterial diversity. 
 As mentioned in Chapter II, selective growth medium overcomes some of the issues 
associated with molecular approaches, including 16S rDNA copy number, PCR amplification-bias, 
amplification of DNA from non-viable bacteria and error associated with next generation 
sequencing. Kanamycin is a bactericidal aminoglycoside produced by Streptomyces kanamyceticus 
(Umezawa et al., 1957). Kanamycin prevents protein synthesis by binding the bacterial 30S 
ribosome, inhibiting translocation of tRNA when N-acetyl-diPhe-tRNA is on the acceptor site and 
deacylated tRNA at the donor site (Misumi and Tanaka, 1980). Kanamycin kills facultative anaerobes 
and not Eukaryotes, since the 30S ribosome is not present (Waitz et al., 1972). Uptake of 
aminoglycosides results from an energy-dependent transport system using oxygen or nitrate as a 
terminal electron acceptor (Bryan et al., 1979). As with other aminoglycosides, uptake of kanamycin 
is probably low under anaerobic conditions, facilitating survival of the Bacteroidetes. Proteobacteria 
and Actinobacteria are broadly expected to be killed by kanamycin. Vancomycin inhibits cell wall 
synthesis in Gram-positive bacteria (Jordan, 1961, Rogosa et al., 1958, Halebian et al., 1981). Low 
concentrations of Vancomycin (˂5 µg/ml) are bactericidal for Actinomyces, Clostridium and 
Lactobacilli in vitro (Rogosa et al., 1958, Halebian et al., 1981). Together, kanamycin and vancomycin 
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are expected to allow survival of nanaerobes from the Bacteroidetes phylum, such as Prevotella, 
Porphyromonas and Bacteroides, making it an appropriate choice to determine if metronidazole kills 
these genera and/or if P5 stimulates growth. 
 
6.2 METHODS 
6.2.1 Administration of treatments into rats 
Inbred ‘specific pathogen free’ female Fischer 344 rats (Animal Resource Centre, Australia) 
were housed in groups of five at the Department of Animal Care, Westmead Hospital. Rats were 
afforded ad libitum access to autoclaved water and chow (Specialty Feeds, Australia). The age of the 
rats is indicated for each experiment. Bedding was replaced bi-weekly (allowing coprophagy). For 
initial administration (2mM final concentration), 10 mM stock treatments were solubilised into 40 µL 
dimethyl sulfoxide (DMSO) before dilution into 160 µL carboxy methyl cellulose (CMC, final 
concentration 1% (w/v)). 2mM treatments included DMSO (40 µL made up to 200 µL with CMC), P5 
(663.5, g L-1), deuteroporphyrin IX [(DPIX) Frontier Scientific, 511.2 g L-1] and metronidazole (171.2, g 
L-1). Carboxymethyl cellulose (‘carrier’, 160 µL) was also gavaged daily into rats. Treatments (200 µl) 
were delivered daily by oral gavage during isoflurane anesthetisation (c. 3.5% per minute) for 5 days. 
In additional experiments following ‘high-dosing’ protocol (Mikelsaar and Siigur, 1992), treatments 
were emulsified into 150 µl CMC [1% (w/v)] only. Approval of animal procedures was granted by 
Westmead Hospital Animal Ethics Committee (protocol 4185.12.11). Reagents were supplied by 
Sigma-Aldrich unless stated otherwise. 
 
6.2.2 Sampling of tissue or faeces and digesta for DNA Extraction and 
Microscopy 
One day after a 5 day administration of treatments, rats were culled with carbon dioxide. In 
the initial experiment, faeces was sampled as indicated in text. In the second experiment, 
approximately 30 mm from the anus, a 10 mm section of colon was sampled. The colon segment 
was prepared in 5 ml paraformaldehyde (2%) with sucrose (5%) and PBS (2x) at 4°C for 24 hours, 
before washing with PBS (2x) and soaking in sucrose (30% v/v, filtered) with PBS (1x) for 24 hours at 
4°C. Approximately 30 mm from the anus, the colonic contents were extracted from a 10 mm piece 
of colonic tissue.  
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Paraformaldehyde fixed sections were next embedded in Tissue Freezing Medium (23°C, 
Tissue Plus, Scigen) for 1 hour and frozen in liquid nitrogen. Embedded samples were stored at -80°C 
until microtomy. 5-6µm thick sections were cut with a microtome (Microm, HM 505E). By serial 
sectioning, a library of 10 sections per sample was made. 2 sections (totalling 40) from each sample 
were warmed to room temperature and stained with toluidine blue before a glass cover slip (22×50 
mm, Matsunami) was mounted (Permount). The 40 sections were examined by a pathologist with 
more than 30 years experience in tissue pathology. Representative images were obtained with a 
Bx60 light microscope (Olympus) with a 40x water immersion lense.  
 
6.2.3 Real time PCR estimations of bacterial populations 
Real time PCR was performed as described in Chapter II, except 25 µL SYBR GreenER 
(Invitrogen) was used instead of Taqman probes and template consisted of 1 µL of a 1/50 dilution of 
extracted DNA (typically reactions contained low ng total DNA). The fluorescent emission of SYBR 
Green, was corrected by ROX. The viable count of B. thetaiotaomicron VPI-5482 grown for 20 hours 
in BHI broth, was taken in triplicate on BHI agar containing 4% sheep blood. An aliquot of this culture 
was extracted using methods described in Chapter II. Genomic DNA from B. thetaiotaomicron was 
quantified with a nanophotometer (Implen), used to construct standard curves, consisting of 
duplicate 10-fold dilutions, over 5-6 orders, for the conversion of threshold cycle (CT) to DNA 
concentration, which was converted to the viable count ascertained above. Bacteroidetes 
populations were assessed with forward (‘BactF341’, 5’-AATGGGCGAGAGCCTGAAC) and reverse 
(‘BactR700’ 5’-AAGCTGCCTTCGCAATCG) primers targeting a region of 16S rDNA specific for 
Bacteroidetes (Nadkarni et al., 2012). Amplicons were assessed by agarose electrophoresis (1% 
agarose, Promega) in the presence of gelred (0.5×, Biotium) or by melt curve analysis.  
 
6.2.4 Pyrosequencing  
Bacterial domain specific forward (5’-TCCTACGGGAGGCAGCAGT) and reverse (5’-
GGACTACCAGGGTATCTAATCCTGTT) primers, targeting regions V3-V4 of the 16S rDNA gene 
(generating a 466 base pair amplicon, corresponding to positions 331 – 797 of Escherichia coli 16S 
rRNA) (Nadkarni et al., 2002)) were appended with DNA barcodes as previously described (Kianoush 
et al., 2014). Amplicons were amplified, such that each sample had a unique DNA barcode. PCR 
products were normalised to 20 ng µL-1 and sent to the Australian Centre for Genomic Analysis 
(AGRF) for sequencing from the forward primer using a 454 FLX instrument with Titanium chemistry. 
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Sequences were demultiplexed by AGRF and were analysed with Mothur (Schloss and Westcott, 
2011) essentially as described (‘454 SOP’, http://www.mothur.org/wiki/454_SOP). Amplicons were 
removed if they had: a length less than 250 bp, a moving average quality score less than 30, more 
than eight homopolymers, or more than two differences to the forward primer. Sequences were 
aligned against the Mothur formatted SILVA reference alignment. Sequences were merged together 
(‘clustered’) if they differed by more than 4 bases (diffs=2) (Huse S.M. et al., 2010). After chimera 
removal, filtered reads were classified against the Greengenes 16S rDNA reference taxonomy 
(‘gg_13_5_99’) using a 70% pseudobootstrap value. Sequences were clustered into OTUs (3% 
similarity threshold). The number of quality filtered sequences within a sample were converted to a 
percentage of the total sequences within the same sample. Taxa that were less than 0.5% 
abundance within a given sample are not shown. The average and standard error of the mean were 
calculated for remaining taxa within each sample type. Metastats, which uses a Student’s T-test 
(White et al., 2009) was used within Mothur to assess statistical significance of OTUs binned at 0.05 
dissimilatory threshold (approximating genus).  
 
6.2.5 Viable bacterial counts 
For testing ‘high-dose’ protocol by (Mikelsaar and Siigur, 1992), fresh faecal content was 
collected from rats (n=4, housed in one cage), before dilution (50 mg) into 4950 µL anaerobically 
equilibrated warmed PBS. For each rat, diluted faeces was plated onto brain heart infusion agar with 
kanamycin (206.4 µM, 100 µg ml-1) and vancomycin (10.3 µM, 15 µg ml-1) (‘KVBHI’) over three 
dilutions (at 10-7, 10-8 and 10-9). KVBHI plates were incubated anaerobically at 37 °C for 4 days before 
counts were made. Diluted faeces was also plated onto BHI agar supplemented with 4% sheep 
blood, and incubated aerobically at 37 °C for 4 days before counts were made.  
 
6.3 RESULTS 
6.3.1 The effect of 2mM P5 on rat faecal microbes 
An initial five day administration of ‘2 mM’ treatments (0.2-0.4 mg per day into 200 gram 
rats, Table 6.1) was carried out to assess the effect of P5 on rat gastrointestinal bacteria and also the 
toxicity of P5 for rats. The total viable faecal count (1.6-3.3 ×1010 bacteria  g-1, Table 6.2) was slightly 
lower than expected from the literature and Bacteroidetes populations tended to be slightly higher 
than expected, particularly in the DPIX treatment. When the total bacterial load increased or  
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Table 6.1: Daily treatments (200 µL of 2 mM stock) given for five days rats weighing ≈180 g. Rats 
were 6-8 weeks old at time of treatment administration. This dose of P5 equates to 103 mg per day 
in a 70 kg human.  
Treatment mg mg kg-1
Deuteroporpyrhin IX (Cl2) 0.2 1.2
Metronidazole 0.1 0.3
P5 0.3 1.3
 
 
decreased, so did the total Bacteroidetes, averaging 54-57%, other than the DPIX treated rats, in 
which the Bacteroidetes populations consisted of 73% of the total detected Bacteria (Table 6.3). 
After a five day administration of ‘2 mM’ treatments into rats, DNA was extracted following ‘DNA 
from stool for pathogen detection’ protocol. Non-treated and DMSO treatments contained similar 
concentrations of bacteria, approximating 1.9 × 1010 bacteria per gram wet weight faeces, which was 
slightly higher than P5 treatment and around half metronidazole and DPIX treatments 2.5-3.3 × 1010 
(Table 6.2). 
 
Table 6.2: Total bacteria and Bacteroidetes detected in rat faeces immediately after ‘2mM 
treatment’ by qPCR. No template control (NTC) contained qPCR reagents without DNA [the 
fluorescent threshold of the NTC was 36.9 (±0.4)]. BD=below detection. 
DNA (ng µl
-1
 ) Bacteria (g
-1
) DNA (ng µl
-1
 ) Bacteria (g
-1
)
NTC 9 (±3) × 10-6 NA BD BD
Carrier 45.6 (±5.9) 1.9 (± 0.3)10 25.5 (±1.8) 1.1 (±0.1)10
DMSO 43.9 (±3.2) 1.9 (± 0.1)10 25.2 (±1.9) 1.1 (±0.1)10
DPIX 60.1 (±8.6) 2.5 (± 0.4)10 42.5 (±6.5) 1.8 (±0.3)10
Metronidazole 78.3 (±11.8) 3.3 (± 0.5)10 39.6 (±5.7) 1.7 (±0.2)10
P5 37.3 (±6.1) 1.6 (± 0.3)10 20.1 (±3.0) 8.5 (±0.1)9
BacteroidetesBacteria
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Table 6.3: Average of Bacteroidetes populations and non-Bacteroidetes recovered immediately from 
the faeces of ‘2mM treatment’ groups detected by qPCR (5 rats per group). ‘Non-Bacteroidetes’ 
were estimated by subtracting the total bacteria from the Bacteroidetes group.  
Rat group
Bacteroides/total 
Bacteria (%)
Non-Bacteroidetes (%)
Carrier 56.0 44.0
DMSO 57.3 42.7
DPIX 71.0 29.0
Metronidazole 50.1 49.9
P5 53.8 46.2
 
 
After 2 weeks, the total detected bacteria from rat faeces was similar, ranging from 1.4-
2.7 ×1010 per gram wet weight, the highest of which was in metronidazole treatment (Table 6.4). 
Total bacteria in DPIX treatment was identical to other groups (2.5 × 1010 g-1), although 
Bacteroidetes populations ranged from 73% to 47% (or 0.6 × 1010 g-1) (Tables 6.4 and 6.5). The 
inflated number of bacteria 3.3 × 1010 g-1 in the metronidazole treatment (which was 1.7 fold higher 
than non-treated or DMSO) observed immediately after treatment had reduced to 2.9 × 1010 g-1 by 
two weeks (Tables 6.4 and 6.5). Changes in populations, in particular a doubling of detected bacteria 
in metronidazole treated rats in respect to DMSO treatment, were taken to represent a 
metronidazole-induced perturbation of bacterial populations of the rat intestine, so a portion of the 
16S rDNA from samples was amplified and sequenced (454 pyrosequenced). 
 
Table 6.4: Total bacteria and Bacteroidetes detected in rat faeces two weeks after ‘2mM treatment’ 
by qPCR. No template control (NTC) contained qPCR reagents without DNA template. No template 
control (NTC) contained qPCR reagents without DNA [the fluorescent threshold of the NTC was 37.6 
(±0.3)]. BD=below detection. 
DNA (ng µl
-1
 ) Bacteria (g
-1
) DNA (ng µl
-1
 ) Bacteria (g
-1
)
NTC 4 (±1) × 10
-6
NA BD BD
Carrier 45.5 (±3.7) 1.9 (± 0.2)10 26.2 (±2.32) 1.1 (±0.1)10
DMSO 64.0 (±8.6) 2.7 (± 0.4)10 32.1 (±3.10) 1.4 (±0.1)10
DPIX 60.1 (±8.6) 2.5 (± 0.4)10 28.3 (±6.28) 1.2 (±0.3)10
Metronidazole 68.2 (±7.0) 2.9 (± 0.3)10 28.2 (±2.84) 1.2 (±0.1)10
P5 32.0 (±8.3) 1.4 (± 0.4)10 17.3 (±2.07) 0.7 (±0.1)10
Bacteria Bacteroidetes
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After quality filtering and chimera removal 67% (156,870 out of 233,259) of sequenced 
amplicons remained (Table 6.6) with an average length of 405 bp. Regions conserved in all 
amplicons were ‘masked’ (removed), because they did not inform taxonomic mapping, leaving an 
average of 274 bp (range 255-290 bp) for identification with the Greengenes reference 16S rDNA 
taxonomy database. 10,725 unique sequences were found, classifying to 1,346 OTUs and 707 OTUs 
at 3% and 5% similarity respectively. An average of ≈6,300 sequences/sample was obtained. None of 
the known contaminants in the QIAamp DNA Stool Mini Kit DNA extraction kit, were detected in the 
samples (Salter et al., 2014). 
 
Table 6.5: Average Bacteroidetes populations and non-Bacteroidetes recovered from the faeces two 
weeks after 2mM treatment using qPCR. ‘Non-Bacteroidetes’ were calculated by extrapolation from 
total bacteria minus Bacteroidetes group.  
Rat group
Bacteroides/total 
Bacteria (%)
Non-Bacteroidetes (%)
Carrier 57.6 42.4
DMSO 50.2 49.8
DPIX 47.2 52.8
Metronidazole 41.3 58.7
P5 54.1 45.9
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Table 6.6: raw sequences from ‘2mM treatment’ of rats and the number of sequences that passed 
filtering, chimera checking and alignment (‘Aligned’). See Section 5.2.4 for details of how the 
sequences were processed. 
Treatment Rat Raw Count Filtered Aligned
1 9,362 7,805 6,716
2 10,197 8,610 7,018
3 9,615 8,017 6,498
4 10,445 8,708 7,341
5 10,180 8,569 7,056
1 10,545 9,065 6,803
2 7,672 6,347 4,990
3 10,502 8,877 6,976
4 8,973 7,201 5,873
5 9,125 7,648 6,205
1 11,029 9,129 7,620
2 9,681 8,043 6,372
3 8,292 6,886 4,847
4 8,385 7,009 5,422
5 8,859 7,439 5,192
1 8,624 7,459 5,686
2 8,399 7,036 5,589
3 8,956 7,393 5,501
4 9,493 7,788 6,570
5 8,371 7,123 5,461
1 9,548 7,916 6,387
2 9,454 7,978 7,055
3 10,378 8,763 7,466
4 9,477 8,071 7,083
5 7,697 6,504 5,143
Total 233,259 195,384 156,870
Carrier
DMSO
DPIX
M
P5
 
 
The Bacteroidetes (average 55.3%) and Firmicutes (average 42.7%) dominated samples, with 
six other phyla (Proteobacteria, Actinobacteria, Deferribacteres and Lentisphaerae (Table 6.7). A 
small number of sequences (214) passed quality control filters, mapped to domain Bacteria and 
were not mapped to a known phylum. The Firmicutes consisted of two groups, mostly Clostridiales 
(Ruminococcaceae 15.5%; Lachnospiraceae 7.6%) which were generally poorly resolved, for example 
one clade of sequences were unidentified past Order (10.1%). The Bacilli from Firmicutes contained 
Lactobacillus reuteri (0.3%) and Lactobacillus spp. (1.3%). The Bacteroidetes were more diverse, 
consisting mostly of S24-7 (37.3%), Prevotella (10.0%), Bacteroides (4.3%) and Rikenellaceae (1.3%) 
(Tables 6.7 and 6.8).  
 
Appendix 
167 
Table 6.7: Summary (in percent) of phylum-level classification of pyrosequencing reads from rat 
faeces immediately after ‘2mM’ treatment. The standard error of the mean from 5 rats are shown in 
brackets. Sequences from five phyla (Actinobacteria, Deferribacteres, Lentisphaerae and sequences 
that were identified as Bacterial, but were unclassified at the Phylum resolution), totalling 0.1-0.3% 
of reads, are not shown. 
Phylum Carrier DMSO DPIX M P5 Average
Bacteroidetes 51.0 (±8.5) 63.2 (±3.6) 52.0 (±5.2) 59.7 (±4.7) 50.4 (±5.0) 55.3
Firmicutes 47.5 (±8.7) 35.0 (±3.5) 46.2 (±5.4) 37.9 (±4.9) 46.8 (±5.3) 42.7
Proteobacteria 1.3 (±0.2) 1.6 (±0.2) 1.6 (±0.2) 2.0 (±0.3) 2.7 (±0.4) 1.8
Total 99.8 99.8 99.8 99.7 99.9  
 
The average number of Bacteroidetes was similar with qPCR results, though unlike the qPCR 
results, the highest population of Bacteroidetes was detected in DMSO treatment and not DPIX 
(Table 6.7). The Proteobacteria were highest in the P5 treatment, with a 2-3 fold increase in 
Desulfovibrio, a genus known to use fumarate reductase and sharing 53% homology to the fumarate 
reductase of B. thetaiotaomicron (Appendix Table A4). However, the total Proteobacterial 
population was small (2.7%) and the Firmicutes and Bacteroidetes were similar in P5 treatment to 
untreated rats. The metronidazole treatment did have a slightly low count of Firmicutes (38%) and a 
relatively high count of Proteobacteria (2%), however, the populations of bacteria in this treatment 
were similar to DMSO treatment. None of the changes in genera were assessed as significant by a 
metastats implementation of the student’s T-test. Since the number of bacteria at the genera level 
were similar, it was concluded that variance in the data was more likely biological and not due to 
chemical perturbations of the bacterial communities. 
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Table 6.8: Summary of bacterial 16S rDNA from the faeces of rats immediately after a 5 day ‘2mM 
treatment’. M=metronidazole. 
Total
Bacterial Clade Av. SEM Av. SEM Av. SEM Av. SEM Av. SEM Av
Bacteroidetes 51.0 8.5 63.2 3.6 52.0 5.2 59.7 4.7 50.4 5.0 55.3
Bacteroidales (unclassified family) 0.5 0.2 1.2 0.1 0.8 0.1 0.7 0.1 1.3 0.2 0.9
Bacteroidaceae Bacteroides spp. 4.3 1.4 5.3 0.9 5.0 1.1 5.2 0.9 5.4 0.5 5.0
 Bacteroides acidifaciens 0.7 0.2 2.0 0.3 1.7 0.4 1.1 0.1 1.4 0.3 1.4
 Bacteroides caccae 0.5 0.2 0.2 0.2 0.0 0.0 0.2 0.1 0.5 0.1 0.3
 Bacteroides ovatus 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0
 Bacteroides uniformis 0.6 0.3 0.4 0.1 0.2 0.1 0.3 0.1 0.3 0.1 0.4
Paraprevotellaceae Prevotella spp. 3.3 0.6 4.6 1.1 4.1 1.6 4.9 0.8 2.8 0.6 4.0
Porphyromonadaceae Parabacteroides spp. 0.5 0.1 0.9 0.1 0.7 0.2 0.6 0.1 0.6 0.1 0.6
Parabacteroides (unclassified species) 0.3 0.1 0.6 0.0 0.5 0.1 0.4 0.1 0.4 0.1 0.4
Parabacteroides distasonis 0.2 0.1 0.3 0.1 0.2 0.1 0.2 0.1 0.2 0.0 0.2
Prevotellaceae Prevotella spp. 4.8 1.3 7.0 0.9 2.9 1.1 10.2 1.7 5.1 0.9 6.0
Rikenellaceae (unclassified genus) 1.1 0.2 1.4 0.1 1.6 0.4 1.0 0.2 1.5 0.5 1.3
S24-7 (unclassified genus) 36.5 5.0 42.7 2.4 36.9 2.5 37.0 2.2 33.6 4.5 37.3
Firmicutes 47.5 8.7 35.0 3.5 46.2 5.4 37.9 4.9 46.8 5.3 42.7
Lactobacillaceae 1.5 0.3 1.7 0.6 0.9 0.2 0.9 0.5 1.3 0.5 1.3
Lactobacillus reuteri 0.3 0.1 0.4 0.2 0.2 0.1 0.2 0.1 0.3 0.1 0.3
 Clostridiales 45.9 9.0 33.1 3.7 45.3 5.3 36.8 4.7 45.3 5.2 41.3
Clostridiales (unclassified genus) 9.3 1.2 9.7 2.0 11.7 3.0 7.2 1.2 12.6 2.1 10.1
Christensenellaceae 0.2 0.1 0.4 0.1 0.3 0.1 0.3 0.0 0.2 0.0 0.3
Clostridiaceae 0.5 0.1 1.2 0.3 1.1 0.3 0.6 0.2 1.5 0.8 1.0
Clostridium  spp. 0.2 0.1 0.4 0.2 0.9 0.3 0.4 0.1 0.4 0.1 0.5
SMB53  spp. 0.2 0.1 0.8 0.3 0.3 0.2 0.2 0.1 1.1 0.8 0.5
 Lachnospiraceae 8.0 1.9 4.1 0.7 10.6 1.6 8.5 2.4 6.9 1.5 7.6
 Lachnospiraceae (unclassified genus) 1.8 0.6 1.3 0.5 5.4 1.3 2.7 1.0 2.3 0.6 2.7
Blauta 0.4 0.2 0.2 0.1 0.1 0.0 0.3 0.1 0.2 0.1 0.2
Coprococcus 0.8 0.2 0.4 0.1 1.5 0.3 0.9 0.2 0.5 0.2 0.8
Dorea 0.2 0.1 0.3 0.2 0.1 0.0 0.1 0.0 0.2 0.0 0.2
Ruminococcus gnavus 0.3 0.1 0.1 0.0 0.4 0.2 0.4 0.1 0.2 0.0 0.3
Lachnospiraceae  (unclassified genus)* 4.3 1.6 1.8 0.3 3.0 0.7 4.1 1.5 3.3 0.9 3.3
 Mogibacteriaceae 0.5 0.1 0.4 0.1 0.2 0.0 0.4 0.1 0.4 0.1 0.4
 Mogibacteriaceae  (unclassified genus) 0.4 0.1 0.4 0.1 0.2 0.0 0.4 0.1 0.4 0.1 0.4
 Peptococcaceae 0.1 0.1 0.2 0.1 0.1 0.0 0.2 0.1 0.3 0.1 0.2
 Ruminococcaceae 13.8 0.6 12.1 1.3 19.3 3.5 15.6 3.0 16.9 1.4 15.5
Ruminococcaceae  (unclassified genus) 2.6 0.4 3.0 0.8 3.5 1.0 6.0 1.8 4.7 0.5 3.9
Oscillospira  spp. 7.1 1.4 5.6 1.6 11.0 2.6 7.1 1.3 9.1 1.6 8.0
Ruminococcus  spp. 3.8 0.9 3.4 0.8 4.6 1.2 2.2 0.6 2.8 0.5 3.3
Proteobacteria 1.3 0.2 1.6 0.2 1.6 0.2 2.0 0.3 2.7 0.4 1.8
Alcaligenaceae Sutterella spp. 0.7 0.3 0.8 0.0 0.7 0.2 1.0 0.3 1.3 0.2 0.9
Desulfovibrionaceae 0.4 0.2 0.6 0.1 0.6 0.2 0.7 0.3 1.1 0.2 0.7
Desulfovibrio spp. 0.3 0.1 0.5 0.1 0.5 0.1 0.5 0.3 1.0 0.2 0.6
Actinobacteria 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1
Deferribacteres 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Lentisphaerae Victivallaceae 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Unclassified Phylum 0.1 0.0 0.1 0.0 0.1 0.1 0.3 0.1 0.0 0.0 0.1
Carrier DMSO DPIX M P5
 
*This clade of Lachnospiraceae (mean 4.3%) was sufficiently divergent (more than 3% dissimilar) to 
the other clade of Lachnospiraceae (mean 1.8%) 
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6.3.2 Optimising P5 and metronidazole treatment concentrations 
From pyrosequencing results, it was apparent that initial 2 mM treatment was insufficient to 
kill susceptible nanaerobes. A thorough culture based assessment of the microbiology after using 
‘high-dose’ metronidazole in the rat gastrointestinal tract detected decreases in nanaerobic cocci 
and other nanaerobes from the colonic mucosa which were not observed in faeces (Mikelsaar and 
Siigur, 1992). In an initial expeirment using similar ‘high-dose’ five-day metronidazole protocol, no 
difference in daily faecal texture or consistency was observed over six days. Also, 3-4 log changes in 
the viable count of susceptible nanaerobes were not detected on kanamycin and vancomycin 
containing BHI medium (results not shown). These results confirmed that an examination the colonic 
mucosa was warranted. To achieve these results, Mikelsaar and Siigur administered high 
concentrations of metronidazole (70 mg kg-1 day-1, equating to a total of 4.9 g per day for a 70 kg 
human). For 5 rats weighing 100 g, a similar protocol requires around 800 mg of P5. Sufficient P5 
was synthesised for these experiments (see Table 6.9). 
Rats require an initial one week acclimatisation before experiments can begin. During this 
period, the weight of rats within each treatment group was similar (Fig. 6.2). After five days 
administering ‘250 mM’ treatments, the percent weight increase over baseline between groups was 
similar [metronidazole (94.5%), carrier (92.4%), DPIX (88.1%), and P5 (72.1%), Fig. 6.2]. Although 
growth rate of P5 treatment was the lowest, this group also had the lowest growth rate before P5 
was administered (Fig. 6.2). In all groups, weight gain plateaued by around 10 days. Strikingly during 
surgery, it was noted the caecum of metronidazole treated rats was distended, doubling in 
size/volume (4.63 ±0.3g) compared with other treatment groups (Fig. 6.3). The caecum size/volume 
was similar in other groups: carrier control (2.12 ±0.2 g), DPIX (2.12 ±0.1g) and P5 (2.18 ±0.2) 
(Fig. 6.3). The caecum of metronidazole-treated rats also had a less pronounced vasculature 
(Fig. 6.3). No other differences in gross anatomy of rats were observed. 
 
Table 6.9: The total amount of daily ‘250 mM’ treatments given for five days to rats weighing ≈80 g. 
Rats were 3-4 weeks old at time of treatment administration. Treatments were administered at 12 
hour intervals in 150 µL of CMC with 250 mM DPIX, metronidazole or P5.  
Treatment mg day
-1
mg kg
-1
 day
-1
Equivalent for a 70 kg human g
-1 
day
-1
Deuteroporpyrhin IX 14.6 182.3 12.8
Metronidazole 4.3 53.5 3.7
P5 16.6 207.3 14.5
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Figure 6.2: Rat weight during a 7-day acclimatisation followed by a 5-day treatment with CMC 
(carrier), DPIX, metronidazole (M) and P5. Treatments were administered twice daily on days 7-12. 
Rats were culled on day 13 for further examination. Rats were 3-4 weeks old at day 0. Error bars 
show standard error of the mean from five rats within each treatment group. 
 
Anatomical changes at a finer resolution were next examined. In relation to the carrier 
control, the large intestine of the metronidazole, DPIX and P5 treatments all exhibited an increase in 
lymphoid follicles, particularly adjacent to the crypts. The metronidazole treatment also exhibited 
goblet cell hyperplasia, and an increase in infiltrating leukocytes (see Fig. 6.4). Due to time 
constraints an exploration into the microbiology associated with colonic mucosa was not possible. 
Nevertheless, these results provide impetus to assess microbiological as well as key changes in host 
epithelial expression, discussed further in future directions (Chapter IV). 
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Figure 6.3: Caecum of rats on day 13 immediately after a 5-day treatment regime. Treatment groups 
included metronidazole (A), P5 (B), carrier (C) and DPIX (D). The numbers at the bottom of the figure 
are in cm. 
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Figure 6.3: Representative sections from the colonic mucosa of rats after a 5-day high dose of carrier 
(‘C’), DPIX, metronidazole and P5. Scale bar=50 M. Slight and pronounced goblet cell hyperplasia are 
marked with one or two blue asterisks respectively. Infiltrating leukocytes are marked with yellow 
asterisks.  
 
6.4 DISCUSSION 
Chapter VI used a rat gastrointestinal model to test the predicted metabolism of P5 based 
on nitroimidazole metabolism and b-cytochrome formation outlined in Chapter III. Real time PCR 
comparisons of total bacteria in ‘2mM treatment’ and Bacteroidetes populations indicated that 
insufficient metronidazole was administered to rats to broadly alter the number of susceptible 
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bacteria. The Bacteroidetes were chosen for assessment since they represent a large portion of the 
rat faecal bacteria and the majority of the genus within this clade are sensitive to metronidazole. 
However, when bacterial populations were assessed by 454 pyrosequencing, the number of 
nanaerobic bacteria susceptible to metronidazole did not appreciably change, indicating treatment 
concentrations were too low. The concentration of administered metronidazole was increased 
accordingly, as described below.  
For initial ‘2mM treatment’ sequencing, the Greengenes 16S rDNA taxonomy was chosen to 
map sequences to, since it is known to contain candidate phyla (new phyla recalcitrant to culturing). 
Indeed, using the RDP reference 16S rDNA taxonomy, many more reads mapped to unknown phyla 
(5%). However, a significant portion of the reads mapped to genera S24-7 (average 37.3%), whereas 
using the RDP reference, a large number of these reads mapped to unclassified 
Porphyromonadaceae (29%) and Barnsiella (4.1% a Porphyromonadaceae). Using the RDP 
classification, no significant changes were detected between treatment groups of these clades, so 
the discrepancy in mapping sequences between RDP and Greengenes classifications was not 
checked with in silico suites such as BLAST. Otherwise, the Firmicutes were mapped with a similar 
taxonomic distribution and like the Greengenes 16S rDNA taxonomy reference, the resolution of the 
RDP database was poor for this clade.  
As mentioned, current molecular profiling studies of bacteria in the faeces of rats are limited 
by severe lack of sequencing depth or by short pyrosequencing reads. Whilst faecal estimations of 
bacteria are a rough approximation, pyrosequencing of the ‘2mM treatment’ experiments 
established that previously unidentified clades (Paraprevotellaceae, Rikenellaceae, Barnsiella/S24-7 
and Oscillospira spp. reside in rats. Importantly, this experiment also established that rat faecal 
Bacteroides spp. populations are lower than in human counterparts. Nevertheless, 454 sequencing 
and real time PCR are sufficiently sensitive to detect more than a 100-fold reduction in this clade. 
Also, there was a surprisingly high variation (2-3 fold) in the number of major bacterial clades of rats 
housed in one cage. This variation could be due to environmental factors (diet, extent of 
coprophagy), handling of microbes (DNA extraction) and molecular bias (PCR amplification and 
sequencing). Using the improved DNA extraction method may help to determine if the apparent 
variability within rat groups was biological or an artefact of the original DNA extraction. Ultimately, 
establishing the types of bacteria and variability within these clades will establish a sound basis for 
the concentrated administration of P5. 
Increasing metronidazole treatment concentration from ‘250 mM’ (a daily dose of 53.5 
mg kg-1 metronidazole, which was a 170-fold increase over initial ’2mM’ treatments) had minimal 
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effect on the weight of treated rats. However, a profound impact on the gastrointestinal tract was 
observed, namely a distended caecum that was double the volume of other treatment groups. The 
caecum of metronidazole-treated rats also had a less pronounced vasculature. No other differences 
in gross anatomy of rats were observed. Sections of the large intestine of the metronidazole, DPIX 
and P5 treatments all exhibited an increase in lymphoid follicles, particularly adjacent to the crypts. 
The metronidazole treatment also exhibited goblet cell hyperplasia. Due to time constraints, the 
microbiology associated with such changes remains to be detailed. Nevertheless, rats exhibited no 
obvious changes in grooming or sociability when administered with a concentrated dose of P5, 
demonstrating that even with high doses, there is no apparent toxicity. Profound changes in tissue 
architecture warrant further investigation, as described in future directions (Chapter IV).  
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